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Abstract 
Pseudomonas aeruginosa is a prevalent nosocomial pathogen predominantly associated with 
infections in immune compromised individuals and long term colonisation and pathogenesis in 
the lungs of Cystic Fibrosis patients. With multi-drug resistant strains increasingly common, 
the discovery of novel targets for antimicrobial chemotherapy is of utmost importance and 
expansion of data on P. aeruginosa’s complex genome could facilitate this. Azoreductases are 
a group of enzymes mainly noted for their reductive capacity against azo and quinone 
compounds. Ubiquitous amongst many classes of organism including prokaryotes and 
eukaryotes, the primary physiological role of azoreductases remains unclear. This study 
characterises azoreductase-like enzymes from P. aeruginosa in terms of biochemical 
properties, substrate specificity and structural analysis. The effect of these enzymes on 
bacterial physiology in P. aeruginosa is also explored in relation to antibiotic susceptibility.  
Three azoreductase-like genes from P. aeruginosa (pa1224, pa1225 and pa4975) were 
overexpressed in E. coli strains following molecular cloning. Recombinant proteins were 
biochemically characterised by means of Thin Layer Chromatography, Differential Scanning 
Fluorimetry and enzymatic assays. All enzymes were noted to be selective for FAD as the 
flavin cofactor and NADPH as the preferred reductant. All three enzymes were confirmed as 
NAD(P)H dependent quinone oxidoreductases (NQOs) with PA1224 also catalysing reduction 
of the azo substrate methyl red, albeit at a rate an order of magnitude lower than that observed 
for the quinone compounds. The preferred flavin cofactor for four previously characterised 
azoreductase and NQO enzymes (PA2280, PA2580, PA1204 and PA0949) was also explored 
and PA2280 and PA0949 were observed to select for FMN while PA2580 and PA1204 were 
selective for FAD. The crystal structure of PA2580 was solved with the nicotinamide group of 
NADPH bound and was noted to form a homodimer with the same short flavodoxin-like fold 
as previously described for other members of this enzyme family. Complemented strains of 
azoreductase-like gene deletion mutants of P. aeruginosa PAO1 were generated via molecular 
cloning and used to monitor the effects of these enzymes on antibiotic susceptibility. 
Antimicrobial sensitivity assays were carried out and although the knockout strains displayed 
increased sensitivity to fluoroquinolones, they did not revert to the wild type phenotype upon 
reinsertion of the genes of interest.  
This study has for the first time characterised three new NQO’s from P. aeruginosa PAO1 and 
solved the crystal structure of an azoreductase/NQO with nicotinamide bound. With these 
findings and a library of complemented strains generated, this original study offers a platform 
for the continued research into the physiological role of these enzymes. 
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 Introduction Chapter 1
 
1.1 Pseudomonas aeruginosa 
Pseudomonas aeruginosa is a gram-negative rod shaped bacterium. Ubiquitous in a variety 
of environmental niches, it encompasses a striking ability to adapt to and thrive in both 
natural and artificial or human-associated ecosystems ranging from plant surfaces and 
waste water to life support equipment and dilute antiseptics (Todar, 2006, Slekovec et al., 
2012). At 6.3 million base pairs, P. aeruginosa possesses a large bacterial genome with a 
high proportion of genes involved in catabolism, efflux and transport of organic 
compounds (Stover et al., 2000). Consistent with this genetic complexity, it exhibits 
numerous virulence factors and is versatile in adapting different phenotypes under 
environmental stress such as mucoidal vs. planktonic growth and aerobic vs. anaerobic 
respiration and this is attributed to the large percentage of genes devoted to regulatory 
systems including environmental sensors and transcriptional regulators (Willey et al., 
2011, Stover et al., 2000).  
Typically an aerobic microorganism, P. aeruginosa can survive in anaerobic or oxygen 
deficient environments such as soil and water or the mucopurulent lung of a Cystic 
Fibrosis (CF) sufferer (Willey et al., 2011, Worlitzsch et al., 2002). This is facilitated by 
the bacterium’s ability to respire as a facultative anaerobe either by arginine fermentation 
via the arginine deiminase pathway or by the use of nitrite, nitrate or nitrous oxide as 
alternative electron acceptors (Vander Wauven et al., 1984, Zannoni, 1989).  
P. aeruginosa can exist in a planktonic or mucoidal form. Planktonic cells are free living 
and exist as single cells suspended in a liquid medium (Spoering and Lewis, 2001). During 
anaerobic growth or proliferation in a nutrient deficient environment, the mucoidal 
phenotype is often observed for P. aeruginosa (Yoon et al., 2002). Mucoidal growth, or 
biofilm formation, is bacterial proliferation which forms surface-associated microbial cells 
that are enclosed in an extracellular polymeric substance (EPS) matrix composed of 
bacterial-derived biomolecules such as exopolysaccharides, polypeptides and extracellular 
DNA (Donlan, 2002). The EPS, which forms the majority of the biofilm, offers robustness 
to the bacterial community both physically and chemically by decreasing penetration of 
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toxic substances and resisting mechanical forces (Hall-Stoodley and Stoodley, 2009, Lieleg 
et al., 2011). 
Other virulence factors of P. aeruginosa include surface appendages such as flagella and 
pili which facilitate both cell motility and adhesion and are implicated in the establishment 
of host infection (Kohler et al., 2000, Yeung et al., 2009, Brimer and Montie, 1998). 
Evolutionally linked to the flagella is the needle-like appendage of the type III secretion 
system which ‘injects’ bacterial exotoxins into the host cells and it is thought that this 
mechanism allows P. aeruginosa to exploit breaches in the epithelial barrier thus 
promoting colonisation (Hauser, 2009). In addition, several proteases are secreted by P. 
aeruginosa which can degrade host defence molecules and disrupt epithelial tight junctions 
(Kipnis et al., 2006). Many of these virulence factors are controlled by quorum sensing 
(QS), a mechanism by which autoinducer molecules are constitutively expressed by each 
bacterial cell. The transcriptional regulatory activity of these molecules is concentration 
dependent: thus when the bacterial population reaches a certain critical mass, a coordinated 
response occurs (Gellatly and Hancock, 2013).  
The versatility of P. aeruginosa and its ability to control gene expression in response to 
environmental stimuli is reflected in the large number of hosts that can be colonised by this 
pathogen ranging from plants such as Arabidopsis thaliana (Thale cress) (Plotnikova et al., 
2000) and Lactuca sativa (Romaine lettuce) (Starkey and Rahme, 2009) to invertebrates 
like Drosophila melanogaster (fruit fly) (D'Argenio et al., 2001) and Galleria mellonella 
(greater wax moth) (Miyata et al., 2003) and also mammals including humans. 
1.1.1 P. aeruginosa infections 
P. aeruginosa is one of the few microorganism species that can infect both plants and 
humans. It has been identified as the causative agent for soft rot in numerous plant species 
including Panax ginseng (Ginseng) (Gao et al., 2014), A. thaliana (Plotnikova et al., 2000) 
and L. sativa (Starkey and Rahme, 2009) and has also been reported to colonise ornamental 
plants such as African violet, azaleas, chrysanthemums, hydrangeas and petunias (Cho, 
1975). Interestingly, studies have shown that there is a high level of molecular 
conservation regarding pathogenesis of P. aeruginosa across plant, invertebrate and 
mammalian hosts indicating that the disease causing ability of P. aeruginosa is credited to 
a basic set of virulence genes or that some of these genes may encode regulatory proteins 
which control different effector molecules which may be specific for plants or animals 
(Miyata et al., 2003, Rahme et al., 1997).  
3 
 
The incidence of P. aeruginosa in the natural human flora can vary and is site-specific. It 
occurs infrequently in the pharynx and mouth (<5% of the population) but can commonly 
occupy the lower gastrointestinal tract (approximately 25% of the population) (Morrison Jr 
and Wenzel, 1984, Todar, 2006). It is an opportunistic pathogen, rarely causing disease in 
immunocompetent individuals with most cases of community acquired infection occurring 
as a result of prolonged exposure to contaminated water (Mena and Gerba, 2009). 
Community acquired infections can often include ulcerative keratitis, otitis externa and 
skin and soft tissue infections (Driscoll et al., 2007). It is infrequently isolated from 
patients with community acquired pneumonia (0.9–1.9% incidence) however in such cases 
it typically results in bacteraemia, thus the mortality rate is relatively high at 30–35% 
(Fujitani et al., 2011, Tsuji et al., 2014, Hatchette et al., 2000).  
An important nosocomial pathogen, P. aeruginosa is estimated to colonise up to 15% of 
hospitalised patients (Cuttelod et al., 2011). International investigations have identified it 
as the most common microorganism to cause infection in intensive care units (ICUs) in 
Central/South America and Asia. Worldwide, it is the most prevalent gram-negative 
organism, isolated from approximately 20% of ICU patients with infection in the ICU 
independently affiliated with prolonged hospitalisation and increased mortality rates 
(Vincent et al., 2006, Vincent et al., 2009, Dasgupta et al., 2015, Volakli et al., 2010). A 
major contributing factor in the case of ICU infections is the ability of P. aeruginosa to 
survive on medical devices such as catheters and mechanical ventilators (Driscoll et al., 
2007). This bacterium (along with Staphylococcus aureus) is the leading cause of 
ventilator associated pneumonia and is often the most commonly isolated pathogen in 
infected burn wounds (Fujitani et al., 2011, Ramírez-Estrada et al., 2016, Yildirim et al., 
2005, Song et al., 2001). It is also commonly identified as the causal agent in surgical site 
infections and nosocomial urinary tract infections (Weinstein et al., 2005).  
As well as being an important nosocomial pathogen, P. aeruginosa is predominantly 
associated with both acute and chronic infections in individuals with compromised host 
defences such as cancer patients, HIV sufferers and people with neutropenia (Driscoll et 
al., 2007, Lyczak et al., 2000). Perhaps most notorious for long term lung colonisation in 
those suffering from CF, it chronically colonises over 70% of adult CF patients with 25% 
infected with multi-drug resistant (MDR) strains (Figure 1.1) (CFF, 2015). CF is an 
autosomal recessive disorder where a mutation in the Cystic Fibrosis transmembrane 
regulator results in dysregulation of epithelial fluid transport in the lung which 
subsequently develops a thickened airway surface liquid (Clunes and Boucher, 2007). The 
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genomic plasticity of P. aeruginosa and its capacity to undergo phenotypic alteration 
enables it to colonise the CF lung long term. As a result, strains from chronic infections are 
less virulent than those isolated from acute infections with many virulence factors 
attenuated including loss of flagella and pili and altered metabolic pathways (Sousa and 
Pereira, 2014). The microorganism’s presentation of the mucoidal phenotype within the CF 
lung forms a protective barrier against the host’s immune system as well as antimicrobial 
treatment making it difficult to eradicate (Ciofu et al., 2012). These phenotypic alterations 
along with prolonged antibiotic exposure achieved from long term colonisation results in 
highly drug resistant bacteria. Thus the issue of P. aeruginosa infections in 
immunocompromised hosts is exacerbated by the microorganism’s intrinsic, acquired and 
adaptive resistance to antibiotics. 
 
 
Figure 1.1 Micro-organisms isolated from the lungs of Cystic Fibrosis patients in 2015 
Graph representing the predominant microorganisms isolated from the lungs of CF patients 
in 2015. Among all species isolated, S. aureus and P. aeruginosa are the most prevalent 
with the former present in >80% of individuals aged between 6 and 17 years old and the 
latter colonising >70% of CF patients aged 25 to 44+. Within the older group 
approximately 25% are infected with MDR P. aeruginosa strains. Figure is taken from the 
2015 Annual Data Report by the Cystic Fibrosis Foundation Patient Registry (CFF, 2015). 
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1.1.2 Antibiotic resistance in P. aeruginosa  
In recent years the resistance of microorganisms to antimicrobial treatment has become a 
major challenge to modern medicine. Continued increases in the number of 
immunocompromised and immune suppressed patients coupled with the ability of bacteria 
to rapidly mutate in response to environmental stimuli has resulted in the emergence of 
‘superbugs’ – strains of bacteria that are resistant to practically all available antimicrobials. 
Antibiotic resistance occurs when a microorganism develops the capacity to resist 
chemotherapeutic treatment to which it is normally susceptible. This evolutionary 
advantage of bacteria is especially true for P. aeruginosa which, with its ability to rapidly 
develop resistance to multiple classes of antibiotics during the course of treating a patient, 
has been labelled by the Centre for Disease Control as a ‘serious threat’ (CDC, 2013) and 
listed by the World Health Organisation (along with Acinetobacter baumannii and 
Enterobacteriaceae) as the MDR pathogen of most critical importance for the discovery of 
new antimicrobials (WHO, 2017). Approximately 13% of healthcare associated P. 
aeruginosa infections are multi-drug resistant and the rise in MDR isolates has been 
estimated to have increased by 10% from the early 1990’s to 2002 (Livermore, 2002, 
Obritsch et al., 2004). Along with developing resistance via horizontal gene transfer and 
adaptive mutations, P. aeruginosa is naturally resistant to many antimicrobials altogether 
making it a particularly difficult pathogen to treat once infection has been established.  
1.1.2.1 Intrinsic resistance 
The intrinsic tolerance of P. aeruginosa to many structurally unrelated antibacterial agents 
is predominantly due to the low permeability of its outer membrane (Figure 1.2). 
Comprising of a dense lipopolysaccharide matrix, the outer membrane has 12-100 fold 
lower permeability than other gram-negative bacteria such as Escherichia coli (Yoshimura 
and Nikaido, 1982, Hancock, 1998). The low levels of antibiotic penetration into the cell 
are thought to be attributed to the small channel size of P. aeruginosa’s outer membrane 
porins OprD and OprB and the limited number of functional large channels of major porin 
OprF (Yoshihara and Nakae, 1989, Hancock, 1998). On the other hand, these porins can 
also facilitate uptake of antimicrobials into the cell, for example OprD has been implicated 
in the diffusion of carbapenems into the bacterial periplasmic space (Lister et al., 2009, 
Trias and Nikaido, 1990). 
The avoidance of antibiotic accumulation in the cell can be aided by another intrinsic 
mechanism, namely, active export by membrane associated pumps (Lister et al., 2009). 
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These complexes typically form a channel spanning the entire membrane which allows the 
transport of toxic molecules from the periplasmic space and cytoplasm into the 
extracellular environment (Lister et al., 2009). Sequence analysis of P. aeruginosa has 
noted efflux pumps from five different superfamilies present in the genome with the largest 
number of pumps belonging to the resistance-nodulation-division family (Stover et al., 
2000). One such pump, MexAB-OprM, is constitutively expressed in wild type cells and 
can export β-lactams such as carboxypenicillins, extended spectrum cephalosporins and 
carbapenems (Poole, 2001).  
 
 
Figure 1.2 Cellular envelope of gram-negative bacteria  
The structure of the cell membrane in gram-negative bacteria is illustrated. The cellular 
envelope is characterised by a cytoplasmic membrane, a periplasmic space and an outer 
membrane. The outer membrane is mainly comprised of a dense lipopolysaccharide matrix 
that is highly hydrophobic and has low permeability for exogenous hydrophilic molecules. 
Figure is from Salmi et al. (Salmi et al., 2008). 
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1.1.2.2 Adaptive resistance 
Adaptive resistance is inducible and occurs in P. aeruginosa as a response to changing 
environmental stimuli and stresses such as differing media conditions, altered growth 
states, a change in pH and of course, antibiotic exposure (Fernandez et al., 2011). These 
environmental cues modulate gene expression leading to adaptions relating to efflux 
pumps, outer membrane porins and enzyme production (Lister et al., 2009). Unlike 
intrinsic resistance, adaptive resistance will be lost upon removal of triggering factors with 
the organism reverting to wild type susceptibility (Breidenstein et al., 2011). The 
significance of adaptive resistance in P. aeruginosa is consistent with the large repertoire 
of regulatory genes within its genome (9.4%) (Stover et al., 2000).  
As mentioned in the previous section, the low permeability of the outer membrane coupled 
with efflux pump mediated removal of toxic agents from the cell grants P. aeruginosa a 
high level of intrinsic tolerance to a broad range of antibiotics. To decrease antimicrobial 
susceptibility in times of environmental strain, the expression of these phenotypes can be 
altered and result in adaptive resistance. 
There is a long since established relationship between outer membrane porin OrpD 
expression and carbapenem sensitivity. OprD has been implicated as the primary portal of 
entry for carbapenems into the cell with loss of OprD from the outer membrane resulting in 
an up to 32 fold decreased susceptibility to carbapenems including meropenem, imipenem 
and doripenem (Trias and Nikaido, 1990). Adaptive resistance relating to OprD involves 
numerous mechanisms which decrease transcriptional expression of oprD and/or mutations 
that disrupt translational production resulting in a dysfunctional porin. These mechanisms 
can include oprD promotor disruptions and premature termination of oprD transcription 
(Lister et al., 2009).  
While loss of OprD assists in developing an effective barrier for drug entry into the cell, 
active export via membrane associated pumps is also functional in reducing drug 
accumulation within the cytoplasm. Although constitutively expressed within the cell, 
mexAB-oprM expression is tightly controlled by several regulatory proteins including 
MexR and NalD (Poole et al., 1996, Sobel et al., 2005). Upregulation of this efflux pump 
has been shown to occur in times of oxidative stress with oxidised MexR proving inactive 
in repression of the mexA promotor, subsequently reducing the efficiency of antimicrobial 
agents such as fluoroquinolones, penicillins, cephalosporins and carbapenems (Chen et al., 
2008).  
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Exposure to β-lactam antibiotics results in the induction of a chromosomally encoded β-
lactamase, AmpC, which is a major adaptive mechanism in P. aeruginosa (Breidenstein et 
al., 2011). Wild type P. aeruginosa constitutively produces low levels of AmpC however 
when expression is increased, resistance is developed to almost all β-lactams, with the 
exception of carbapenems (Colom et al., 1995, Sanders and Sanders, 1986). Although the 
mechanisms by which AmpC is overexpressed are not clear, induction involves the binding 
of a β-lactam or β-lactamase inhibitor to penicillin binding proteins (Sanders et al., 1997). 
Like other adaptive mechanisms, once the inducing factor is no longer present, wild type 
expression is reinstated (Lister et al., 2009). 
The molecular mechanisms behind adaptive resistance have only recently begun to be 
investigated and much remains to be understood. It is evident that the mechanisms are 
complex involving intricate regulatory responses. Transcriptome analysis upon exposure to 
antibiotics and toxic compounds could assist in identifying modulating genes and offer 
new targets to tackle antimicrobial resistance.  
1.1.2.3 Acquired resistance 
Another attribute of P. aeruginosa responsible for reducing its sensitivity to antibiotics is 
acquired resistance. Acquired resistance manifests via horizontal transfer of genetic 
elements and chromosomal mutations. Horizontal transfer of antimicrobial resistance genes 
can be achieved by conjugation, transformation and transduction of DNA elements 
(including plasmids, transposons, integrons, prophages and resistance cassettes) which can 
lead to MDR organisms (Breidenstein et al., 2011). This type of acquisition is particularly 
relevant for aminoglycoside and β-lactam resistance. One such resistance mechanism is a 
group of enzymes referred to as the aminoglycoside modifying enzymes. Transferred via 
mobile genetic elements they function by acetylation, phosphorylation or adenylylation of 
the aminoglycoside antibiotics, altering their structure and reducing affinity with their main 
target, the 30S ribosomal subunit (Vakulenko and Mobashery, 2003). P. aeruginosa can 
also acquire plasmids encoding β-lactamases such as PSE-1 and PSE-4, and of particular 
concern, extended spectrum β-lactamases including OXA types and IMP and VIM 
metallo-β-lactamases (Livermore, 1995). A P. aeruginosa strain harbouring the latter three 
is susceptible to only polymyxins and ciprofloxacin (Livermore, 2002).  
The second form of acquired resistance is mutational resistance. These spontaneous 
mutations occur at varying frequencies depending on the bacterial growth conditions. For 
example, incidence of mutations increases in the presence of DNA damaging agents with 
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proliferation in the presence of sub-inhibitory levels of ciprofloxacin giving rise to 
mutational resistance to meropenem (Tanimoto et al., 2008). Similarly, a large increase in 
mutation frequency for ciprofloxacin resistance (>100 fold) occurs during mucoidal growth 
compared to that observed in free living cells (Driffield et al., 2008). This is likely due to 
the downregulation of antioxidant enzymes during growth in a biofilm leading to increased 
DNA damage.  
As with intrinsic and adaptive resistance, outer membrane porins, efflux pumps and AmpC 
expression are all also implicated in acquired resistance mechanisms. Mutations in the 
OprD porin or to the regulatory genes mexT or mexS which control OprD expression can 
lead to multiple antibiotic resistance (Walsh and Amyes, 2007). Additionally, derepression 
of the MexAB-OprM pump can occur as a result of mutations in either of the genes 
encoding mexR and mexZ which can lead to aminoglycoside, fluoroquinolone and 
cefepime resistance in P. aeruginosa (Stickland et al., 2010, Muller et al., 2011). Finally 
hyperproduction of β-lactamases results from mutation of an effector of the ampC β-
lactamase, AmpD, which controls activity of the AmpR regulatory protein (Juan et al., 
2006).  
From the available literature on mutation-derived acquired resistance, it is evident that 
such mutations occur in a vast number of unrelated genes and can grant resistance to a 
variety of antimicrobial agents. To illustrate this point, the aminoglycoside resistome 
involves 150 different genes relating to energy metabolism, lipopolysaccharide 
biosynthesis and DNA replication and repair (Dötsch et al., 2009, Alvarez-Ortega et al., 
2010). Also, the fluoroquinolone resistome involves efflux regulators, iron transport genes, 
phage-related genes and NADH dehydrogenase genes (Dötsch et al., 2009, Breidenstein et 
al., 2008). The vast array of genes and mechanisms involved in acquired resistance to 
multiple antibiotics highlights the difficulties in finding reliable novel targets for 
antimicrobial chemotherapy of P. aeruginosa.  
The genetic versatility of P. aeruginosa as discussed here and its outstanding ability to co-
regulate multiple resistance mechanisms make it a continuously moving target and a great 
therapeutic challenge. Despite the increasing pandemic of MDR P. aeruginosa, there is a 
paradoxical decrease in the development of new antibiotics, thus the identification and 
development of novel targets for antimicrobial chemotherapy is essential. Understanding 
unexplored parts of the genome may give new leads in the fight against resistance.  
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1.2 Azoreductases 
Azoreductases are a group of enzymes which catalyse the reductive cleavage of the azo 
bond (-N=N-). The majority of characterised azoreductases are FMN or FAD dependent 
and require NAD(P)H as an electron donor to carry out the reduction reaction (Nakanishi 
et al., 2001, Ryan et al., 2010a). The reduction is a double displacement reaction and 
occurs via an obligate two electron process where a hydride is transferred from NAD(P)H 
to the flavin and then on to the substrate in question (Ryan et al., 2010a). In addition to azo 
compounds, the enzymes have been shown to reduce a range of other substrates including 
quinones and nitroaromatics (Ryan et al., 2010b, Ryan et al., 2014, Liu et al., 2007a, Ryan 
et al., 2011). The reduction of azo and quinone substrates occurs via a similar mechanism 
with the exception that azoreduction is a double ping pong bi bi reaction where two 
NAD(P)H are required to reduce the substrate, while reduction of quinone compounds only 
requires one NAD(P)H molecule (Ryan et al., 2010a, Ito et al., 2006). For this reason, 
Ryan and colleagues (2014) proposed that azoreductases and NAD(P)H quinone 
oxidoreductases (NQOs) are part of the same enzyme superfamily.  
1.2.1 Azoreductases in bioremediation and medicine 
Azoreductase enzymes are predominantly associated with their ability to detoxify azo dyes 
and activate azo pro-drugs. Per annum, 1-1.5 × 105 tons of dyestuff is released into 
effluent wastewaters from textile and other manufacturing industries and among these, azo 
dyes are the most common (Rai et al., 2005). This can negatively affect water quality 
which subsequently disrupts photosynthesis, decreasing dissolved oxygen levels and 
severely disturbing aquatic ecosystems (Rai et al., 2005, van der Zee and Villaverde, 
2005). It also has implications for human health with many of these compounds and their 
breakdown products (often aromatic amines) toxic and potentially carcinogenic depending 
on their structure, substitution groups and reactivity (Golka et al., 2004, Schneider et al., 
2004, Maran and Slid, 2003). For this reason, much research on azoreductases focuses on 
their possible use in the bioremediation of these substances as enzymatic treatment can 
carry out complete mineralisation of dye chemicals and their metabolites while remaining 
low cost and environmentally friendly (Chen, 2006, Husain, 2006, Mahmood et al., 2016).  
Azo pro-drugs such as sulfasalazine and balsalazide are frequently used in the treatment of 
inflammatory bowel disease. They have been developed by cross linking an inert carrier 
molecule to the non-steroidal anti-inflammatory, 5-aminosalicylic acid (5-ASA), via an azo 
bond to prevent rapid adsorption in the gastrointestinal tract (Haagen Nielsen and 
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Bondesen, 1983, Makins and Cowan, 2001). Upon cleavage of the azo bond by 
azoreductases synthesised by gut microflora, 5-ASA is released and its anti-inflammatory 
properties are activated (Peppercorn and Goldman, 1972). Along with anti-inflammatory 
compounds, azo chemistry has also been used in the development of other drugs such as 
antibiotics and anticancer therapeutics (Deka et al., 2015, Sharma et al., 2013).  
1.2.2 Azoreductases and their associations in physiological functions 
Azoreductases are found ubiquitously across many bacterial species including E. coli, 
Enterococcus faecalis, Bacillus subtilis, Rhodobacter sphaeroides, S. aureus and 
pseudomonads as well as in yeasts and humans (Nakanishi et al., 2001, Chen et al., 2004, 
Sugiura et al., 2006, Liu et al., 2007a, Chen et al., 2005, Wang et al., 2007, Jadhav et al., 
2007, Cui et al., 1995). Extensive bioinformatics analysis based on homology of 
azoreductases from other species has led to the identification of several new azoreductase 
and NQO enzymes in P. aeruginosa including some from previously distinct enzyme 
families namely, modulator of drug activity B (MdaB), arsenic resistance protein H 
(ArsH), YieF and tryptophan repressor binding protein A (WrbA) (Wang et al., 2007, 
Ryan et al., 2014) (Table 1.1, Figure 1.3). Upon characterisation, many of these have been 
confirmed as NAD(P)H dependent flavoenzymes with the majority of those capable of 
reduction of azo, nitro and quinone compounds (Wang et al., 2007, Ryan et al., 2014, Ryan 
et al., 2010a, Ryan et al., 2011, Crescente et al., 2016). The identification of enzymes from 
this family is difficult due to the large sequence diversity amongst members and this is 
perhaps why until recently, azoreductases and NQOs were considered two distinct enzyme 
groups (Ryan et al., 2014).  
Although the enzymatic activities of azoreductases from P. aeruginosa and other bacterial 
species have been extensively described, their primary physiological role remains unclear. 
Along with their uses in medicine and bioremediation and their ability to reduce a range of 
substrates, azoreductases and NQOs have also been implicated in other seemingly 
unrelated systems including QS, biofilm formation, host colonisation and antimicrobial 
resistance (Table 1.2) (Tan et al., 2014, Goudeau et al., 2013, Cattò et al., 2015, 
Landstorfer et al., 2014, Rakhimova et al., 2008, Wang et al., 2016, Van der Linden et al., 
2016).  
The E. coli NQO, WrbA, which is a homologue of WrbA in P. aeruginosa PAO1, has been 
proven to interact with the anti-biofilm compound, Zosteric Acid, and the wrbA gene has 
been identified as one of the regulation targets for the master regulator of biofilm 
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formation (CsgD) in E. coli, indicating that this enzyme may be involved in the 
development of biofilms (Cattò et al., 2015, Ogasawara et al., 2011). A role in quorum 
sensing has been suggested as a result of an azoreductase and NQO from P. aeruginosa, 
MdaB, being significantly upregulated upon treatment with the QS inhibitor, Iberin (Tan et 
al., 2014).  
Azoreductases have been implied to play a fundamental role in plant colonisation with 
significant overexpression observed during E. coli O157 growth on radish sprouts and 
butterhead lettuce leaves (Landstorfer et al., 2014, Van der Linden et al., 2016). Similarly, 
AzoR is upregulated >100 fold in Salmonella enterica servar typhimurium during growth 
on lettuce and cilantro leaves (Goudeau et al., 2013). Evidence for an involvement in 
mammalian infections has also been observed. Gene deletion mutants of Yersinia 
pseudotuberculosis lacking the NQO encoding gene, wrbA, when infecting a mouse 
caecum display less virulence than the wild type and fail to establish a persistent infection 
(Avican et al., 2015). In P. aeruginosa, azoreductase and NQO knockout strains are less 
capable of survival and dissemination in a murine infection model with reduced or total 
lack of survival apparent in the lung, caecum and spleen (Rakhimova et al., 2008, Skurnik 
et al., 2013).  
Perhaps linked to their putative role in host colonisation, these enzymes have also been 
associated with the response to oxidative stress. Quinones can form semi-quinones when 
reduced by one electron reductases such as lipoyl dehydrogenase (Gonzalez et al., 2005). 
These semi-quinones can generate superoxide radicals in the presence of molecular oxygen 
which can then be converted to hydrogen peroxide which in turn, can yield highly 
damaging hydroxyl radicals (Valko et al., 2005, Cadenas et al., 1992). Azoreductases and 
indeed, NQO’s, act as two electron reductases which prevent the formation of semi-
quinones, instead generating two electron reduced and redox stable quinols which can also 
scavenge and detoxify reactive oxygen species (ROS) (Soballe and Poole, 2000, Ross and 
Siegel, 2004). In Pseudomonas syringae, a 65% identical homologue of paAzoR2 is 
significantly upregulated in response to acetosyringae which is a plant phenol that induces 
oxidative stress against invading pathogens (Postnikova et al., 2015). Liu and colleagues 
(2009) found that AzoR in E. coli protects against thiol-specific stress caused by 
electrophilic quinones and Landstorfer et al. (2015) speculated that this enzyme was 
involved in detoxification of oxidative stress inducing secondary plant metabolites such as 
salicylic acid and jasmonic acid. This data implies that these enzymes are important for a 
detoxification role in nature.  
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The literature implicates azoreductases and NQOs in a variety of systems crucial for 
bacterial pathogenesis and resistance to host defence mechanisms as well as antimicrobials 
(which will be discussed in Chapter 6). As of yet, their primary physiological function 
remains to be defined. A deeper understanding of their function within the bacterial 
genome may lead to new pathways in antimicrobial treatments. 
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Table 1.1 New azoreductase-like enzymes identified in P. aeruginosa PAO1  
Details of P. aeruginosa PAO1 azoreductase-like proteins identified by Ryan and 
colleagues (2014) based on sequence homology, structural comparisons and enzymatic 
function. Annotated functions were taken from the Pseudomonas Genome Database 
(Winsor et al., 2016). 
Protein 
ID 
Annotated 
function 
Homologues 
Azo/Quinone 
reduction 
Homologues 
azo/quinone 
reduction 
PA2280 Oxidoreductase smArsH 
Azo- and quinone 
oxidoreductase 
(Crescente et al., 
2016)  
Azoreductase 
(Hervás et al., 2012) 
PA2580 
Conserved 
hypothetical 
protein 
ecMdaB and 
hpMdaB 
Azo- and quinone 
oxidoreductase 
(Crescente et al., 
2016) 
Quinone 
oxidoreductase 
(Hayashi et al., 1996, 
Wang and Maier, 
2004) 
PA1204 
NAD(P)H 
quinone 
oxidoreductase 
atNQO 
Azo- and quinone 
oxidoreductase 
(Crescente et al., 
2016) 
Quinone 
oxidoreductase 
(Sparla et al., 1999) 
PA0949 
Tryptophan 
repressor binding 
protein 
ecWrbA 
Quinone 
oxidoreductase 
(Crescente et al., 
2016) 
Quinone 
oxidoreductase 
(Patridge and Ferry, 
2006) 
PA4975 
NAD(P)H 
quinone 
oxidoreductase 
hNQO2 
Quinone 
oxidoreductase 
(Green et al., 2014) 
Azo- and quinone 
oxidoreductase (Wu 
et al., 1997) 
PA1224 
Probable 
NAD(P)H 
dehydrogenase 
hNQO1 and 
hNQO2 - 
Azo- and quinone 
oxidoreductase (Wu 
et al., 1997) 
PA1225 
Probable 
NAD(P)H 
dehydrogenase 
hNQO1 and 
hNQO2 - 
Azo- and quinone 
oxidoreductase (Wu 
et al., 1997) 
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Figure 1.3 Phylogenetic tree showing the relationship between known and putative 
azoreductases from P. aeruginosa PAO1  
Phylogenetic tree showing the relationship between enzymes from P. aeruginosa (red), 
other bacterial (green), mammalian (blue), plant (purple), fungal (pink) and archeal 
(yellow). PA0949, PA1204, PA1224, PA1225, PA2280, PA2580, and PA4975 are proteins 
from P. aeruginosa PAO1. ecAzoR, bsAzoR, efAzoR and rsAzoR are azoreductases from 
E. coli, B. subtilis, E. faecalus and R. sphaeroides. hNQO1 hNQO2, rNQO1 and rNQO2 
are human and rat azoreductases. xaAzoR is an azoreductase from Xenophilus azovorans. 
ecMdaB, ecYieF and ecWrbA are NQOs from E. coli. afNQO, pnNQO, tmNQO, pcNQO 
and atNQO are NQOs from Archaeoglobus fulgidus, Paracoccus denitrificans, Triticum 
monococcum, Phanerochaete chrysosporium and A. thaliana respectively. ArsH is an 
azoreductase from Sinorhizobium meliloti. dgFlav and ecFlav are flavodoxins from 
Desulfovibrio gigas and E. coli respectively. shNQO, reNQO and erNQO are 
uncharacterised proteins from Staphylococcus haemolyticus, Ralstonia eutropha and 
Erwinia chrysanthemi. Figure is from Ryan et al. (2014). 
 
 
 
  
Table 1.2 Azoreductases and azoreductase-like genes implicated in bacterial physiological functions  
Overview of the azoreductase and azoreductase-like genes and their associations in various bacterial phenotypes.  
Physiological 
function 
Gene(s) Bacteria Observed phenotype 
Plant colonisation ecazoR, seazoR E. coli, S. enterica 
Upregulation during E. coli growth on radish sprouts and butterhead lettuce 
(Landstorfer et al., 2014, Van der Linden et al., 2016), overexpression during S. 
enterica colonisation of lettuce and coriander (Goudeau et al., 2013) 
Mammalian 
colonisation 
pa0785, pa1962, 
pa3223, pa2280, 
pa2580, pa1204, 
pa4975, ypwrbA 
P. aeruginosa, Y. 
pseudotuberculosis 
Δpa0785 strains fail to survive in murine lung (Rakhimova et al., 2008), 
Δpa2280, Δpa2580 and Δpa1204 fail to colonise mouse GI tract or disseminate to 
spleen, Δpa1962 colonises GI tract and disseminates at reduced rate compared to 
the WT, Δpa3223 and Δpa4975 fail to spread to spleen from GI tract (Skurnik et 
al., 2013), ypwrbA mutants more easily cleared from murine spleen than WT 
(Avican et al., 2015) 
Virulence ypwrbA Y. pseudotuberculosis 
wrbA gene deletion mutants cause less severe disease in mouse than WT (Avican 
et al., 2015) 
Biofilm formation ecwrbA E. coli 
Target gene for biofilm regulator CsgD (Ogasawara et al., 2011) interacts with 
anti-biofilm compound Zosteric acid (Cattò et al., 2015) 
Quorum sensing pa2580 P. aeruginosa 
Significantly upregulated upon treatment with QS inhibitor Iberin (Tan et al., 
2014) 
Defence against 
electrophilic 
quinones 
ecazoR E.coli 
Treatment with catechol, menadione and 2-methylhydroquinone results in 
significant upregulation of azoR and impaired growth of azoR gene deletion 
strains compared to WT (Liu et al., 2009)  
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1.3 Aims 
The prevalence and severity of P. aeruginosa infections constitutes a major health concern 
for immunocompromised individuals, particularly sufferers of CF. With MDR strains 
continuing to emerge, a comprehensive understanding of the complex P. aeruginosa 
genome would be crucial in developing insights to bacterial pathogenesis and antibiotic 
resistance.  
Numerous studies have demonstrated evidence for the possible role of P. aeruginosa 
azoreductases and NQOs in host infection and antibiotic resistance processes. The 
identification of new azoreductases and NQOs and a development towards understanding 
their molecular and physiological roles is therefore a crucial step towards combatting this 
pathogen. 
The aims of this study are: 
1. Cloning of putative P. aeruginosa PAO1 azoreductase and NQO genes 
2. Production and purification of suspected P. aeruginosa PAO1 azoreductase and 
NQO enzymes as recombinant proteins 
3. Biochemical and enzymatic analyses of proposed P. aeruginosa PAO1 
azoreductase and NQO recombinant proteins 
4. Structural determination and analysis of P. aeruginosa PAO1 azoreductase and 
NQO, PA2580 
5. Analysis of P. aeruginosa PAO1 antibiotic resistance using azoreductase and NQO 
single gene transposon mutants and corresponding complemented strains 
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 Materials and methods Chapter 2
 
2.1 Chemicals and reagents 
All chemicals and reagents including oligonucleotide primers used in this study were 
obtained from Sigma-Aldrich unless otherwise stated. DNA and RNA extraction and 
purification kits were supplied by Qiagen and restriction enzymes were purchased from 
New England Biolabs (NEB). 
 
2.2 Bacterial strains and growth conditions 
P. aeruginosa PAO1 was kindly provided by Dr. Gail Preston, Department of Plant 
Sciences, University of Oxford. The single gene transposon mutants of P. aeruginosa 
PAO1 were provided by the Manoil laboratory, University of Washington (Jacobs et al., 
2003). E. coli JM109 and BL21 were supplied by Agilent. P. aeruginosa TBCF 10839 
strains were kindly provided by Prof. Burkhard Tümmler, Hannover Medical School 
(Rakhimova et al., 2008). Details of all bacterial strains used are displayed in Table 2.1. 
Growth medium was prepared in accordance with the manufacturer’s instructions and 
sterilised, by standard sterilisation conditions, for 15 minutes at 121°C. Where necessary, 
antibiotics were filter sterilised through a 0.22 µm filter and added following the media 
sterilisation process. Bacterial cultures were routinely grown overnight at 37°C in 
Lysogeny broth (LB) liquid medium or on LB agar plates with additional supplements 
added where needed, as shown in Table 2.2. Liquid cultures were grown with gentle 
shaking at 120 RPM. P. aeruginosa PAO1 transposon mutants and E. coli JM109 
containing the pUCP24 plasmids were cultured in 10 µg/mL gentamicin. For selection of 
E. coli strains transformed with pET-28b 30 µg/mL kanamycin was added. 
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Table 2.1 Details of P. aeruginosa and E. coli strains  
Bacterial strains used in this study including their mutated genes are listed below. P. 
aeruginosa PAO1 and the transposon insertion mutants were provided by The Manoil lab 
at the University of Washington (UW), P. aeruginosa TBCF 10839 strains were supplied 
by Prof. Burkhard Tümmler, MH Hannover (MHH), E.coli JM109 was sourced from 
Promega and the E. coli BL21 strains were received from Agilent. 
Strain Mutation Plasmid Source 
P. aeruginosa PAO1 - - UW 
P. aeruginosa PAO1 pa0785 - UW 
P. aeruginosa PAO1 pa1962 - UW 
P. aeruginosa PAO1 pa3223 - UW 
P. aeruginosa PAO1 pa2280 - UW 
P. aeruginosa PAO1 pa2580 - UW 
P. aeruginosa PAO1 pa1204 - UW 
P. aeruginosa PAO1 pa0949 - UW 
P. aeruginosa PAO1 pa4975 - UW 
P. aeruginosa TBCF10839 - - MHH 
P. aeruginosa TBCF10839 pa0785 - MHH 
P. aeruginosa TBCF10839 pa0785 pUCP20::pa0785 MHH 
P. aeruginosa TBCF10839 pa0785 pUCP20::pa0785-0787 MHH 
E. coli JM109 - - Agilent 
E. coli BL21(DE3) - - Agilent 
E. coli BL21-CodonPlus(DE3)-RP - - Agilent 
 
 
Table 2.2 Media used in this study  
Table showing the media used in this study including components and concentrations. 
Medium Components  Concentration (g/L) 
Lysogeny broth 
Trypone 
NaCl 
Yeast extract 
10 
10 
5 
Lysogeny broth Agar 
Trypone 
NaCl 
Yeast extract 
Bacto agar 
10 
10 
5 
15 
Mueller Hinton Broth 
Beef infusion solids 
Casein hydrolysate 
Starch 
2 
17.5 
1.5 
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2.3 Cloning of putative azoreductase genes 
2.3.1 Genomic DNA extraction 
Wild type P. aeruginosa PAO1 was grown overnight in 5 mL liquid culture as previously 
described (section 2.2). Total genomic DNA was extracted using Gentra Puregene 
Yeast/Bact. Kit following the supplier’s protocol. Quantitive and qualitive analysis was 
carried out on the extracted DNA using NanoVue 
TM
 Plus spectrophotometers (VWR).  
2.3.2 Agarose gel analysis of DNA samples 
Except where otherwise stated, DNA samples were analysed on 1% w/v agarose gel 
(Fisher) in 1 × Tris/Borate/EDTA (TBE) buffer pH 8 (Table 2.3) and Sybr safe (Life 
Technologies). Gel loading dye (Table 2.3) was added to each DNA sample in a ratio of 
1:5. 5 µL DNA plus loading dye samples were added to agarose gel wells and 1 Kb Plus 
DNA ladder (PCRBIO) was used as a molecular weight marker. Agarose gels were run for 
45 minutes to one hour at 90 volts (BIO-RAD Power-Pac 300) in an electrophoresis flow 
chamber (Flowgen) using 1 × TBE as running buffer. Gels were visualised using 
Molecular Imager Gel Doc
TM
 XR+ (BIO-RAD) and molecular weights were always 
determined using the molecular weight analysis tool in ImageLab 5.2.1 (BIO-RAD).  
 
Table 2.3 Materials used for nucleic acid gel electrophoresis  
1 × TBE was used as a running buffer and to make the 1% w/v agarose gel. Gel loading 
dye was added to the DNA sample in a ratio of 1:5. 
Buffer Components Concentration 
1 × TBE 
Tris base 
Boric acid 
EDTA disodium salt 
HCl 
89 mM 
89 mM 
2.6 mM 
to pH 8 
Gel loading dye 
Glycerol 
Bromophenol blue 
ddH20 
30% v/v 
0.25% w/v 
69.75% v/v 
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2.3.3 Plasmid Extraction 
E. coli JM109 strains containing relevant plasmids were grown overnight in 5 mL LB 
containing appropriate antibiotics (Table 2.4). Plasmids were extracted from the overnight 
cultures using the QIAprep Spin Miniprep kit in accordance with the instructions provided 
by the manufacturer. Plasmid preps were quantified using a Nanovue 
TM
 Plus 
spectrophotometer.  
 
Table 2.4 Plasmids used in this study   
pET-28b was supplied by Novagen and transformed into E. coli strains JM109 and BL21 
for cloning and expression respectively. pUCP24, kindly provided by Dr. Gail Preston, 
Department of Plant Sciences Oxford University, was used to clone the azoreductase-like 
genes into each corresponding transposon insertion mutant (West et al., 1994).  
Plasmid Selectivity  Source 
pET-28b 30 µg/mL Kanamycin Novagen 
pUCP24 10 µg/mL Gentamicin Dr. Gail Preston (Oxford University) 
 
 
2.3.4 Putative azoreductase gene amplification for cloning into pET-28b 
Gene sequences for putative azoreductase genes pa1224 and pa1225 were obtained from 
the Pseudomonas Genome Database (Winsor et al., 2016). Gene-specific primers were 
designed for each of these genes (Table 2.5) and analysed for predicted melting 
temperatures and hairpin formation using Integrated DNA technologies Oligoanalyzer tool 
(Owczarzy et al., 2008). Primers were designed to amplify the specific gene sequence with 
the forward and reverse primers incorporating restriction sites NdeI and SacI respectively. 
Using these primers polymerase chain reaction (PCR) amplification was carried out on P. 
aeruginosa PAO1 genomic DNA using Hotstar HiFi DNA polymerase. The components 
used for each PCR reaction are listed in Table 2.6. The conditions used for thermal cycling 
are displayed in Table 2.7. All PCR products were analysed on 1% w/v agarose gel stained 
with Sybr safe as described in section 2.3.2. 
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Table 2.5 Primers used for the cloning process of azoreductase-like genes pa1224 and 
pa1225 from P. aeruginosa PAO1   
Table showing the forward (fwd) and reverse (rev) primers used for the amplification of 
putative azoreductase genes pa1224 and pa1225. Primers were designed to include 
restriction sites for NdeI and SacI which are underlined. 
Primer Sequence 
Annealing 
Temp. 
pa1224 fwd CCGGAGACCCCATATGAACGTACTCATCGTCTATGCCC 
60°C 
pa1224 rev GCCGCTGGAGGCCTGAGCTCCGGGGTCATTCGGCC 
pa1225 fwd CGGAGGAATTCGCATATGCATGCCCTGATCGTCGTCGC 
60°C 
pa1225 rev CCTGGCCGAATGAGCTCGGGGGTCACGCCTCCAGC 
  
 
Table 2.6 PCR reaction mix for PCR using HotStar HiFi DNA polymerase 
PCR reaction mix components including their quantities and concentrations are listed 
below. 
Component Volume (µL) Concentration 
Genomic DNA 1 ~100 ng 
Forward Primer 5 1 µM 
Reverse Primer 5 1 µM 
HotStar HiFi DNA polymerase 1 - 
HotStar HiFi buffer 5× 10 1× 
Q-solution 5× 10 1× 
RNase-free H2O 18 - 
 
 
Table 2.7 Thermocycling conditions for PCR using HotStar HiFi DNA polymerase  
Thermocycling conditions and the corresponding duration used with HotStar HiFi DNA 
polymerase are listed below. 
Step Temperature (°C) Time No. of cycles 
Denaturation 95 5 minutes 1 
Annealing 50-60 30 seconds 
35 Extension 72 1 minute 
Denaturation 95 30 seconds 
Annealing 50-60 30 seconds 1 
Extension 72 10 minutes 1 
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2.3.5 Putative azoreductase gene amplification for cloning into pUCP24 
Gene sequences for the azoreductase-like genes pa0785, pa1962, pa3223, pa2280, pa2580, 
pa1204, pa0949 and pa4975 were obtained from the Pseudomonas Genome Database 
(Winsor et al., 2016). Gene-specific primers were designed for each of these genes (Table 
2.8) using the methods laid out in section 2.3.4. Primers were designed to amplify the 
specific gene sequence with the forward and reverse primers incorporating restriction sites 
BamHI and SalI respectively. PCR amplification was carried out on P. aeruginosa PAO1 
genomic DNA as described in section 2.3.4. All PCR products were analysed on 1% w/v 
agarose gel stained with Sybr safe as described in section 2.3.2. 
 
Table 2.8 Primers used for the cloning process of azoreductase-like genes from P. 
aeruginosa PAO1 into pUCP24 vector   
Table showing the forward (fwd) and reverse (rev) primers used for the amplification of 
azoreductase-like genes pa0785, pa1962, pa3223, pa2280, pa2580, pa1204, pa0949 and 
pa4975. Primers were designed to include restriction sites BamHI and SalI which are 
underlined. 
Primer Sequence 
Annealing 
temp. 
pa0785 fwd CCAAGGGGATCCAGATGAGTAGAATTCTTGC 
55°C 
pa0785 rev CCAGGCGATGTCGACTCCTCAGGCC 
pa1962 fwd CCACACTGGGATCCCGCACTTTCAGG 
50°C 
pa1962 rev CCGGCCAGTCGACACGCAGC   
pa3223 fwd GCGCAGTGGATCCAGGTCGAGTCATGTCC 
55°C 
pa3223 rev GGAAGGGGGTCGACCGGGTGCTGC 
pa2280 fwd GGAGGATCCATGTCCGAACAACTACCC 
50°C 
pa2280 rev GCGAGTGAGGTCGACGCGGTTCAGAGCG 
pa2580 fwd GCATCTACGGATCCCCATGAAAAACATTCTCCTGC 
55°C 
pa2580 rev GGCCCGTCGACGAACTCAGCCGGC 
pa1204 fwd CGCACAACGAGGATCCCGGCATGAGCG 
55°C 
pa1204 rev GGCTCTCCGTCGACGAGGCATTCAACCG 
pa0949 fwd CCTGGGGATCCTCGCTTGAGCAGTCCC 
55°C 
pa0949 rev GCTGAGCGCCAGGGTCGACTGCAGCCACGC 
pa4975 fwd CCGGTCACCACGATTCGGATCCCACGATGAACG 
55°C 
pa4975 rev GGCCTGGCGCGCGTCGACCGGCTCAGC 
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2.3.6 Double endonuclease restriction digest 
All restriction digests were carried out using the mixtures laid out in Table 2.9 and 
incubated at 37°C for 2 hours followed by endonuclease denaturation at 65°C for 15 
minutes. The pET-28b plasmid was digested using restriction enzymes NdeI and SacI, the 
pUCP24 was digested with BamHI and SalI. Digested plasmids were observed on 1% w/v 
agarose gel stained with Sybr safe.  
 
Table 2.9 Restriction digest of vectors and inserts   
Listed below are the reaction mix components and volumes for (double) restriction digests 
of PCR products and plasmids. Cutsmart buffer was used with restriction enzymes NdeI 
and SacI. Buffer 3:1 was used with BamHI and SalI. 
Solution Concentration/Volume 
DNA 0.1-3 µg 
Restriction enzyme I 1 µL/ng DNA 
Restriction enzyme II 1 µL/ng DNA 
1:10 BSA 4 µL 
Buffer 4 µL 
RNase/DNase-free H2O To a final volume of 40 µL 
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2.3.7 Antarctic phosphatase digestion 
Linearised plasmids were treated with Antarctic phosphatase to dephosphorylate the 5’ 
phosphate group and enable ligation with the gene of interest. The reaction was carried out 
in 0.5 mL microcentrifuge tubes. Samples were prepared as described in Table 2.10 and 
incubated at 37°C for 2 hours followed by endonuclease denaturation at 65°C for 15 
minutes. 
 
Table 2.10 Antarctic phosphatase digestion components and concentrations  
Listed below are the reaction mix components and volumes for dephosphorylation of the 5’ 
end of the linearised plasmids. 
Solution Concentration/Volume 
DNA 0.1-3 µg 
Antarctic phophatase 1 µL/ng DNA 
Antarctic phosphatase 
buffer 10× 
4 µL 
RNase/DNase-free H2O To a final volume of 40 µL 
 
 
2.3.8 DNA purification 
PCR products were purified before and after endonuclease digestion using a MinElute PCR 
purification kit. Plasmid DNA was purified following both digestion steps using a 
QIAquick PCR purification kit. In both circumstances, procedures were carried out 
following the supplier’s instructions. Quantity and quality of purified samples were 
assessed using a Nanovue 
TM
 Plus spectrophotometer.  
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2.3.9 Ligation 
The following formula was used to determine the quantities of plasmid and insert to be 
used in the ligation reaction mixture: 
 
(𝑛𝑔 𝑜𝑓 𝑣𝑒𝑐𝑡𝑜𝑟) × (𝐾𝑏 𝑜𝑓 𝑖𝑛𝑠𝑒𝑟𝑡)
𝐾𝑏 𝑠𝑖𝑧𝑒 𝑜𝑓 𝑣𝑒𝑐𝑡𝑜𝑟 
 × 𝑚𝑜𝑙𝑎𝑟 𝑟𝑎𝑡𝑖𝑜 𝑜𝑓 
𝑖𝑛𝑠𝑒𝑟𝑡
𝑣𝑒𝑐𝑡𝑜𝑟  = 𝑛𝑔 𝑜𝑓 𝑖𝑛𝑠𝑒𝑟𝑡 
∗ With the molar ratio of insert over vector being 1: 3, 1: 1 and 3: 1 
Plasmid concentration was kept constant at 100 ng for each ligation reaction. Reaction 
volumes of 10 µL were used and included 1 µL T4 ligase (Promega) and 1 µL 10 × T4 
ligase buffer. A negative control where no insert was added to the mix was always 
included in the procedure to ensure that no plasmid self-ligation was occurring. Ligation 
reactions were incubated at 22°C for 3 hours.  
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2.3.10 Preparation of chemically competent E. coli 
Chemically competent E. coli JM109 and E. coli BL21(DE3) were prepared in accordance 
with a procedure kindly offered by Andrew Spiers (Department of Plant Sciences, 
University of Oxford). LB was inoculated with E. coli overnight culture and grown at 37˚C 
120 RPM to an OD600 of 0.6. Cells were harvested by centrifugation at 4,500 × g for 5 
minutes and resuspended in 1/10 initial volumes of ice-cold 50 mM CaCl2. Following 30 
minutes incubation on ice, cells were harvested again at 4,500 × g for 5 minutes. The cell 
pellet was resuspended in 0.05 volumes of cold 50 mM CaCl2 and incubated on ice 
overnight. Glycerol was added to a final concentration v/v of 10% and 200 µL aliquots 
were flash frozen in liquid nitrogen and stored at -80˚C.  
2.3.11 Preparation of chemically competent P. aeruginosa PAO1 wild type and 
transposon insertion mutants  
Chemically competent P. aeruginosa PAO1 were prepared as previously described 
(Chuanchuen et al., 2002). Briefly, 1 mL of overnight culture was added to a prechilled 
microcentrifuge tube and centrifuged for 30 seconds at 13,000 × g. Cells were resuspended 
in 1 mL cold 0.1 M MgCl2. Centrifugation was repeated as before and the cell pellet was 
resuspended in 1 mL cold transformation salts comprising 75 mM CaCl2, 6 mM MgCl2 and 
15% v/v glycerol. Following an incubation of ten minutes on ice, centrifugation was 
repeated again and the cells were resuspended in 200 µL cold transformation salts. 
Competent cells were flash frozen in liquid nitrogen and stored at -80˚C. 
2.3.12 Heat shock transformation 
Plasmids were transformed into chemically competent cells using a previously described 
heat shock method (Froger and Hall, 2007). Briefly, 100 µL of competent cells were 
thawed on ice and added to 10 µL ligation mixture in a 1.5 mL microcentrifuge tube. This 
mixture was incubated on ice for 5 minutes before being plunged into a water bath at 42˚C 
for 45 seconds. Immediately the tube was returned to the ice and incubated for a further 5 
minutes after which 1 mL of LB was added and the mixture was incubated in a static 
incubator for 1 hour at 37˚C. A positive control of competent cells with undigested plasmid 
was always included in the protocol. When transforming a plasmid extraction instead of a 
ligation mixture, 2 µL of plasmid solution was used.   
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2.3.13 Selection of successful transformants 
Transformation mixtures were concentrated by centrifugation and spread onto LB agar 
containing appropriate antibiotics (Table 2.4). Untransformed competent cells were also 
spread onto antibiotic containing LB agar plates as a negative control. The plates were 
incubated overnight in a static incubator at 37˚C. Colonies were picked and used as a 
template for PCR analysis. Primers used in this analysis either annealed to the vector on 
either side of the insertion site (M13 primers for pUCP24 clones, Table 2.12) or were 
specific for a nucleotide sequence which overlapped plasmid and gene insert (Table 2.11). 
Colonies with the correct size of inserted DNA were grown in 5 mL LB containing suitable 
antibiotic for 6 hours before being concentrated in LB containing 10% v/v glycerol and 
flash frozen in liquid nitrogen for long term storage at -80˚C. 
 
Table 2.11 Primers used to screen for successful clones of azoreductase-like genes 
pa1224, pa1225 and pa4975  
Table showing the forward (fwd) and reverse (rev) primers used to check for the presence 
of pET-28b with the inserted gene. The primers were designed specifically to overlap a 
section which included parts of both the vector sequence and the gene sequence. Primers 
for CLpa4975 were designed by Dr. Vincenzo Crescente. 
Primer Sequence 
Annealing 
Temp. 
CLpa1224 
fwd 
GCCGCGCGACAGCCATATGAACGTACTAATCG 
60°C 
CLpa1224 
rev 
GGCCGAATGACCCAGGACCTCCATCGACAAGCTTG
CGG 
CLpa1225 
fwd 
GCAGCCGCCATATGCATGCCCTGATCG 
60°C 
CLpa1225 
rev 
GCTTGTCGGCGGAGCTCGAGGGTCAGGCC 
CLpa4975 
fwd 
CGCGCGGCAGCCATATGAACGTACTGATCGTCC 
55°C 
CLpa4975 
rev 
CCGCAAGCTTGTCGACGGAGCTCAGCGCGCCAG 
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2.3.14 DNA sequence analysis 
Plasmid extraction was carried out on successful transformants using the method laid out 
in section 2.3.3. Plasmid solutions along with appropriate sequencing primers (Table 2.12) 
were sent to Eurofins MWG Operon for sequencing in the volumes and concentrations 
recommended by the company. The sequencing results were then compared with the 
azoreductase-like gene sequence from the Pseudomonas Genome Database using the 
ClustalW multiple alignment feature in Bioedit (Thompson et al., 1994, Hall, 1999).  
 
Table 2.12 Primers used for sequencing of positive clones  
Primers used to sequence the azoreductase-like genes cloned. pET-28b seq primers were 
used to sequence pa1224 and pa1225 in the pET-28b vector. M13 primers were used to 
sequence the azoreductase-like genes in pUCP24. 
Primer Sequence 
pET-28b seq fwd CATCATCACAGCAGCGGCCTGGTGC 
pET-28b seq rev GGCTTTGTTAGCAGCCGGATCTCAGTGG 
M13 fwd GTAAAACGACGGCCAGT 
M13 rev CAGGAAACAGCTATGAC 
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2.4 Gene expression and production of recombinant protein 
For recombinant protein expression, the pET-28b plasmids containing putative 
azoreductases pa1224, pa1225, pa2580 and pa4975 were extracted from E. coli JM109 
and transformed into E. coli BL21 strains via the heat shock method. Successful 
transformants were screened using PCR as previously described (section 2.3.13).   
2.4.1 Expression of putative azoreductase genes 
Overexpression of recombinant protein was carried out following a method adapted from 
Wang et al. (2007). A starter culture of E. coli BL21(DE3) containing pET-28b and the 
gene to be expressed was grown overnight in LB supplemented with 30 µg/mL kanamycin. 
Fernbach flasks containing LB supplemented with 1 M sorbitol, 2.5 mM betaine and 30 
µg/mL kanamycin were inoculated with 1% v/v overnight culture and grown at 37˚C 120 
RPM until bacteria reached the exponential phase (OD600 of 0.4-0.6). As standard, 50 mL 
cultures in 200 mL flasks were used for expression (small scale), however where 
appropriate this was scaled up to 500 mL cultures in 2 L flasks (large scale). To induce 
protein expression, 0.1-0.5 mM isopropyl-β-D-thiogalactopyranoside (IPTG) was added 
and the cultures were incubated at 16˚C 120 RPM for 16 hours. After this expression 
period, cultures were centrifuged at 4,500 × g for 20 minutes at 4˚C. The supernatant was 
discarded and the cells were resuspended in an enzymatic lysis buffer (20 mM Tris HCl, 
100 mM NaCl, 1 EDTA-free protease inhibitor tablet (Roche), 0.02 mg/ml DNase and 0.2 
mg/ml lysozyme, pH 8). The amount of lysis buffer added was always 2% v/v of the initial 
culture volume. Samples underwent 4 freeze/thaw cycles using liquid nitrogen and a 37˚C 
static incubator. For large scale protein preparations an extra lysis step was added at this 
point where samples on ice were sonicated using a MSE Soniprep 150 for 30 cycles - 45 
seconds on, 30 seconds off. The cell lysate was then centrifuged at 16,000 × g for 20 
minutes at 4˚C to separate the soluble and insoluble protein fractions (the supernatant and 
the pellet respectively). Prior to this step, a whole cell lysate sample was taken and set 
aside for later analysis. The supernatant was collected and stored on ice. To enable a direct 
comparison to be drawn between fractions the pellet was resuspended in 20 mM Tris HCl 
100 mM NaCl pH 8 to the same volume that was used for the lysis buffer. The whole cell 
lysate, along with samples from the soluble and insoluble fractions were analysed on SDS-
PAGE. For every procedure of recombinant protein production carried out, E. coli BL21 
transformed with empty pET-28b was included in the preparation as a negative control.  
31 
 
2.4.2 SDS-PAGE analysis of recombinant proteins 
Except where otherwise stated, all protein samples at each purification stage were analysed 
by SDS-PAGE. The gels consisted of a 12% w/v acrylamide resolving gel and a 6% w/v 
acrylamide stacking gel. Gels were run in a MiniProtean Tetra system (BIO-RAD) with a 
SDS running buffer (National Diagnostics). Protein samples were prepared by adding a 
loading dye in a ratio of 1:3 (Table 2.13). Sample mixes were then denatured for 5 minutes 
at 95˚C to avoid the protein structure affecting the molecular weight determination. 12 µL 
of protein sample was always loaded into each well. Except where otherwise stated, ECL 
Full-range Rainbow Molecular weight marker (Amersham) was used as the molecular 
weight marker. Electrophoresis was carried out by applying 180 V for 45 to 60 minutes 
(BIO-RAD Power Pak 300). Gels were stained for 30 minutes in a Coomassie Blue stain 
solution (Table 2.13) followed by destaining with 10% v/v ethanol, 10% v/v acetic acid for 
a further 12 hours. Staining and destaining were carried out at room temperature with 90 
RPM gentle shaking. Gels were visualised and captured using Molecular Imager Gel 
Doc
TM
 XR+ (BIO-RAD) and molecular weights were determined using the molecular 
weight analysis tool in ImageLab 5.2.1 (BIO-RAD). Quantification of protein bands was 
calculated using the volume analysis tool in ImageLab 5.2.1 (BIORAD). 
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Table 2.13 Materials used for SDS-PAGE  
12% SDS-PAGE was used to analyse protein samples. Gel loading dye was added to the 
protein solution in a 1:3 ratio. 
Material Components Concentration 
Resolving gel 
Acrylamide:bis acrylamide (29:1) 
SDS 
Ammonium persulphate 
Tetramethylethylenediamine (TEMED) 
Tris HCl 
12% v/v 
0.125% w/v 
0.05% w/v 
0.002% v/v 
390 mM 
Stacking gel 
Acrylamide:bis acrylamide (29:1) 
SDS 
Ammonium persulphate 
TEMED 
Tris HCl 
6% v/v 
0.125% w/v 
0.05% w/v 
0.002% v/v 
116.6 mM 
Gel loading dye 
Sucrose 
Bromophenol blue 
Dithiothreitol (DTT) 
40% w/v 
0.25% w/v 
5 mg/mL 
SDS running buffer 
Tris 
Glycine 
SDS 
0.25 M 
1.95 M 
1% w/v 
Staining solution 
Coomassie brilliant blue 
Ethanol 
Acetic acid 
H20 
0.0024% w/v 
50% v/v 
10% v/v 
40% v/v 
Destaining solution 
Ethanol 
Acetic Acid 
H20 
10% v/v 
10% v/v 
80% v/v 
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2.5 Purification and quantification of recombinant protein 
2.5.1 Immobilised Metal-ion Affinity Chromatography 
Purification of the recombinant putative azoreductase proteins was carried out using the 
immobilised metal-ion affinity chromatography (IMAC) method. Ni-NTA agarose mix 
was purchased from Invitrogen and was used to bind the hexahistidine residues present on 
each recombinant protein. According to the manufacturer’s instructions, 1 mL of resin 
binds ~10 mg protein therefore 4 mL of Ni-NTA beads suspended as a 50% slurry in 20% 
v/v ethanol was loaded into a 10 mL IMAC column (BIO-RAD). The beads were left to 
settle on the porous polymer support at the bottom of the column and the ethanol was 
slowly removed. The beads were washed twice with 5 mL 20mM Tris HCl 100 mM NaCl 
pH 8 to remove any residual ethanol. The soluble fraction was then added to the column 
and mixed with the beads by inverting the tube numerous times. The liquid phase was 
removed by allowing the beads to settle and applying gentle pressure to the column with 
the aid of a syringe and halting the process as soon as the solution reached 1 mm above the 
beads. This fraction was collected as flow through and where a particularly high yield of 
protein was obtained, it could be reapplied to the column at a later stage. Increasing 
concentrations of imidazole (0 mM, 10 mM, 25 mM, 50 mM, 100 mM and 250 mM) were 
prepared in 20 mM Tris HCl 100 mM NaCl pH 8 and used to elute the protein. All elutions 
were collected and analysed via SDS-PAGE.  
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2.5.2 Dialysis 
The fractions containing recombinant protein were carefully inserted into dialysis tubing - 
a porous membrane with a molecular weight cut-off point of 12-14 kDa (SPECTRUM®, 
Spectrum Laboratories Inc.). The dialysis tubing was then sealed and placed into 4 L of 
dialysis buffer (20 mM Tris HCl 100 mM NaCl pH 8) and stored overnight at 4˚C with 
gentle magnetic stirring. This process was carried out to remove any excess imidazole from 
the protein solutions.   
2.5.3 Protein quantification and concentration 
Protein concentration of the purified sample was determined using the Beer -Lambert law, 
A=ƐCL, where A is the absorbance, Ɛ is the extinction coefficient, C is the protein 
concentration and L is the light path length in cm. The Ɛ value was calculated for each 
protein by inputting the full amino acid sequence for the protein in question along with the 
hexahistidine tag residues into the online tool, ExPASy ProtParam (Gasteiger et al., 2005). 
The absorbance of the purified protein was read at 280 nm using a biophotometer 
(Eppendorf) and this value along with the Ɛ value and the light path length (constant at 1 
cm) were used to determine the protein concentration in mg/mL. As standard, all proteins 
were concentrated to either 1 or 2 mg/mL using a Sartorius ultracentrifugation concentrator 
with a cut-off of 10 kDa. For long term storage 5% v/v glycerol was added to protein 
solutions before they were flash frozen in liquid nitrogen and stored at -80˚C. 
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2.6 Characterisation of putative azoreductases from P. aeruginosa PAO1 
2.6.1 Thin Layer Chromatography 
Thin layer chromatography (TLC) was carried out to determine the flavin specificity for 
PA1224 and PA1225. The method used was adapted from that previously described (Liu et 
al., 2008). A mobile solvent comprising of N-butanol, acetic acid and H2O in a 2:1:1 ratio 
was used with 0.1 mm thick silica gel-coated aluminium plates. The optimum 
concentration of flavin for TLC was found by testing a range of concentrations comprising 
of 20 mM, 10 mM, 5 mM, 1 mM and 0.5 mM pure FMN and FAD. Proteins were 
concentrated to 20 mg/mL using the method described in section 2.5.3. The TLC plate was 
spotted with 1 µL protein and 1 µL flavin and placed in a sealed beaker containing the 
mobile solvent. The procedure was stopped when the solvent reached 1 cm from the top of 
the TLC plate. The retention factor (Rf) of each protein was compared to the Rf of FAD 
and FMN and was calculated using the formula below: 
 R𝑓 =
𝑑𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑡𝑟𝑎𝑣𝑒𝑙𝑙𝑒𝑑 𝑏𝑦 𝑡ℎ𝑒 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑
𝑑𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑡𝑟𝑎𝑣𝑒𝑙𝑙𝑒𝑑 𝑏𝑦 𝑡ℎ𝑒 𝑠𝑜𝑙𝑣𝑒𝑛𝑡
 
 
2.6.2 Differential Scanning Fluorimetry 
Differential scanning fluormetry (DSF) was carried out using a modified method from that 
described in Niesen et al. (2007). Putative azoreductase proteins were diluted to 64 µg/mL 
in 20 mM Tris HCl 100 mM NaCl pH 8 containing 5 × Sypro Orange (Invitrogen). 
Fluorescence was measured using an Mx3005p qRT-PCR instrument (Stratagene) with the 
temperature increased from 25˚C to 95˚C at a rate of 1˚C/minute. Data analysis was 
completed in Graphpad Prism (version 7) with fitting to a Boltzman sigmoidal function. 
DSF was also carried out with 1-20 µM FMN and FAD added to the mix.  
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2.6.3 Spectral properties of putative azoreductases and determination of 
flavin saturation level 
Samples of purified PA2280, PA2580, PA1204, PA0949, PA1224 and PA1225 were 
diluted in 20 mM Tris HCl 100 mM NaCl pH 8 to a concentration of 400 µg/mL and added 
to a synthetic far-UV quartz cuvette (Hellma Worldwide). An absorbance scan was carried 
out on each protein using an Infinite M200 PRO plate reader (TECAN) and spectra were 
recorded across the wavelength of 250 nm to 600 nm. Pure stocks of 20 µM FMN and 
FAD were measured at 450 nm and 445 nm respectively. The molecular ratio of protein to 
flavin was then determined by comparing the OD450 or OD445 value of the protein to that of 
the 20 µM flavin stock.  
2.6.4 Absorption spectra of substrates and calculation of molar extinction 
coefficients 
The absorption spectra of NADH, NADPH, the azo compounds and the quinone 
compounds were generated by adding 100 µL of substrate (500 µM for NAD(P)H in 20 
mM Tris HCl 100 mM NaCl, 100 µM for azo/quinone compounds in DMSO) to a 96-well 
Nunclon flat transparent plate and taking absorbance readings at 5 nm intervals between 
300 nm and 700 nm. The maximum wavelengths (λmax) for each compound were used to 
calculate the molar extinction coefficient (Ɛ). This was done by dispensing 100 µL of 
decreasing concentrations of compound into a 96-well plate (500-0 µM for NAD(P)H, 
100-0 µM for azo compounds) and reading absorbance at their λmax. Linear regression 
analysis was performed on the values using Microsoft Excel to determine the Ɛ value for 
each compound.  
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2.6.5 Enzymatic activity assays for the putative azoreductases 
The activities of the recombinant putative azoreductases were characterised by carrying out 
enzymatic assays against a range of substrates, predominantly azo and quinone compounds 
(Table 2.14). A series of assays were completed initially where different combinations of 
NAD(P)H, FMN and FAD were used and the reduction rates compared to determine the 
flavin and nicotinamide selectivity. Flavin selectivity was also decided by TLC and DSF 
analysis (as referred to in sections 2.6.1 and 2.6.2 respectively). This information was then 
used to carry out assays using a range of azo and quinone substrates where the optimum 
cofactor (where necessary) was included and the appropriate nicotinamide was used as an 
electron donor. All enzyme assays were carried out in Nunclon 96-well flat transparent 
plates in 100 µL volumes. The components of the reaction mixtures are listed in Table 
2.15. Varying concentrations of enzyme (in 10 µL volumes) were added to the plate in 
triplicate (0-20 µg for azo substrates, 0-10 µg for quinones) and the reaction was initiated 
by the addition of 90 µL master mix comprising of all the other reaction components. 
Absorbance readings were taken every 10 seconds for 10 minutes using the Infinite M200 
PRO plate reader. Absorbance readings were taken at the λmax for each azo compound to 
monitor azo reduction. For quinone substrates, readings were taken at the λmax for 
NAD(P)H to observe NAD(P)H oxidation. Given one molecule of NAD(P)H is used to 
reduce one molecule of quinone, this could be used to determine the rate of quinone 
reduction. In order to calculate reduction rates, linear regression analysis was performed in 
Microsoft Excel over the time period for which the reaction was linear (usually within the 
first 150 seconds). This was then divided by the Ɛ value followed by the amount of protein 
used in the reaction (in mg/mL). This method gave the rate in µM of substrate reduced per 
second per mg of protein (µM ∙s-1 ∙mg-1). 
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Table 2.14 Substrates used for the characterisation of the P. aeruginosa putative 
azoreductase proteins   
Table showing the substrates used for the enzymatic characterisation of the putative 
azoreductases. A: azo compound; Q: Quinone. Structures of these substrates are listed in 
APPENDIX I and APPENDIX II.  
Name/Abbreviation Compound Class 
Amaranth 
1-(4-sulfo-1-napthylazo)-2-naphthol-3, 6-disulfonic acid 
trisodium salt 
A 
Balsalazide 
5-[4-(2-Carboxyethylcarbamoyl)phenylazo]salicylic acid 
disodium salt 
A 
Methyl red 2-(4-Dimethylaminophenylazo)benzoic acid A 
Olsalazine 3, 3-azobis(6-hydroxybenzoate)salicylic acid A 
Orange G 1-Phenylazo-2naphthol-6,8-disulfonic acid disodium salt A 
Orange II 
4-[(2-Hydroxy-1-napthalenyl)azo]benzenesulfonic acid 
monosodium salt 
A 
Ponceau BS 
Disodium 2-[(2-hydroxy-1-naphthyl)azo]-5-(4-
sulfonatophenyl)azo-benzenesulfonate 
A 
Ponceau S 
3-Hydroxy-4-(2-sulfo-4-[4-sulfophenylazo]phenylazo)-2, 
7-naphthalenedisulfonic acid sodium salt 
A 
Sudan I 1-Phenylazo-2-naphthol A 
Sulfasalazine 
6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl] 
hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid 
A 
Tropaeolin 4-([2,4-Dihydroxyphenyl]azo)benzenesulfonic acid A 
ANI N, N-dimethylindoaniline Q 
AQS Sodium anthraquinone–2 –sulfonic acid Q 
BZQ 1, 4-benzoquinone Q 
DCB 2, 5–dichloro-1, 4-benzoquinone Q 
HNQ 5–hydroxy–1, 4–napthoquinone Q 
IBC 2, 6–dichloroquinone-4-chloroimide Q 
LAW 2–hydroxy–1, 4-napthoquinone Q 
MEN 2–methyl–1, 4-napthoquinone Q 
ONO 1, 2-napthoquinone Q 
PLU 5–hydroxyl–2–methyl–1, 4-napthoquinone Q 
UQO Coenzyme Q10 Q 
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Table 2.15 Reaction mix used for the enzymatic assays   
Reaction components and concentrations for characterisation of putative azoreductases, 
including NAD(P)H and flavin determination and generation of substrate specificity 
profiles. 
Component Volume (µL) Concentration 
Enzyme 10 0-20 µg 
Substrate 5 100 µM 
NAD(P)H 5 500 µM 
Flavin (where necessary) 5 1 µM 
20 mM Tris HCl 100 mM NaCl pH 8 To a final volume of 100 µL - 
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2.7 Crystallisation of PA2580 and x-ray diffraction data collection 
2.7.1 Synthesis of H2NADPH 
The ultra-pure 1,4,5,6-tetrahydro analogue of NADPH, H2NADPH, was synthesised by Dr. 
Onur Atasoylu (University of East Anglia) and purified by Dr. Chris Morris (University of 
East Anglia). The compound was prepared as previously described (Bhakta, 2007). 
2.7.2 Crystallisation of PA2580 with H2NADPH  
To remove NaCl, pure recombinant PA2580 was washed with 20 mM Tris HCl pH 8 using 
a Sartorius ultracentrifugation concentrator with a cut-off of 10 kDa. The protein was 
resuspended to a final concentration of 10 mg/mL in 20 mM Tris HCl 500 µM FMN 2 mM 
H2NADPH. Crystals were grown at 22°C (room temperature) by the sitting drop vapour 
diffusion method. Equal volumes (0.2 µL) of protein solution were mixed in sitting drop 
format with the appropriate precipitation buffer using a Mosquito crystallisation robot 
(TTP Labtech). The screening conditions trialled were PACT premier, JCSG-plus and 
Morpheus (Molecular Dimensions).  
2.7.3 Optimisation of crystallisation conditions for PA2580 
Larger scale crystal trials were laid down for Morpheus screen conditions B6 (0.09 M 
Halogens, 0.1 M Sodium HEPES, 0.1 M MOPS, 20% v/v ethylene glycol, 10% w/v 
polyethylene glycol (PEG) 8000 pH 7.5) and F10 (0.12 M Monosaccharides, 0.1 M Bicine, 
0.1 M Tris, 20% v/v ethylene glycol, 10% w/v PEG 8000 pH 8.5) (Gorrec, 2009) by 
mixing equal volumes (2 µL) of protein solution (containing 2 mM H2NADPH) with the 
suitable buffer in MRC maxi plates (Molecular Dimensions). Following crystallisation, 
some crystals were soaked overnight in 4 µL 10 mM H2NADPH. All of these were carried 
out using the sitting drop vapour diffusion method at 23°C.  
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2.7.4 X-ray diffraction data collection and analysis 
Crystals were mounted with a CryoMount mesh set (Molecular Dimensions) and flash 
frozen in liquid nitrogen. It is important to note that it was not necessary to add 
cryoprotectant to the crystals prior to freezing as the Morpheus screening conditions B6 
and F10 contain 20% ethylene glycol and 10% w/v PEG 8000 which will serve this 
function (Gorrec, 2009). All x-ray diffraction data was kindly collected by Dr. Edward 
Lowe (Oxford University). Data for PA2580 was gathered on beamline I03 at Diamond 
light source using a Pilatus 6M detector. Data from PA2580-H2NADPH was generated on 
beamline ID23-2 at the ESRF using a Pilatus 2M detector. Data was processed in xia2 
(Winter, 2010) using XDS (Kabsch, 2010) and XSCALE. The 1.29 Å structure of PA2580 
was solved using the molecular replacement software PHASER (McCoy et al., 2007). 
MdaB from E. coli (59.4% sequence identity to PA2580) and MdaB from Yersinia pestis 
(51.8% sequence identity to PA2580), PCSB PDB accession codes 2B3D and 3RPE 
respectively, were used as templates for molecular replacement for the PA2580 model. The 
atomic model was built and refined with Coot (Emsley et al., 2010) against the electron 
density map. Further refinement was performed in PHENIX (Adams et al., 2010). FAD 
model was added with Coot (Emsley et al., 2010) as were water molecules.  
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2.8 Phenotypic characterisation of P. aeruginosa strains 
2.8.1 Confirmation of transposon insertion in P. aeruginosa PAO1 gene 
deletion strains 
To ensure the presence of the transposon and the subsequent mutation of the azoreductase 
and azoreductase-like genes, PCR amplification was carried out using the primers listed in 
Table 2.16. All primers were gene-specific and overlapped part of the coding and non-
coding sequence of the gene. Primers were designed by Dr. Vincenzo Crescente (Kingston 
University) using the same method as laid out in section 2.3.4 with the exceptions of the 
primers for pa0785, pa1962 and pa3223 which were designed by Wang and colleagues as 
described in Wang et al. (2007). PCR was carried out using the Hotstar HiFi DNA 
polymerase kit as described in section 2.3.4 with an annealing temperature of 55°C used 
for each reaction. The transposon mutants have the ISphoA/hah (5 kb) or ISlacZ/hah (6.7 
kb) inserted within the coding region of the mutated gene. The azoreductase-like genes, 
pa0785, pa1962, pa3223, pa2280, pa2580, pa1204, pa0949 and pa4975, are all less than 
800 bp in size. Hotstar HiFi DNA polymerase amplifies DNA at a rate of 1 Kb per minute; 
therefore an extension time of one minute was used. This would allow any of the 
azoreductase-like genes in their wild type state to amplify in this time while the transposon 
containing genes would be too large. PCR products were analysed on 1% w/v agarose gel 
as described in section 2.3.2. 
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Table 2.16 Gene-specific primers used to confirm the transposon insertion in the 
azoreductase-like genes   
Primers were designed to overlap the coding and non-coding sequence for each gene. An 
annealing temperature of 55°C was used for each of these primers. Primers for pa0785, 
pa1962, pa3223 were designed by Dr. Chan Ju Wang (Wang et al., 2007), all other primers 
listed were designed by Dr. Vincenzo Crescente (Kingston University). 
Primer Sequence 
pa0785 KO fwd CATTCGAGTCTAGCCGAATCCAAGGAG 
pa0785 KO rev CACCAGCAGATGGAACCAAGGCCATG 
pa1962 KO fwd GATGCAAACCACTCGATCGCCAACCACTG 
pa1962 KO rev GATGCAAACCACTCGATCGCCAACACTG 
pa3223 KO fwd GATACATATGTCCCGTGTCCTGGTTATCG 
pa3223 KO rev CCCGGCCGTCACACCGCAACCAT 
pa2280 KO fwd CCGGAGGACATATGTCCGAACAACTACCCAACCTCG 
pa2280 KO rev GGCGGACGGAGCTCAGAGCGAACGCTGGGTCGACCC 
pa2580 KO fwd CCAGCATGTACGGAACCATATGAAAATCATTCTCCTGC 
pa2580 KO rev GGCCCGAGCTCGAACTCAGCCGGCGCG 
pa1204 KO fwd CGAGGAGCACCATATGAGCGACGACATCAAGGTATTG 
pa1204 KO rev CATGTTCGAGCTCTCCGGTGACGAGGCATTCAAC 
pa0949 KO fwd GAGTCCTGGAGATCCTCATATGAGCAGTCCCTACATCCTG 
pa0949 KO rev GTGAGCTCTTGCGGGCCATTTCAACTCCCCAGCTTG 
pa4975 KO fwd CGGAAACCCATATGAACGTACTGATCGTCCACGC 
pa4975 KO rev CACCGAGCTCAGCGCGCCAGCGGCTGG 
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2.8.2 RNA extraction and cDNA synthesis from P. aeruginosa PAO1, the 
azoreductase-like gene deletion strains and the complemented strains 
RNA was extracted from overnight cultures of all the gene deletion mutant strains of P. 
aeruginosa PAO1 and their equivalent complemented strain. Of each culture, 0.5 mL (~3.5 
× 108 CFU) was treated with RNA protect bacteria reagent (Qiagen) prior to RNA 
extraction using the RNeasy Mini kit. On column DNase digestion was performed using 
the RNase-free DNase set (Qiagen). Purified RNA samples were visually analysed via 
agarose gel electrophoresis and quantified using a Nanovue 
TM
 plus spectrophotometer as 
described in sections 2.3.2 and 2.3.8. cDNA was synthesised from 1 µg of RNA using the 
QuantiTect kit (Qiagen).  
2.8.3 Detection of gene expression in P. aeruginosa PAO1 strains 
PCR was carried out on the synthesised cDNA using the protocol described in section 
2.3.4. Gene-specific primers were designed to amplify within the coding region as per the 
method in section 2.3.4 and are listed in Table 2.17. Primers specific for the house keeping 
gene rpoD were used as a positive control. PCR products were analysed by agarose gel 
electrophoresis as described in section 2.3.2. 
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Table 2.17 Internal gene-specific primers used to check for gene expression   
Primers listed below were designed to amplify the sequence between the first and last 
100bp of the appropriate gene. cDNA synthesised from extracted RNA was used as the  
DNA template. rpoD primers represented the positive control. An annealing temperature of 
55°C was used with these primers. 
Primer Sequence 
pa0785 exp fwd GAGTAGAATTCTTGCAGTGCATGCCAG 
pa0785 exp rev CCTCGAAGGACCTGCCGCCGGATTCCTCGCC 
pa1962 exp fwd CGCCTCCGCTTCCCGCCAACTGAGCG 
pa1962 exp rev GCGAACTGCCCGGCGATCTGC 
pa3223 exp fwd CCCGTGTCCTGGTTATCGAGAGCAGTGCC 
pa3223 exp rev GTTGGCAGAGGGACGCAAAGGGA 
pa2280 exp fwd CCGAACAACTACCCAACCTCGATCCC 
pa2280 exp rev GCGGTCCACCAGGAAGTCCGTGCGC 
pa2580 exp fwd GCGGAAAGCGTTTCGCCCATTCCG 
pa2580 exp rev CGCGCCCGAACACCCTGTCCAGGTGC 
pa1204 exp fwd GCGACGACATCAAGGTATTGGGC 
pa1204 exp rev GGCGCACCCATAGCTGCAGGGCC 
pa0949 exp fwd CCCTACATCCTGGTGCTGTACTACAGTCGC 
pa0949 exp rev CGACACAGGGTCAGTTCGTGCTCATCGAGGC 
pa4975 exp fwd CGTCCACGCCCACAACGAACCGC 
pa4975 exp rev CGGCTGGAGCAGCGCGTCGAACTGC 
rpoD exp fwd GGGCGAAGAAGGAAATGGTC 
rpoD exp rev CAGGTGGCGTAGGTGGAGAA 
 
 
 
2.8.4 Growth analysis of P. aeruginosa PAO1 and P. aeruginosa TBCF 10839 
strains 
Overnight cultures of all P. aeruginosa strains were added in 5 µL volumes to 95 µL 
Mueller Hinton (MH) broth in Nunclon flat transparent 96-well plates. Each bacterial 
inoculation was standardised to a final OD600 of 0.02. Plates were sealed with sterile 
thermal adhesive sealing films (Thermo Scientific) and incubated at 37°C in the Infinite 
M200 PRO plate reader (TECAN) for 18 hours. OD600 was measured every 30 minutes 
with 5 seconds plate shaking before each absorbance reading.  
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2.8.5 Determination of Minimum Inhibitory Concentration (MIC)  
Doubling dilutions of fluoroquinolones (ciprofloxacin, levofloxacin, naladixic acid, 
sparfloxacin and prulifloxacin), a -lactam (ceftazidime), an aminoglycoside (amikacin) 
and a polymyxin (colistin) were prepared in MH broth to cover a 64 fold range of 
concentrations. Prior to this step the fluoroquinolones were first dissolved in 0.1 M HCl 
and all other antibiotics dissolved in sterile ddH2O. Overnight cultures of each P. 
aeruginosa strain were standardised to a final OD600 of 0.02 and added in triplicate to each 
concentration of antibiotic in Nunclon flat transparent 96-well microtitre plates to a final 
volume of 100 µL. MH broth containing no antibiotic was added to a sample of each strain 
as a positive control. Plates were sealed with sterile thermal adhesive sealing films 
(Thermo Scientific) and incubated in a static incubator at 37°C for 16 hours before OD600 
of each well was determined using a Tecan Infinate M200PRO plate reader. MIC was 
assumed to be the lowest concentration at which OD600 was <0.1. 
2.8.6 Determination of Colony Forming Units (CFU)/mL of P. aeruginosa 
PAO1 and P. aeruginosa TBCF 10839 strains 
Overnight cultures of P. aeruginosa PAO1 along with the transposon insertion mutants and 
those containing the pUCP24 vector were standardised in LB to an OD600 of 0.02. Serial 
dilutions were prepared in phosphate buffered saline (Oxoid) covering dilution factors of 
10
-1
, 10
-2
, 10
-3
, 10
-4
. 10
-5
, 10
-6
 and 10
-7
. In triplicate, 5 µL of each dilution was dropped 
onto LB agar and incubated overnight at 37°C. Drops containing 20-200 colonies were 
counted and the mean CFU/mL was determined using the following formula: 
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 ×  𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 ×  
1000
𝑣𝑜𝑙𝑢𝑚𝑒 𝑎𝑑𝑑𝑒𝑑 𝑡𝑜 𝐿𝐵
 =  𝐶𝐹𝑈/𝑚𝐿 
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 Cloning and expression of putative azoreductases PA1224, Chapter 3
PA1225 and PA4975 
 
3.1 Introduction 
Azoreductases in P. aeruginosa have been gaining interest in recent years following 
reports that they play a key role in mammalian colonisation (Rakhimova et al., 2008, 
Skurnik et al., 2013). As of yet, the primary physiological role of azoreductases has not 
been determined however their function has been closely linked to the reduction of 
cytotoxic quinones, often secreted by invertebrates and plants as a defence mechanism 
(Ryan et al., 2014, Cerenius et al., 2008, Mayer, 2006). A BLAST search carried out by 
Wang et al. (2007) identified three azoreductases in P. aeruginosa PAO1, PA0785, 
PA1962 and PA3223. These were subsequently characterised and asserted as NAD(P)H 
dependent flavoenzymes capable of reducing azo and quinone compounds (Wang et al., 
2007, Ryan et al., 2010b). An extensive bioinformatics study by Ryan et al. (2014) based 
on sequence and structural comparisons identified a further seven putative azoreductases in 
the P. aeruginosa PAO1 genome (Table 3.1). Of these, four (PA2280, PA2580, PA1204, 
PA0949) have successfully been overexpressed in E. coli and substrate specificity profiles 
have been established for each enzyme, confirming each of them as flavin and NAD(P)H 
dependent quinone reductases and three of them as flavin and NAD(P)H dependent 
azoreductases (Crescente et al., 2016). The cloning of pa1224 and pa1225 will be reported 
on in this chapter. Expression of these two genes along with the third remaining gene, 
pa4975, followed by purification of the resultant recombinant proteins will also be 
described.  
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Table 3.1 Gene details of known azoreductases and azoreductase-like genes from P. 
aeruginosa PAO1   
Table showing the name, location in the genome and the size of the azoreductase and 
azoreductase-like genes from P. aeruginosa PAO1. 
 
 
 
 
 
 
 
PA1224 was identified as a suspected azoreductase due to the 54% sequence similarity 
between PA1224 and the human azoreductase hNQO1, and the 41% sequence identity 
between PA1224 and hNQO1 and hNQO2 (Ryan et al., 2014). Also, known as a DT-
diaphorase, hNQO1 regulates proteasomal degradation, and overexpression in stomach 
cancer, breast cancer and cervical cancer and has been linked with a poor prognosis (Xu 
and Jaiswal, 2012, Biasini et al., 2014, Kumar, 2012, Yang et al., 2014). In addition, the 
structure of hNQO1 has been solved and has the same overall fold as paAzoR1 (Skelly et 
al., 1999, Ryan et al., 2011) (Figure 3.1). PA1225 and PA4975 were considered as 
potential azoreductases due to their significant sequence homology to another human 
azoreductase, hNQO2 (61% and 48% respectively) (Ryan et al., 2014). Like hNQO1, 
hNQO2 structurally has the same overall fold as paAzoR1 (Foster et al., 1999). The 
enzyme hNQO2 also plays a role in regulation of proteasomal degradation of proteins and 
is involved in the tumour necrosis factor signalling pathway (Ahn et al., 2007). Although 
PA1224 and PA1225 are adjacent on the bacterial chromosome they are encoded on 
different strands so are therefore unlikely to be co-regulated as an operon. As of yet little is 
known of the function of either gene in P. aeruginosa. PA4975 on the other hand, has been 
shown to have NQO activity and is likely to play a role in arginine metabolism (Yang and 
Lu, 2007, Green et al., 2014).  
Gene  Alternative name Genome location (bp) Size (bp) 
pa0785 azoR1 857998-858636 639 
pa1962 azoR2 2145984-2146502 609 
pa3223 azoR3 3611254-3611895 642 
pa2280 arsH 2508775-2509467 693 
pa2580 mdaB 2916158-2916748 591 
pa1204 yieF 1303892-1304449 558 
pa0949 wrbA 1036579-1037175 597 
pa4975 - 5585615-5586319 705 
pa1224 - 1327024-1327803 780 
pa1225 - 1327813-1328439 627 
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Figure 3.1 Structural comparison of hNQO1 and paAzoR1 
paAzoR1 (represented in blue) and hNQO1 (represented in gold) are shown with flavin 
cofactor bound (green). The structure of paAzoR1 is from PDB 3R6W (Ryan et al., 2011) 
and the structure of hNQO1 is from PDB 5EAI (Pidugu et al., 2016). The two structures 
align with an RMSD value of 2.18. The image was generated and manipulated in 
CCP4MG (McNicholas et al., 2011) and compared using the superpose tool in CCP4MG 
(Krissinel and Henrick, 2004). 
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Overexpression and subsequent characterisation of recombinant protein encoded by a gene 
of interest is one of the most popular means of examining gene function. The first step in 
this process is molecular cloning. The pET-28b vector (Figure 3.2 a) was previously used 
to clone azoreductase-like genes from P. aeruginosa PAO1 into E. coli (Wang et al., 2007, 
Ryan et al., 2010b, Crescente et al., 2016) and cells containing the plasmid can be selected 
for by cultivation in kanamycin (Rosano and Ceccarelli, 2014). It carries multiple 
restriction sites (Figure 3.2 b), appropriate for insertion of a gene sequence, and includes a 
transcriptional hybrid promoter (T7/lac). The expression system in pET-28b is tightly 
controlled to eliminate basal expression of the gene of interest by the LacI repressor 
protein constitutively expressed by lacI, present in both the plasmid sequence and the E. 
coli genome (Sorensen and Mortensen, 2005, Rosano and Ceccarelli, 2014). In the absence 
of lactose, LacI binds to the lacUV5 promoter of T7 RNA polymerase in the host strain, 
blocking the binding of E. coli RNA polymerase and thus inhibiting production of T7 RNA 
polymerase (Novagen, 2005). When lactose, or indeed its non-hydrolysable analogue, 
IPTG, binds to LacI, a conformational change occurs in the protein which renders it unable 
to bind to the operator sequence (Daber et al., 2007). As a result, the T7 RNA polymerase 
gene can be transcribed which will in turn induce expression of the target gene in pET-28b.  
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Figure 3.2 pET-28b vector map 
pET-28b vector map showing the area of multiple restriction sites (MRS) with NdeI and 
SacI labelled (a). Multiple cloning site sequence showing the position of each restriction 
site as well as the His-tag coding region and the thrombin cleavage site (b). This figure was 
adapted from the Novagen website and the vector map generated using BVTech Plasmid.  
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In a protein characterisation study where a purified sample is essential, it is helpful to have 
a means to easily separate the recombinant protein from the host strain cellular milieu. One 
of the most utilised methods for this is purification via affinity tags which are amino acid 
sequences with high affinity for a specific biological or chemical ligand (Arnau et al., 
2006). The polyhistidine tag (His-tag) is an amino acid sequence that includes at least six 
consecutive histidine residues and is the most widely used affinity tag with more than 60% 
of proteins produced for structural studies including a His-tag (Derewenda, 2004). His-
tagged proteins are purified using chelated metal ions as affinity ligands where the metal 
ion is attached to an immobilised chelating agent, with a nitrilotriacetic acid ligand 
immobilising nickel (Ni-NTA) in a sepharose matrix the most frequently used for 
purification of His-tagged proteins (Arnau et al., 2006). Thus recombinant protein 
expression using pET-28b enables purification of the desired protein from the crude extract 
of the host cells in a single step. This system enables the application of a common protocol 
for the purification of proteins with a previously unknown biochemical profile, eliminating 
the need for a customised, protein-specific, and thus time consuming procedure.  
Recombinant protein production in a different host strain is often essential as it can be 
difficult to produce sufficient soluble protein for structural and biochemical 
characterisation in the natural host. The genome of E. coli has been extensively 
characterised and is well understood so it is often used as the host for molecular cloning 
and protein overexpression. Also, many strains have been chromosomally engineered to 
facilitate this process (Baneyx and Mujacic, 2004). E. coli JM109 is a suitable strain for the 
initial transformation of a plasmid ligated with a gene of interest. This is due to the fact it 
has been genetically modified to be recA- and endA-. The deletion of recA prevents 
recombination of foreign or extrachromosomal DNA with host DNA, increasing the 
stability of the cloned plasmid, while the endA mutation eliminates the presence of non-
specific endonuclease in the cell, improving plasmid quality and yield (Casali, 2003).  
As previously mentioned, for recombinant protein expression using the pET system it is 
essential to transform the cloned vector into a strain that can produce T7 RNA polymerase 
(RNAP) which will in turn, induce expression of the gene of interest. E. coli BL21(DE3) 
and its derivatives are suitable hosts as they contain a chromosomal copy of the T7 RNAP 
gene under control of the lacUV5 promoter (Daegelen et al., 2009, Rosano and Ceccarelli, 
2014). An extra advantage of using the E. coli BL21 cell lineage is that they are deficient 
in Lon protease which rapidly degrades proteins foreign to the host (Maurizi et al., 1985). 
In addition, BL21 cells are also lacking in the OmpT outer membrane protease which has 
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the function of degrading extracellular proteins (Grodberg and Dunn, 1988). Upon cell 
lysis during extraction of recombinant protein, the OmpT protease if present, could digest 
the desired overexpressed protein.  
Recombinant protein production in E. coli can be limited by a lack of tRNAs in the host 
strain that would be abundant in the organism from which the protein is derived. This can 
occur as a result of codon usage bias which is the likelihood that a particular codon will be 
used to code for a specific amino acid over another codon which codes for the same amino 
acid. During overexpression of the recombinant protein, a depletion of low abundance 
tRNA occurs which can lead to translational errors including amino acid substitutions, 
translational frameshifting and polypeptide truncation (Rosano and Ceccarelli, 2014). 
When expressing recombinant protein from P. aeruginosa, it is important to consider the 
high GC content (66.6%) of the P. aeruginosa genome which can influence codon bias 
(Stover et al., 2000). A means of remedying the issue of codon bias in recombinant protein 
expression is co-transforming the host with a plasmid containing a gene encoding the 
tRNA cognate for the rare codons. E. coli BL21-CodonPlus(DE3)-RP, a derivative of E. 
coli BL21, is engineered to contain extra copies of genes that encode tRNAs from 
organisms with GC-rich genomes (Agilent, 2016). 
Previous studies have described the cloning, expression and purification of azoreductases 
from P. aeruginosa PAO1 using methods relating to those listed above (Wang et al., 2007, 
Ryan et al., 2010b, Crescente et al., 2016). This chapter describes the cloning, expression 
and purification including molecular weight determination of three putative azoreductases; 
PA1224, PA1225 and PA4975, from P. aeruginosa PAO1.  
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3.2 Results 
3.2.1 Cloning of the putative azoreductase genes pa1224 and pa1225 
The protocols used in this section are described in Chapter 2, however the following results 
are closely linked to the experimental procedures and therefore this results section also 
describes where specific adaptions were applied to the general methods.  
3.2.1.1 Preparation of genes of interest 
The DNA sequences of pa1224 and pa1225 were obtained from the Pseudomonas Genome 
Database (Winsor et al., 2016). Gene-specific primers were designed to overlap coding and 
non-coding regions of the appropriate genes. NdeI and SacI restriction sites were 
incorporated into the forward and reverse primers respectively. These were chosen to 
correspond with restriction sites present in pET-28b (Figure 3.2 b) and were particularly 
appropriate due to the NdeI restriction site sequence including the start codon of the three 
putative azoreductases (CATATG) and the SacI restriction site having a high GC content 
(GAGCTC). This pairing of restriction sites would also enable the incorporation of a His-
tag coding region which encodes hexahistidine residues upstream of the inserted gene 
sequence (Figure 3.2 b). This in turn would include the hexahistidine at the N-terminus of 
the recombinant protein and thus allow for protein purification using the IMAC method. 
The primers were used to carry out a PCR reaction using High Fidelity Taq polymerase 
and extracted P. aeruginosa PAO1 genomic DNA as a template. On examination using 1% 
w/v agarose gel, PCR products estimated at 795 bp and 692 bp for pa1224 and pa1225 
respectively were to be seen (Figure 3.3). Given the limitations and approximations of the 
technique these bands were considered to correspond with the expected sizes of 818 bp and 
664 bp for pa1224 and pa1225 respectively. The PCR products were purified and 
quantified before a double restriction digest with NdeI and SacI restriction enzymes. 
Following this, the samples were purified and quantified once more, ready for ligation into 
the cloning vector. 
 
55 
 
 
Figure 3.3 PCR amplification of pa1224 and pa1225 from P. aeruginosa PAO1 
1% w/v agarose gel showing the putative azoreductases amplified from total P. 
aeruginosa PAO1 genomic DNA using HiFidelity Taq polymerase. Samples shown are 1 
Kb Plus DNA ladder (lane M), pa1224 (lane 1) and pa1225 (lane 2). PCR products were 
of the expected sizes at 795 bp for pa1224 and 692 bp for pa1225 – actual sizes are 818 
bp and 664 bp respectively.  
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3.2.1.2 Preparation of the cloning vector 
The plasmid pET-28b was extracted from E. coli JM109 and quantified. A restriction 
digest was carried out on the extracted plasmid using the restriction enzymes NdeI and 
SacI. This double restriction digest was performed to prevent self-ligation of the plasmid. 
To ensure successful digestion had occurred, a sample of the digested plasmid was run 
alongside undigested plasmid on 1% w/v agarose gel (Figure 3.4). The undigested plasmid 
showed typical bands of supercoiled circular plasmid whereas the digested sample 
appeared as a defined single band representing linearization of the plasmid. Following 
purification and quantification the digested plasmid was treated with a phosphatase 
enzyme to remove the phosphate group at the 5’ end. It is important to note that this step 
was omitted in the gene preparation stage as one 5’ phosphate group is necessary for the 
ligation process. The phosphatase-treated plasmid was then purified and quantified. 
 
Figure 3.4 Endonuclease restriction digest of pET-28b  
1% w/v agarose gel showing the pET-28b plasmid before and after endonuclease digestion 
with restriction enzymes NdeI and SacI. Digested samples (lanes 2, 4 and 6) display a 
linearised plasmid while the undigested samples (lanes 1, 3 and 5) show the supercoiled 
plasmid form. 1 Kb Plus DNA ladder (lane M) was used as standard.  
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3.2.1.3 Obtaining and screening successful clones 
The plasmids and PCR products for pa1224 and pa1225 were ligated together before being 
transformed via the heat shock method into E. coli JM109. The cells were then grown on 
LB agar containing kanamycin so as to select for cells containing circular pET-28b which 
confers kanamycin resistance. Colonies were picked and grown in selective LB. Colonies 
containing empty, undigested pET-28b, which had been used as a positive control for the 
transformation, were also grown in the same selective medium. Colonies from each 
potential clone and one containing the empty plasmid were screened via PCR using 
primers designed to anneal to a section overlapping the vector and gene insert. This would 
allow for amplification only where both the plasmid and gene of interest were present 
meaning a PCR product would only be visible on agarose gel where there was a successful 
clone. PCR products were analysed on 1% w/v agarose gel. Bands of expected size were 
observed for the potential clones (Figure 3.5) indicating that cloning of the putative 
azoreductase genes had been successful. PCR-confirmed colonies for each clone were 
grown in selective LB and the plasmids were extracted and sequenced. The sequencing 
results were aligned with the appropriate sequences from the Pseudomonas Genome 
Database (data shown in APPENDIX V). This confirmed that no point mutations had 
occurred during the cloning process and that successful clones had been obtained.  
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Figure 3.5 E. coli JM109 colony screening for successful clones  
1% w/v agarose gel showing the PCR products for the genes pa1224 (lanes 1-4) and 
pa1225 (lanes 5-8) in pET-28b transformed into E. coli JM109. PCR products were of the 
expected size indicated by black arrows. 1 Kb plus DNA ladder was used as standard (lane 
M). 
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3.2.2 Expression of putative azoreductases PA1224, PA1225 and PA4975 
3.2.2.1 Transformation into expression hosts E. coli BL21(DE3) and E. coli BL21 
CodonPlus(DE3)-RP   
Following confirmation of successful cloning by PCR and sequencing, plasmid extractions 
were performed on overnight cultures of positive clones for pa1224, pa1225 and pa4975. 
The E. coli JM109 strain containing pET-28b::pa4975 was generated by Dr. Vincenzo 
Crescente (Crescente, 2015). The extracted plasmids containing each gene of interest were 
then transformed into E. coli BL21(DE3) and E. coli BL21-CodonPlus(DE3)-RP (pET-
28b::pa4975 only). Individual colonies were selected and screened via PCR using primers 
specific for the gene of interest and the vector (Figure 3.6 a and b). Each expression host 
was also transformed with empty pET-28b to be used as a negative control for protein 
expression.  
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Figure 3.6 E. coli BL21(DE3) and E. coli BL21 CodonPlus(DE3)-RP transformants 
screening    
1% w/v agarose gels showing the PCR products for the azoreductase-like genes in pET-
28b. PCR products displayed represent pa1224 (lanes 2-5) and pa1225 (lanes 7-9) in pET-
28b transformed into E. coli BL21(DE3). Lanes 1 and 6 represent the empty plasmid in E. 
coli BL21(DE3) (a). PCR products from transformants of E. coli BL21(DE3) and E. coli 
BL21 CodonPlus(DE3)-RP containing pET-28b::pa4975 are displayed in lanes 2-4 and 5-7 
respectively. The PCR reaction was also performed on E. coli BL21 CodonPlus(DE3)-RP 
containing pET-28b (lane 1) (b). 1 Kb plus DNA ladder was used as standard (lane M). 
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3.2.2.2 Overexpression of recombinant proteins  
The process used to overexpress recombinant protein was adapted from a method 
published by Wang et al. (2007) where azoreductases from P. aeruginosa were cloned, 
expressed and characterised. This method is described in section 2.4.1. In order to optimise 
the procedure to generate a suitable yield of soluble protein, various parameters were 
implemented and they will be described briefly for each individual protein.  
3.2.2.2.1 Overexpression of PA1224 
Small scale (50 mL volume) protein production of PA1224 was initially carried out in LB 
1 M sorbitol 2.5 mM betaine 30 µg/mL kanamycin. As the cultures entered the exponential 
growth phase (OD600 0.4-0.6), expression was induced with the addition of 0.5 mM IPTG. 
These cultures were then incubated overnight at 16°C 120 RPM.  Following bacterial cell 
lysis and separation of fractions the protein samples were analysed via SDS-PAGE (Figure 
3.7 a). The cloned sample showed evidence of protein overproduction characterised by the 
appearance of a single intense band of appropriate molecular weight (product size 
estimated at 28.9 kDa using ExPASy ProtParam (Gasteiger E., 2005)) that was not present 
in the negative control. Comparison of the soluble and insoluble fractions of the clone 
shows that approximately 46% of the recombinant protein was soluble while 54% was 
insoluble. In an attempt to increase the yield of soluble protein, the same overexpression 
process was repeated with 1 mM FMN supplemented into the media. PA1224 is a 
suspected flavoprotein therefore addition of FMN to the expression media can stabilise the 
structure due to hydrogen bond formation between the flavin and the protein backbone 
(Ryan et al., 2010a), limiting the chance of protein aggregation. In addition, the 
azoreductase active site is often shown as a highly conserved hydrophobic pocket where 
the flavin cofactor binds (Wang et al., 2007). Binding of the flavin will decrease the 
exposure of a hydrophobic surface and may increase protein solubility. Comparison of the 
soluble protein produced with no FMN added against the soluble protein produced with 1 
mM FMN in the media did not show any difference in yield with approximately 38% of 
the protein produced soluble with no FMN incorporated and 36% expressed in the soluble 
form in the presence of FMN (Figure 3.7 b). For this reason, no FMN was added when the 
process was scaled up to 500 mL. Results visible on SDS-PAGE indicated that 
overexpression was successful however a lower yield of protein was generated in the 
soluble fraction (approximately 24%) while expression appeared majorly in the insoluble 
counterpart (approximately 76%) (Figure 3.7 c). In order to obtain a desirable quantity of 
soluble protein, eight 100 mL cultures were induced for expression following the small 
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scale protein production protocol (section 2.4.1). These individual cultures were combined 
prior to the first centrifugation step where the cell pellet is formed. The cell pellets were 
then treated as described for the large scale procedure (section 2.4.1) and equivalent results 
to those of the small scale production were obtained. By this method, sufficient soluble 
PA1224 was produced for further analysis. 
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Figure 3.7 Overexpression of PA1224 recombinant protein in E. coli BL21(DE3)  
Coomassie blue stained SDS-PAGE showing optimisation of PA1224 recombinant protein 
expression to favour the production of soluble protein. Small scale protein production in 50 
mL culture volumes was compared between E. coli BL21(DE3) transformed with pET-
28b::pa1224 (lanes 2, 4 and 6) and a negative control of E. coli BL21(DE3)-pET-28b 
(lanes 1, 3 and 5) (a). Protein overexpression was compared in the presence (lanes 2, 4, 6, 
8, 10 and 12) and absence (lanes 1, 3, 5, 7, 9 and 11) of FMN in the media. E. coli 
BL21(DE3) containing the empty vector pET-28b was used as a negative control (lanes 1, 
2, 5, 6, 9 and 10) (b). Large scale protein production in 500 mL culture volumes depicts 
overexpression in the pa1224 clone (lanes 2, 4 and 6) compared to the negative control of 
E. coli BL21(DE3)-pET-28b (lanes 1, 3 and 5) (c). Lanes marked ‘M’ represent the 
molecular weight marker. 
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3.2.2.2.2 Overexpression of PA1225 
Small scale (50 mL volume) protein production of PA1225 was carried out in LB with 1 M 
sorbitol, 2.5 mM betaine and 30 µg/mL kanamycin added. Expression was induced during 
the exponential growth phase of the cultures (OD600 0.4-0.6) by the addition of 0.5 mM 
IPTG. These cultures were then incubated overnight at 16°C 120 RPM.  Following the 
separation of fractions the protein samples were analysed via SDS-PAGE. No obvious 
difference was apparent upon comparison of each fraction; the whole cell lysate, insoluble 
fraction and soluble fraction, against those from the negative control indicating that protein 
expression had been unsuccessful with this method (Figure 3.8 a). Considering the OD600 
measurement of the cloned strain following the overnight expression period was similar to 
that of the control at 2.77 and 2.67 respectively, it was unlikely that this was due to the 
protein being toxic to the expression host. The same expression conditions were trialled 
again however this time using a different isolate of E. coli BL21(DE3)-pET-28b::pa1225 
and with 1 mM FMN added to the culture as this has been thought to reduce non-specific 
protein production and thus increase yield of the desired protein (Rafii et al., 1990). The 
procedure was also carried out simultaneously in the absence of FMN so as a comparison 
could be drawn on the effect of flavin using the same bacterial isolate. On examination via 
SDS-PAGE it was noted that there was small but clear band at the appropriate molecular 
weight (product size estimated at 24.7 kDa using ExPASy ProtParam (Gasteiger E., 2005)) 
indicating that this particular isolate was expressing recombinant PA1225 (Figure 3.8 b). 
The addition of FMN did not appear to have any effect on protein yield or solubility. The 
presence of 1 M sorbitol and 2.5 mM betaine has been shown to increase the production of 
soluble protein (Blackwell and Horgan, 1991) however such osmolytes in the media will 
also put the cells under osmotic stress (Oganesyan et al., 2007). It was thus decided to trial 
expression using just L, the most commonly used media for culturing E. coli (Rosano and 
Ceccarelli, 2014). Initially, three 50 mL cultures were grown to the log phase and 
overexpression was induced with the addition of 0.1 mM, 0.5 mM and 1 mM IPTG. An 
expression period of 3 hours at 37°C 120 RPM followed before the cells were lysed and 
fractions separated. Through SDS-PAGE analysis it was evident that recombinant protein 
was produced in each sample with the culture induced with 0.1 mM IPTG displaying 
approximately 75% protein in the soluble fraction when compared to the corresponding 
insoluble fraction. The 0.5 mM and 1 mM IPTG induced samples had approximately 43% 
and 51% soluble protein produced respectively (Figure 3.8 c). E. coli BL21(DE3)-pET-28b 
induced with 1 mM ITPG was used as a negative control. Following on from this result, E. 
coli BL21(DE3)-pET-28b::pa1225 was cultured in 50 mL LB 30 µg/mL kanamycin and 
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induced at the exponential phase with 0.1 mM IPTG. This time expression was continued 
for 16 hours at 37°C 120 RPM. Expression was successful with adequate protein yield 
appearing in the soluble fraction (67%) (Figure 3.9 a). This suggested that scaling up the 
procedure to 500 mL cultures would be worthwhile in order to obtain a higher volume of 
soluble protein. SDS-PAGE results of the large scale production showed that 
overexpression was achieved however less protein was obtained in the soluble fraction 
(42%) than when expression was carried out on a smaller scale (Figure 3.9 b). The same 
approach adopted for production of PA1224 (section 3.2.2.2.1) was thus applied where 
eight 100 mL cultures were used to overexpress soluble PA1225 and a similar percentage 
of soluble protein was obtained as from the 50 mL culture.  
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Figure 3.8 Optimisation of PA1225 recombinant protein overexpression in E. coli 
BL21(DE3)   
Coomassie blue stained SDS-PAGE showing optimisation of PA1225 recombinant protein 
expression in 50 mL culture volumes to favour the production of soluble protein. Protein 
production was compared between E. coli BL21(DE3) transformed with pET-28b::pa1225 
(lanes 2, 4 and 6) and a negative control of E. coli BL21(DE3)-pET-28b (lanes 1, 3 and 5) 
(a). Protein overexpression was compared in the presence (lanes 2, 4, 6, 8, 10 and 12) and 
absence (lanes 1, 3, 5, 7, 9 and 11) of FMN in the media.  E. coli BL21(DE3) containing 
the empty vector pET-28b was used as a negative control (lanes 1, 2, 5, 6, 9 and 10) (b). 
Overexpression was trialled using LB as the culturing media. Protein production was 
initiated by the addition of 0.1 mM (lanes 2, 6 and 10), 0.5 mM (lanes 3, 7 and 11) and 1 
mM IPTG (lanes 4, 8 and 12) with an expression period of 3 hours at 37°C to follow. 
Lanes 1, 5 and 9 represent the E. coli BL21(DE3)-pET-28b negative control induced with 
1 mM IPTG (c). Lanes marked ‘M’ represent the molecular weight marker. 
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Figure 3.9 Overexpression of PA1225 recombinant protein in E. coli BL21(DE3)  
Coomassie blue stained SDS-PAGE showing overexpression of PA1225 recombinant 
protein after 16 hours on a small and large scale. Small scale protein production in 50 mL 
culture volumes was compared between E. coli BL21(DE3) transformed with pET-
28b::pa1225 (lanes 2, 4 and 6) and a negative control of E. coli BL21(DE3)-pET-28b 
(lanes 1, 3 and 5) (a). Large scale production was carried out in 500 mL culture volumes. 
Lanes 1, 3 and 5 represent the negative control while lanes 2, 4 and 6 depict the pa1225 
clone (b). Lanes marked ‘M’ represent the molecular weight marker (Fisher Pre-stained 
Rec Protein ladder (a)). 
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3.2.2.2.3 Overexpression of PA4975 
Small scale (50 mL volume) protein expression of PA4975 was initially attempted using 
LB containing 1 M sorbitol 2.5 mM betaine 30 µg/mL kanamycin. When the cultures 
reached the log phase of growth, indicated by OD600 of 0.4-0.6, recombinant protein 
production was induced by addition of 0.5 mM IPTG. These cultures were then incubated 
overnight at 16°C 120 RPM.  Following the separation of fractions the protein samples 
were analysed via SDS-PAGE (Figure 3.10 a). Overexpression of PA4975 was successful 
with a band appearing at the correct molecular weight (28.5 kDa as estimated by ExPASy 
ProtParam (Gasteiger E., 2005)). Approximately 29% of the protein was soluble compared 
to the insoluble sample. In order to optimise the method to favour production of soluble 
protein a range of conditions were trialled. Firstly, expression was induced with 0.1 mM, 
0.2 mM, 0.3 mM, 0.4 mM and 0.5 mM IPTG. For this experiment the negative control was 
uninduced E. coli BL21(DE3)-pET-28b::pa4975. When the soluble fractions from each 
sample were compared on SDS-PAGE (Figure 3.10 b), there was little improvement 
apparent in the protein yield, however although overall there was little difference to be 
seen, the sample produced from the induction with 0.4 mM IPTG was arguably the most 
successful. Overexpression of recombinant protein resulting in a highly concentrated 
protein sample can sometimes result in aggregation and thus insoluble protein (Rosano and 
Ceccarelli, 2014), it was therefore decided to test shorter expression periods of 2 hours, 4 
hours and 6 hours. Based on the previous result, induction was commenced with the 
addition of 0.4 mM IPTG. The samples were compared using SDS-PAGE (Figure 3.10 c). 
Expression was apparent in each sample however there was minimal protein present, even 
at 6 hours, and the protein remained predominantly in the insoluble fraction. The most 
soluble protein was produced after 6 hours. In a final attempt to gain soluble protein it was 
decided to transform pET-28b::pa4975 into a different host strain for expression.  E. coli 
BL21-CodonPlus(DE3)-RP was selected it is specially adapted to possess extra tRNAs for 
rare codons in E. coli, in particular those originating from organisms with a high genomic 
GC content (Kleber-Janke and Becker, 2000). Cells were cultured as before in LB 1 M 
sorbitol 2.5 mM betaine 30 µg/mL kanamycin and expression was induced with 0.4 mM 
IPTG. Expression was continued for 16 hours at 16°C. The separated fractions were 
analysed on SDS-PAGE and overexpression was successful (Figure 3.11 a). The negative 
control was represented by E. coli BL21-CodonPlus(DE3)-RP containing pET-28b and 
was treated in the same manner as the strain containing the gene of interest. Although most 
protein remained insoluble (68%), the process was scaled up into two 500 L cultures in a 
bid to gain and characterise any soluble protein that was produced however low the yield. 
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When the fractions were viewed on SDS-PAGE it was clear that soluble protein was 
present although only at a yield of approximately 29% total protein produced (Figure 3.11 
b).  
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Figure 3.10 Overexpression of PA4975 recombinant protein in E. coli BL21(DE3)  
Coomassie blue stained SDS-PAGE showing optimisation of PA4975 recombinant protein 
expression in 50 mL culture volumes to favour the production of soluble protein. Protein 
production was compared between E. coli BL21(DE3) transformed with pET-28b::pa4975 
(lanes 2, 4 and 6) and a negative control of E. coli BL21(DE3)-pET-28b (lanes 1, 3 and 5) 
(a). Protein overexpression was trialled using varying concentrations of IPTG for 
induction. Samples represented include the whole cell lysates (lanes 1, 4, 7, 10, 13 and 16), 
the soluble fractions (lanes 2, 5, 8, 11, 14 and 17) and the insoluble fractions (lanes 3, 6, 9, 
12, 15 and 18) (b). Protein expression was induced with 0.4 mM IPTG and varying 
induction times at 16°C followed prior to cell lysis and separation of fractions. There is 
little difference to be seen between the negative control of E. coli BL21(DE3)-pET-28b  
(lanes 1-3, 7-9 and 13-15) and the azoreductase clone (lanes 4-6, 10-12 and 16-18). 
Samples shown are the whole cell lysates (lanes, 1, 4, 7, 10, 13 and 16), the insoluble 
fractions (lanes 2, 5, 8, 11, 14 and 17) and the soluble fractions (lanes 3, 6, 9, 12, 15 and 
18) (c). Lanes marked ‘M’ represent the molecular weight marker (ThermoFisher 
prestained protein ladder (b)). 
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Figure 3.11 Overexpression of PA4975 recombinant protein in E. coli BL21-
CodonPlus(DE3)-RP 
Coomassie blue stained SDS-PAGE showing expression of recombinant PA4975. Small 
scale protein production in 50 mL culture volumes was compared between E. coli BL21-
CodonPlus(DE3)-RP transformed with pET-28b::pa4975 (lanes 4-6) and a negative control 
of E. coli BL21-CodonPlus(DE3)-RP-pET-28b (lanes 1, 3 and 5) (a). The procedure was 
scaled up to two 500 mL cultures (b). For both gels lanes 1 and 4 depict the whole cell 
lysates, lanes 2 and 5 represent the insoluble fraction and lanes 3 and 6 show the soluble 
fraction. Lanes marked ‘M’ represent Fisher Pre-stained Rec Protein ladder. 
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3.2.3 Purification and quantification of recombinant proteins 
3.2.3.1 Purification with Immobilised Metal-ion Affinity Chromatography 
All protein purification was carried out using the IMAC method. A volume of 4 mL 50% 
Ni-NTA slurry was loaded into a 10 mL column and the Ni-NTA beads washed twice with 
20 mM Tris HCl 100 mM NaCl pH 8. For the purification of PA4975 only 2 mL of 50% 
Ni-NTA slurry was used due to the apparent low yield of protein as an overload of Ni-
NTA can result in non-specific binding. The soluble fraction from each protein produced 
was applied to the column and mixed with the Ni-NTA before the liquid phase containing 
any unbound protein was removed by applying gentle pressure using a syringe. This flow 
through was collected for further analysis to confirm that the protein of interest was not 
present. The bound protein was eluted using increasing concentrations of imidazole (0-250 
mM) which would act as a competitor for the hexahistidine tag. The protein elution 
depends on the number of histidine residues present; therefore it was likely that the protein 
would be eluted between the 100 mM and 250 mM imidazole concentrations. The protein 
of interest, due to the bound flavin, appears bright yellow in colour therefore it was 
possible to determine whether or not there was bound protein prior to analysis of the 
elutions on SDS-PAGE as the blue nickel beads would turn green in the presence of this 
protein. All eluates were analysed via SDS-PAGE along with the flow through and un-
purified soluble fraction (Figure 3.12 a, b and c).  
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Figure 3.12 Purification of putative P. aeruginosa PAO1 recombinant azoreductase 
protein using IMAC  
Coomassie blue stained SDS-PAGE showing the purification of the soluble fractions from 
expression lysates. Ni-NTA columns were loaded with the soluble fractions and eluted with 
buffer (20 mM Tris HCl, 100 mM NaCl, pH 8) containing increasing concentrations of 
imidazole (10, 25, 50, 100 and 250 mM). PA1224 (29 kDa) protein purification (a), 
PA1225 (25 kDa) protein purification (b), PA4975 (28 kDa) protein purification (c). All 
gel samples shown are labelled as follows: the molecular weight marker (lane M) (NEB 
broad range protein ladder (a), Fisher Pre-stained Rec Protein ladder (c)), soluble fraction 
(lane 1), flow through (lane 2), 0 mM imidazole (lane 3), 10 mM imidazole (lane 4), 25 
mM imidazole (lane 5), 50 mM imidazole (lane 6), 100 mM imidazole (lane 7) and 250 
mM imidazole (lane 8). 
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3.2.3.2 Dialysis and quantification of protein stocks 
Following protein purification each sample was suspended in a buffer containing imidazole 
(50 mM, 100 mM, 250 mM for PA1224, 100 mM, 250 mM for PA1225 and 250 mM for 
PA4975). In order to remove excess imidazole, dialysis was performed by suspending 
molecular porous tubing containing the protein solutions in 4 L of dialysis buffer overnight 
(section 2.5.2). The molecular weight cut-off of 12-14 kDa of the dialysis tubing minimises 
protein loss during this process. Considering the difference in protein solution volume (4 
mL for PA1224 and PA1225 and 2 mL for PA4975) and dialysis buffer volume (4 L), the 
imidazole concentration would be diluted roughly 1000 times for PA1224 and PA1225 and 
2000 times for PA4975, meaning that the final imidazole concentration would be <1 mM. 
After removal of imidazole, the concentration of protein in each sample was determined by 
absorbance measurement at 280 nm and standardised in 20 mM Tris HCl 100 mM NaCl 
pH 8 5% v/v glycerol to 2 mg/mL for PA1224 and 1 mg/mL for PA1225 and PA4975. The 
aliquoted samples were stored at -80°C. PA1224 was obtained at 24.2 mg soluble purified 
protein per L culture. PA1225 expression yielded 16.7 mg purified recombinant protein/L 
culture in the soluble fraction. Much less soluble protein was gained from PA4975 
expression with only 4.2 mg achieved per L culture. The actual amounts of protein 
obtained are listed in Table 3.2. 
 
Table 3.2 Table listing the total yield of recombinant putative azoreductases produced  
The yields of protein achieved following IMAC purification are listed along with the 
insoluble vs soluble protein percentage. The yields were calculated by determining the 
concentration of protein using the specific extinction coefficient as calculated by 
ProtParam available on ExPASy Bioinformatic Resource Portal (Gasteiger et al., 2005). 
Percentages of insoluble and soluble protein gained were estimated using the volume 
analysis tool in Image Lab 5.2.1 (BIO-RAD). 
  
Protein Purified yield (mg) Insoluble % Soluble % 
PA1224 19.4 62 38 
PA1225 13.4 33 67 
PA4975 4.2 71 29 
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3.2.3.3 Protein molecular weight determination 
The molecular weight of each protein was determined by comparing their migration 
against the migration of molecular weight marker bands on SDS-PAGE (Figure 3.13) 
using the molecular weight analysis tool in ImageLab 5.2.1 (BIO-RAD). The predicted 
molecular weights for each protein were calculated using ProtParam, available on ExPASy 
Bioinformatic Resource Portal (Gasteiger et al., 2005) and based on their amino acid 
sequences with the hexahistidine tag included at the N-terminus. The amino acid sequence 
was obtained from the Pseudomonas Genome Database (Winsor et al., 2016). The 
calculated molecular weights were similar to those predicted from analysis on SDS-PAGE 
(Table 3.3). 
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Figure 3.13 Purified recombinant proteins following ion exchange dialysis 
preparation for storage   
Coomassie blue stained SDS-PAGE showing a single band for each putative azoreductase. 
PA1224 (lane 1) was concentrated to 2 mg/mL and PA1225 (lane 2) and PA4975 (lane 3) 
were concentrated to 1 mg/mL in 5% v/v glycerol for long term storage at -80°C (lane 1). 
Lane M represents a Fisher Pre-stained Rec Protein ladder. 
 
  
Table 3.3 Estimated molecular weight of each purified recombinant protein along 
with the actual molecular weight   
The molecular weight of each protein was estimated by comparing the migration of the 
single protein bands against the migration of bands from a standard molecular weight 
marker. The molecular weight analysis tool in Image Lab 5.2.1 (BIO-RAD) was used to 
estimate these molecular weights. The actual molecular weights were calculated using 
ProtParam available on ExPASy Bioinformatic Resource Portal (Gasteiger et al., 2005) 
and were based on the amino acid sequences of each protein available from the 
Pseudomonas Genome Database with the His-tag sequence added at the N-terminus. 
  
Protein Estimated molecular weight (kDa) 
Actual molecular 
weight (kDa) 
PA1224 29 29.1 
PA1225 26 24.7 
PA4975 29 28.5 
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3.3 Discussion 
The objectives listed in section 1.3 have been met as follows: 
i. The azoreductase-like genes pa1224 and pa1225 have been amplified by PCR and 
inserted into the pET-28b vector. The vectors containing the genes of interest were 
transformed into E. coli JM109. Gene sequencing has confirmed successful ligation 
of these genes into the plasmids with a complete absence of any point mutations. 
ii. The pET-28b vectors containing the azoreductase-like genes pa1224, pa1225 and 
pa4975 have been extracted from E. coli JM109 and transformed into E. coli 
BL21(DE3). pET-28b::pa4975 has also been transformed into E. coli BL21-
CodonPlus(DE3)-RP. This transformation was confirmed by PCR.  
iii. Putative azoreductases, PA1224, PA1225 and PA4975, from P. aeruginosa PAO1 
were overexpressed in E. coli BL21 strains.  
iv. The recombinant proteins produced were purified and molecular weights 
determined, confirming similarity to the expected molecular weight of each protein. 
 
 
P. aeruginosa possesses a striking ability to adapt to and thrive in a variety of 
environments including soil, marine habitats and plant and mammalian tissues. It is 
thought that this unique capacity of P. aeruginosa to activate suitable phenotypes under 
environmental stress is attributed to its large and complex genome (Stover et al., 2000). 
The publication of the full genome sequence of P. aeruginosa PAO1 by Stover et al. 
(2000) and the subsequent development of the Pseudomonas Genome Database online 
(Winsor et al., 2011) has enabled full genomic analysis of this organism which can lead to 
the identification of genes with a putative and potentially critical function. Following the 
successful identification and characterisation of several new members of the azoreductase 
family in P. aeruginosa PAO1 by Wang et al. (2007), Ryan et al. (2010b) and Crescente et 
al. (2016), similar methods were adapted in this study to examine suspected azoreductase 
encoding genes pa1224, pa1225 and pa4975. 
The process of cloning DNA is a well-established and understood system for examining 
the molecular and physiological role of specific genes. The particular method used in this 
study for cloning putative azoreductases from P. aeruginosa PAO1 into E. coli was 
directly adapted from that successfully utilised by Crescente et al. (2016). Following PCR 
analysis and gene sequencing, the cloning process was deemed to have worked efficiently 
with no point mutations occurring within the genes of interest.  
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In 2007, Wang and colleagues established a protocol for the expression of an azoreductase 
from P. aeruginosa PAO1. Following the successful production of soluble recombinant 
paAzoR1, the same method was applied by Ryan et al. (2010b) to generate stocks of 
paAzoR2 and paAzoR3 which they would subsequently characterise. The procedure 
proved effective once more in overexpression of azoreductases from P. aeruginosa PAO1 
when Crescente and colleagues (2016) employed the pET system in E. coli BL21 to 
produce recombinant PA2280, PA2580, PA1204 and PA0949. It was thus deemed 
appropriate to initially trial expression of PA1224, PA1225 and PA4975 using this same 
technique where LB supplemented with 1 M sorbitol 2.5 mM betaine and 30 µg/mL 
kanamycin would be the expression medium, 0.5 mM IPTG would induce recombinant 
protein production and expression would be carried out for 16 hours at 16°C 120 RPM.  
Upon SDS-PAGE analysis, PA1224 and PA4975 appeared to have been overexpressed 
using this procedure, although PA4975 was mainly insoluble. The addition of FMN to the 
media prior to expression did not seem to increase the yield of soluble protein in either 
PA1224 or PA1225, reasons for which will be discussed in the next chapter.  
Given that approximately 40% of PA1224 expressed was in the soluble fraction the 
process was scaled up ten fold in order to produce sufficient recombinant protein to 
characterise. It was found to be the case however, that increasing the culture volume to 500 
mL reduced the yield of soluble protein. This was potentially due to oxygenation of the 
cultures which can have a profound influence on growth and can also act as a regulatory 
signal affecting the metabolic capacities of the cell (Losen et al., 2004, Unden et al., 1995, 
Islam et al., 2008). To abolish this issue a simple approach was undertaken where 
expression was induced simultaneously in eight 100 mL culture volumes and the products 
compiled prior to fractionation. This method achieved a satisfactory yield of soluble 
recombinant protein.  
Gaining protein in the soluble fraction is essential when the objectives of a study include 
examination of the activity of the protein in question. Methods of solubilising the protein 
post-purification such as urea or guanidine hydrochloride denaturation are not 
recommended in this instance as they can reduce or eliminate any enzymatic activity 
(Dunbar et al., 1997, Hedoux et al., 2010). Non-peptide fusion partners including maltose-
binding protein and glutathione S-transferase can act as solubility enhancers although the 
specific mechanism remains unclear (Raran-Kurussi and Waugh, 2012). The attachment of 
a large fusion tag, however can affect protein functionality so removal is essential prior to 
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activity assays and the final solubility of the desired product following this can be 
unpredictable (Esposito and Chatterjee, 2006). Through SDS-PAGE analysis of 
recombinant PA4975 it was evident that the protein was heavily overexpressed. The E. coli 
microenvironment differs from that of P. aeruginosa in terms of pH, osmolarity and 
folding mechanisms, thus overexpression of a non-native protein can result in protein 
aggregation and inclusion body formation. For this reason, the method was altered in a bid 
to slow down expression of PA4975 where lower concentrations of IPTG were used for 
induction and expression was carried out for substantially shorter time periods. These 
adaptations however, proved mainly ineffective in increasing the soluble protein yield.  
Another reason why insoluble protein is produced may be attributed to codon usage bias 
where the foreign coding DNA is significantly different to that of the host strain resulting 
in amino acid misincorporation and/or protein truncation (Rosano and Ceccarelli, 2014). 
The pattern of codon usage in P. aeruginosa differs from that of E. coli in that the latter 
preferentially uses codons which form codon-anticodon interactions with intermediate 
binding energy while P. aeruginosa employs codons with the strongest codon-anticodon 
interaction – a pattern often observed in microorganisms with a high GC content (West and 
Iglewski, 1988). For this reason, the pET-28b vector containing pa4975 was transformed 
into E. coli BL21-CodonPlus(DE3)-RP as this strain produces rare tRNAs often associated 
with GC-rich genomes (Casali, 2003). This method however, only marginally improved 
the yield of soluble vs insoluble recombinant protein. On further inspection of the rare 
tRNA genes present in this E. coli strain, namely AGA, AGG (argU) and CCC (proL), it 
was found that two of these three (AGA and AGG) are actually rarely, if at all, used in P. 
aeruginosa (West and Iglewski, 1988). This may explain why little improvement was 
observed with recombinant protein expression in this strain. On the other hand, solving the 
issue of codon usage bias with a specially designed host strain can often improve overall 
protein yield but this overexpression can have a deleterious effect on the quantity of 
soluble protein gained (Rosano and Ceccarelli, 2009). This CodonPlus-RP strain carries an 
extra plasmid which will carry genes encoding for the rare tRNAs. As the presence of 
extrachromosomal DNA in the bacterial cytosol is energy draining for the cell (Hayes and 
Wolf, 1990), it is possible that this may slow down metabolic processes including 
recombinant protein expression. It could therefore be suggested that although the 
CodonPlus-RP strain was not suitable to correct codon usage bias in this case, it may have 
slowed down protein production sufficiently to slightly reduce protein aggregation. The 
overall soluble protein yield was still very low at 4.2 mg/L however this was decided to be 
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sufficient as usually minimal protein is needed for enzymatic characterisation. Finally, 
expression of hNQO2, which is a 43% identical homologue of PA4975, by Wu et al. 
(1997) generated a comparable 3 mg/L protein from expression in E. coli so perhaps this 
low yield, although different to that gained with the other azoreductases from P. 
aeruginosa PAO1, was not so unusual.  
The expression of recombinant PA1225 proved more troublesome than anticipated with the 
typical system for expressing proposed azoreductases from P. aeruginosa PAO1 failing to 
generate any visible protein. To begin with, the same standard process was repeated with 
all three E. coli BL21(DE3) clones. This was to ensure that there was a problem with the 
expression method rather than a particular isolate as even though precautions such as PCR 
and agarose gel analysis were implemented to confirm successful transformation of each 
selected colony, we have found it to be the case that different clones can produce 
recombinant protein slightly differently (Vethanayagam and Flower, 2005). From this 
examination, one isolate appeared to express recombinant protein when compared to the 
negative control although the protein yield was still minimal. To troubleshoot this issue the 
protocol was altered to provide the E. coli strain with its optimum growth conditions for 
expression. LB was used for bacterial growth and protein expression without the addition 
of 1 M sorbitol and 2.5 mM betaine as the supplementation of compounds into the media 
can put the cells under osmotic stress (Oganesyan et al., 2007). Additionally, protein 
expression following induction with IPTG was carried out at 37°C which is the optimum 
temperature for growth of E. coli (WHO, 2016). Recombinant protein expression under 
these conditions was successful with a 0.1 mM concentration of IPTG proving most 
suitable for gaining predominantly soluble protein. Why this clone failed to produce any 
obvious recombinant protein following the method that was successful for the generation 
of all the other suspected azoreductases remains unclear however the fact that PA1225 was 
indeed expressed following a method alteration indicated that this was not due to protein 
toxicity. Upon scaling up the procedure in order to obtain a higher yield of protein a 
similar problem was encountered to that experienced with PA1224 expression where little 
soluble protein was produced. The protocol was thus scaled down once more and 16.4 
mg/L soluble protein was achieved following purification.  
The next chapter will describe the characterisation of these three recombinant proteins.  
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 Characterisation of purified recombinant proteins PA1224, Chapter 4
PA1225 and PA4975 
4.1 Introduction 
Azoreductases are a genetically diverse group of flavoenzymes that have been 
characterised in many bacterial species including E. coli, B. subtilis, S. aureus, R. 
sphaeroides and P. aeruginosa (Nakanishi et al., 2001, Sugiura et al., 2006, Chen et al., 
2005, Liu et al., 2007a, Wang et al., 2007). Due to their capacity to catalyse reduction of 
the azo bond (-N=N-) found in azo dyes and azo pro-drugs, much research to date has 
focused on their use in bioremediation regarding the treatment of effluent waste water from 
textile and cosmetic industries (Singh et al., 2015). As azo compounds and their 
breakdown products are often mutagenic and thus harmful in an ecosystem, bioremediation 
is essential and bacterial degradation via enzyme production has proved a successful 
method in detoxification (Saratale et al., 2009). It is important to note that many azo 
compounds are not degraded efficiently; it is therefore advantageous to identify 
microorganisms that synthesise azoreductases with broad substrate specificity profiles.  
Azo compounds, including dyes and pro-drugs, are man-made substances. It is thus unclear 
the role bacterial azoreductases play in the natural environment. Along with the reduction 
of azo compounds, azoreductases have also been implicated in mammalian colonisation by 
P. aeruginosa (Rakhimova et al., 2008, Skurnik et al., 2013) and plant infection by E. coli, 
S. enterica, P. syringae and E. chrysanthemi (Landstorfer et al., 2014, Goudeau et al., 
2013, Okinaka et al., 2002). The specific function of azoreductases in relation to host 
survival is not yet known however these enzymes are upregulated in E. coli, P. syringae 
and E. chrysanthemi during plant colonisation and in response to oxidative stress induced 
by plant metabolites (Landstorfer et al., 2014, Postnikova et al., 2015, Okinaka et al., 
2002). 
 
Water soluble quinones are produced by plants and fungi as a response to bacterial 
invasion (Mayer, 2006). These quinones are highly redox active molecules which can 
generate ROS causing severe oxidative stress within the cell (Bolton et al., 2000). 
NAD(P)H quinone oxidoreductases reduce water soluble quinones to the less reactive 
quinol via a two electron transfer (Chesis et al., 1984). Until recently, azoreductases and 
NAD(P)H quinone oxidoreductases were thought to be two distinct classes of enzyme 
(Nakanishi et al., 2001, Chen et al., 2005), however based on the mechanism of 
azoreduction (discussed below), Ryan and colleagues (2014) proposed that these two 
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classes of enzyme are part of an enzyme superfamily. This hypothesis was confirmed by 
Ryan et al. (2014) and Crescente et al. (2016) where they described how azoreductases 
from P. aeruginosa PAO1 were capable of reducing both azo and quinone compounds. 
Keeping in mind the activity of quinones as part of the innate defence mechanism in plants, 
this may provide an insight into the physiological role of bacterial azoreductases.  
 
The azoreductases catalyse the reaction only in the presence of reducing agents NADH 
and/or NADPH as these molecules act as electron donors (Singh et al., 2015). These flavin 
dependent azoreductases have been identified as enzymes which use NADH only 
(Nakanishi et al., 2001), those that use only NADPH (Chen et al., 2005) and those that can 
utilise both (Wang et al., 2007). The particular flavin cofactor can also affect activity with 
some azoreductases showing increased reductive capacity with FMN in the reaction while 
others favour FAD (Crescente et al., 2016). It is therefore necessary to determine the 
selectivity of each azoreductase for both NAD(P)H and flavin in order to define the 
optimal reaction conditions. 
Reduction of both azo and quinone substrates occurs via a ping pong bi bi mechanism 
(Wang et al., 2010). For the reduction of azo substrates, two NAD(P)H molecules are 
required as NAD(P)H + H
+
 is a two-electron carrier and four electrons are needed to 
complete the reaction. It could therefore be suggested that the reduction of azo substrates is 
likely to be a double ping pong bi bi mechanism (Nakanishi et al., 2001, Wang et al., 
2007). The bound flavin undergoes two cycles of two-electron reduction (from FMN to 
FMNH2 or FAD to FADH2) with NAD(P)H acting as an electron donor. Before the azo 
bond can be reduced it must tautomerise to its hydrazone form, creating a quinoneimine 
structure. This explains the ability of these enzymes to reduce both quinone and azo 
substrates. Reduction then occurs via a hydride transfer from the flavin to the tautomerised 
substrate (Ryan et al., 2010a) (Figure 4.1). Since the reducing agent and substrate cannot 
bind to the enzyme simultaneously this is also known as a double displacement reaction 
meaning the binding and subsequent reduction of the azo substrate occurs when the 
NAD(P)
+
 leaves the active site (Cleland, 1963, Yang et al., 2005). Reduction of quinones 
occurs via a similar mechanism however only two electrons are needed to complete this 
reaction (Ryan et al., 2014).  
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Figure 4.1 Proposed reduction mechanism for azo compound balsalazide by paAzor1 
Following FMN reduction to FMNH- by NADPH there is a subsequent hydride transfer to 
balsalazide. For simplicity, only the isoalloxazine ring of FMN and the nicotinamide group 
of NADPH are shown. Figure is taken from (Ryan, 2017). 
 
As previously mentioned in Chapter 1Chapter 3, multiple enzymes from P. aeruginosa 
PAO1 have been identified as both azoreductases and NAD(P)H quinone oxidoreductases 
(Table 1.1) (Wang et al., 2007, Ryan et al., 2010a, Crescente et al., 2016). All of these 
enzymes reduce quinone substrates with greater efficiency than they reduce azo substrates 
with rates of quinone reduction up to two orders of magnitude higher in all cases 
(Crescente et al., 2016). Of the seven putative azoreductases identified by Ryan and 
colleagues (2014), three have yet to be characterised: PA1224, PA1225 and PA4975.  
The structure of a quinone reductase from K. pneumoniae with 67% sequence identity to 
PA1224 has been solved (Kumar, 2012). Due to the moderately high sequence identity 
between this enzyme and PA1224, it is likely that they would have a similar structure and a 
model of the PA1224 structure based on that of the protein from K. pneumonia displays a 
flavodoxin-like fold similar to that of hNQO1 (Figure 4.2) (Kumar, 2012, Skelly et al., 
1999). Given that the overall fold of hNQO1 is similar to that of paAzoR1 (Figure 3.1), it 
could therefore be suggested that PA1224 may have similar catalytic properties to 
paAzoR1 and other azoreductases from P. aeruginosa PAO1.  
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Figure 4.2 PA1224 structure modelled on a quinone reductase from Klebsiella 
pneumoniae with 67% sequence identity superposed against hNQO1   
PA1224 (represented in blue) and hNQO1 (represented in gold) shown with the FAD 
cofactor bound (green). The structure of PA1224 was generated using Swiss-model 
(Biasini et al., 2014) and based on PDB 4GI5 (Kumar, 2012). The structure of hNQO1 is 
from PDB 5EAI (Pidugu et al., 2016). The two structures align with an RMSD value of 
1.35. The image was generated and manipulated in CCP4MG (McNicholas et al., 2011) 
and overlaid using the superpose tool in CCP4MG (Krissinel and Henrick, 2004, Goudeau 
et al., 2013, Postnikova et al., 2015, Okinaka et al., 2002). 
 
As discussed in Chapter 3, hNQO1 displays sequence homology with PA1224 and hNQO2 
shows sequence homology with PA1225 and PA4975 (Ryan et al., 2014). Given that 
hNQO1 and hNQO2 can reduce azo and quinone substrates (Wu et al., 1997), it is possible 
that these three proteins from P. aeruginosa PAO1 may also be able to catalyse such 
reactions. This chapter describes the biochemical and enzymatic characterisation of 
PA1224, PA1225 and PA4975 in terms of thermostability, NAD(P)H and flavin selectivity 
and substrate specificity. 
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4.2 Results 
4.2.1 Characterisation of recombinant putative azoreductases 
A number of biochemical assays were carried out on the purified recombinant proteins 
PA1224, PA1225 and PA4975 in order to determine their flavin and NAD(P)H selectivity 
for enzymatic reduction and establish their substrate specificity profiles. In addition, the 
molecular ratio of flavin molecule per protein monomer was calculated. All statistical 
analysis was performed using GraphPad Prism (version 7). 
4.2.1.1 Determination of flavin selectivity for putative azoreductase proteins from P. 
aeruginosa PAO1  
To establish the presence of FMN or FAD molecules on recombinant proteins PA1224 and 
PA1225, absorption spectra and TLC analysis were conducted on each protein and results 
compared with that of free FMN and FAD molecules. These specific assays were unable to 
be performed on PA4975 due to the low yield obtained during protein production (section 
3.2.3.2).  
4.2.1.2 Absorbance spectra of FMN, FAD, PA1224 and PA1225 
To ascertain the presence of flavin molecules within the proteins, absorption spectra 
between 250 and 600 nm were generated for the pure proteins PA1224 and PA1225. 
Spectra were also obtained using solutions containing 20 µM free FMN or FAD for 
comparison with the protein spectral data, due to the overly high absorbance readings 
obtained for the flavin solutions within the UV spectrum, the readings in this case began at 
300 nm. The flavin spectra were typical with two distinct peaks at 360 nm and 450 nm 
(Figure 4.3 a and b). Both PA1224 and PA1225 displayed spectra similar to the flavin 
groups (Figure 4.4) with well-defined peaks appearing at 360 and 450 nm with the latter 
slightly more prominent in both cases. For this reason, the absorbance reading at 450 nm 
was used to determine the molar ratio of protein molecule to flavin molecule. Upon initial 
comparison of the absorption spectra of PA1224 against that of PA1225, higher 
absorbance readings were shown for PA1224 at the two flavin peaks (360 and 450 nm) 
indicating that this is the protein with the greater flavin content (Figure 4.4). 
Ideally, the molar ratio of protein monomer to flavin molecule should be 1:1 however the 
actual calculated molar ratios were 1.9:1 and 2.4:1 for PA1224 and PA1225 respectively. 
This indicates a relatively successful incorporation of flavin during recombinant protein 
expression when compared to other azoreductase-like enzymes from P. aeruginosa PAO1 
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such as PA0949 which has a molar ratio of protein to flavin molecule of 6:1 (Crescente et 
al., 2016). This data also suggests that PA1224 and PA1225 are indeed flavoproteins and 
confirms that more flavin is present in PA1224 than in PA1225. 
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Figure 4.3 Absorption spectra for PA1224 and PA1225    
Absorbance spectra of the purified recombinant proteins PA1224 (a) and PA1225 (b) 
compared with FMN and FAD absorption spectra, showing two absorption shoulders for 
the free flavin molecules (λmax 360 and 450 nm). 400 µg/mL protein solutions were 
prepared in 20 mM Tris HCl 100 mM NaCl pH 8 and placed in UV transparent cuvettes for 
the spectra determination. 20 µM FMN and FAD solutions were prepared in the same 
buffer and analysed via the same method as the protein solutions. Absorption spectra were 
generated in triplicate using Infinite M200 PRO plate reader between 300 and 600 nm. 
 
 
 
 
Figure 4.4 Absorption spectra comparison of recombinant proteins from P. 
aeruginosa PAO1  
Comparison of absorption spectra of PA1224 (blue) and PA1225 (red) showing the 
different absorbances at 280, 360 and 450 nm. 400 µg/mL protein solutions were prepared 
in 20 mM Tris HCl 100 mM NaCl pH 8 and placed in UV transparent cuvettes for the 
spectra determination. Absorption spectra were generated in triplicate using Infinite M200 
PRO plate reader between 250 and 600 nm. 
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4.2.1.3 Thin Layer Chromatography 
In order to further confirm the presence of flavin within the proteins PA1224 and PA1225 
and also to establish whether the flavin in question was FMN or FAD, the proteins were 
analysed using TLC. Flavin molecules can be separated on TLC plates due to the 
difference in polarity, thus concentrated protein samples were ran on TLC plates alongside 
free FMN and FAD for comparison. Prior to this, the experiment was optimised to find the 
appropriate flavin concentration. Five concentrations ranging from 0.5-20 mM were tested 
for each flavin and it was decided that 1 mM gave the most suitable result (Figure 4.5 a). 
Purified PA1224 and PA1225 were concentrated to 20 mg/mL and spotted on TLC plates 
alongside FMN and FAD. The results show a visible spot for both proteins at a similar 
migrated distance to that of FAD (Figure 4.5 b). Consistent with the data from section 
4.2.1.2 where PA1224 has a higher ratio of flavin molecule per protein monomer than 
PA1225, a more intense spot for PA1224 is evident when compared to that of PA1225. 
Retention factors (Rf) were calculated for both proteins and compared with those obtained 
for FMN and FAD. Although the FMN samples did not produce a well-defined spot, the Rf 
was calculated from where the smearing of the sample began as this was comparable to 
results from previous experiments (Crescente et al., 2016). Rf values of 0.24 and 0.29 were 
achieved for PA1224 and PA1225 respectively. Although these are not identical to the Rf 
of 0.27 for FAD, they are much closer to FAD than FMN which was found to have an Rf 
of 0.44. These results suggest that FAD is the preferred flavin for these proteins and also 
confirms PA1224 and PA1225 as flavoproteins.  
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Figure 4.5 TLC optimisation of free FMN and FAD (a) and TLC profiles of PA1224 
and PA1225 (b)  
TLC analysis of FMN and FAD on silica coated aluminium plates showing the migrations 
of FMN and FAD. Optimisation was performed using 20, 10, 5, 1 and 0.5 mM of free 
flavins (a). TLC analysis was performed to compare the migration of PA1224 and PA1225 
against that of FMN and FAD. A single spot was found for both proteins similar to that of 
FAD (Rf: PA1224 0.24, PA1225 0.29, FMN 0.44, FAD 0.27). Solutions used were 20 
mg/mL protein and 1 mM flavin (b). All solutions were prepared in 20 mM Tris HCl 100 
mM NaCl pH 8, 1 µL of each solution was spotted on the plates. A mixture of N-butanol, 
acetic acid and water (2:1:1) was used as solvent. 
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4.2.1.4 Differential Scanning Fluorimetry 
To investigate the thermostability of the recombinant proteins PA1224, PA1225 and 
PA4975, DSF was carried out. This method was also used to examine any thermal shift 
occurring upon addition of FMN or FAD to the protein. The procedure was carried out as 
described in section 2.6.2 where a sample containing protein and a dye (Sypro Orange) is 
slowly heated. The dye has an affinity for hydrophobic parts of the protein which are 
exposed upon unfolding. The temperature at which the protein unfolds is ascertained by the 
increase in fluorescence of the dye as it binds to the unfolded protein (Niesen et al., 2007). 
All determined melting temperature (TM) values are listed in Table 4.1. The TM for PA1224 
was 41.1°C. Upon addition of 1 µM FMN the protein was destabilised while the presence 
of 1 µM FAD made no difference. However, a significant increase in thermostability was 
seen following the introduction of 5 µM and 10 µM FAD indicating binding of flavin to 
the protein. This stabilisation occurs as a result of hydrogen bond formation between the 
flavin and the protein backbone (Ryan et al., 2010a). No thermal shift was apparent upon 
the inclusion of 5 µM or 10 µM of FMN. A TM of 57.6°C was established for PA1225. 
This time a significant thermal shift of >10°C occurred upon inclusion of both FMN and 
FAD at concentrations of 1 µM and 5 µM with a higher increase visible in the samples 
containing FAD. At 10 µM flavin, the increase in thermostability remained for the sample 
with FAD while the solution with FMN had a TM similar to that of PA1225 without added 
flavin. These results are consistent with the findings from TLC where both PA1224 and 
PA1225 are selective for FAD. Regarding PA4975, a significant increase in the TM of 
48.6°C was to be seen upon inclusion of 1 µM, 5 µM and 10 µM FMN while 
supplementation with 1 µM and 5 µM FAD slightly but significantly destabilised the 
protein. Incorporation of 10 µM FAD failed to incur any thermal shift. This data indicates 
FMN binding to PA4975 thus suggesting it to be the preferred flavin for this protein.  
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Table 4.1 Binding of flavin cofactors to purified recombinant proteins  
Changes in protein thermostability were measured in response to addition of either FMN or 
FAD. Protein was at 64 µg/mL in 20 mM Tris HCl 100 mM NaCl pH 8. The measurements 
displayed depict the mean values with ± standard deviation (n=3). Fitting of the melting 
curve was performed using Graphpad Prism (version 7) to a Boltzman sigmoidal 
distribution. 
 
 
  
 + FMN + FAD 
Protein TM/°C TM + 1 µM TM + 5 µM TM + 10 µM TM + 1 µM TM + 5 µM TM + 10 µM 
PA1224 41.1±0.1 38.6±0.4 40.7±0.6 41.2±0.4 41.6±0.0 45.2±0.4 46.1±0.1 
PA1225 57.6±0.2 68.0±0.4 68.0±0.1 58.1±0.4 72.1±0.5 71.3±0.5 71.0±0.3 
PA4975 48.6±0.4 50.5±0.2 51.5±0.4 51.0±0.1 47.0±0.3 46.8±0.2 47.9±0.3 
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4.2.2 Enzymatic activity of putative azoreductases from P. aeruginosa PAO1 
To confirm enzymatic activity in the recombinant proteins PA1224, PA1225 and PA4975, 
a series of assays were conducted initially in the presence of different cofactors and then 
against a range of azo and quinone substrates. From these enzymatic assays it would also 
be possible to gain information on the cofactor selectivity regarding FMN and FAD and 
also verify the preferred nicotinamide reductant. Enzyme activity was calculated by 
monitoring the reduction of azo compounds. For quinone substrates, NAD(P)H oxidation 
was recorded. This was due to the fact that many of the quinone reduction reactions would 
have been difficult to record as the majority of the quinones tested have little absorbance in 
the visible spectrum however the maximum absorbance (λmax) of NAD(P)H is 340 nm 
(Figure 4.6). Each quinone requires a single two electron transfer from one NAD(P)H 
molecule to complete the reduction while azo compounds require two two electron 
transfers to complete the process (Ryan et al., 2010a). This means that the rate of quinone 
reduction is equal to the rate of NAD(P)H oxidation thus NAD(P)H oxidation is a valid 
method to observe quinone reduction. Each azo substrate tested has a λmax different from 
NAD(P)H that lies within the visible spectrum (Table 4.2). Therefore it was possible to 
directly record the reduction of the azo compounds. In order to obtain the reduction and 
oxidation data for the substrates it was essential to determine the λmax for each of the 
molecules tested.  
4.2.2.1 Calculation of the molar extinction coefficient for NAD(P)H, ANI and the azo 
substrates  
Absorbance scans were carried out for all of the azo substrates as well as NADH and 
NADPH in order to find the λmax for each compound. This was also carried out for each 
quinone however as mentioned previously, many failed to have an appropriate λmax for 
observing their reduction. Each azo compound as well as NADH and NADPH was found 
to have a λmax within the detectable range of 300-700 nm (Figure 4.6, Table 4.2). The 
maximum wavelengths for each compound were used to determine the molar extinction 
coefficient (Ɛ) needed to calculate the rate of reduction for each substrate. The absorbance 
of increasing concentrations of each substrate along with NAD(P)H was measured and 
linear regression analysis was performed on all of the absorbance data (Figure 4.7). From 
this, the Ɛ value was obtained. The λmax and Ɛ value of each substrate is listed in Table 4.2. 
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Figure 4.6 Absorption spectra of NADH (a), NADPH (b), PLU (c), ANI (d), methyl 
red (e) and amaranth (f)  
Absorbance spectra for NADH (a) and NADPH (b) showing a λmax for each compound at 
340 nm. Of the two quinone substrates listed here PLU (c), like many of the quinone 
compounds does not show any considerable absorption level within the wavelength range 
tested while ANI (d) has a λmax of 660 nm. Regarding the azo substrates, methyl red (e) has 
a λmax  of 440 nm and amaranth (f) has a λmax of 540 nm. 
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Figure 4.7 Determination of molar extinction coefficient for NADH (a), NADPH (b), 
ANI (c) and methyl red (d)   
Graphs showing molar extinction factor calculation using different concentrations (µM) of  
NADH (a), NADPH (b), ANI (c) and methyl red (d). Absorbance values were obtained 
measuring each compound/cofactor using their specific λmax. Linear regression was applied 
to obtain molar extinction coefficient values. 
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Table 4.2 NAD(P)H, ANI and azo compounds λmax and molar extinction coefficients 
Maximum absorbance wavelengths obtained for NAD(P)H, ANI and the azo compounds 
from the absorbance spectra analysis and related molar extinction coefficient values 
generated for each of them. 100 µM solutions were used and absorption spectra were 
generated in Nunclon 96-well plates reading within the range of 300 to 700 nm using an 
Infinite M200 PRO plate reader. 
Substrate 
Absorbance peak 
(λmax, nm) 
Molar extinction factor 
(M
-1
 cm
-1
) 
NADH 340  3.3 ∙ 103 
NADPH 340  2.8 ∙ 103 
ANI 660  1.4 ∙ 104 
Amaranth 540  7.5 ∙ 103 
Balsalazide 410  3.3 ∙ 103 
Methyl Red 440  1.4 ∙ 104 
Olsalazine 420  2.3 ∙ 104 
Orange G 500  1.1 ∙ 104 
Orange II 480  2.1 ∙ 104 
Ponceau S 540  2.1 ∙ 104 
Ponceau BS 520  1.8 ∙ 105 
Sudan I 475  1.1 ∙ 104 
Sulfasalazine 430  2.3 ∙ 105 
Tropaeolin 410  9.5 ∙ 103 
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4.2.2.2 Identifying cofactor selectivity of PA1224, PA1225 and PA4975 
To measure the reductive activity of the putative azoreductases and compare the rates 
when using NADH or NADPH as an electron donor, enzyme assays were carried out using 
ANI as a substrate. These assays were then repeated in the presence of FMN and FAD 
separately to observe whether the addition of a flavin cofactor affected the rate of 
reduction. All reaction components and combinations are listed in Table 4.3. ANI was 
chosen as the substrate for this part as it has previously been shown as a good substrate for 
azoreductases from P. aeruginosa PAO1 (Crescente et al., 2016) and has a λmax of 660nm, 
therefore the reduction of this quinone can be measured directly without interference from 
NAD(P)H oxidation. All reactions were performed in triplicate with the reduction 
measured every 10 seconds. A decrease in absorbance, representing substrate reduction, 
was to be seen over time (Figure 4.8). Linear regression analysis was carried out on each 
data set and the rate was determined in µM of substrate reduced per second per mg of 
protein. No enzymatic activity was observed in the absence of NAD(P)H confirming 
PA1224, PA1225 and PA4975 as NAD(P)H dependent enzymes.  
The rate of reduction of ANI by PA1224 showed greater efficiency with NADPH as the 
electron donor (2328.2 ±103.5 µM ∙s-1 ∙mg-1) as opposed to NADH (1386.1 ±81.4 µM ∙s-
1 ∙mg-1) (Figure 4.9 a). An unpaired t-test was performed on the two data sets which 
confirmed that they were significantly different (p<0.001), thus PA1224 is selective for 
NADPH as the electron donor. 
Upon addition of 1 µM flavin to this reaction, the rates of reduction were slightly lowered 
with both FMN and FAD at 2191.8 ±75.8 µM ∙s-1 ∙mg-1 with FMN and 2167.3 ±168.6 
µM ∙s-1 ∙mg-1 with FAD (Figure 4.9 a). Upon statistical analysis using a one-way ANOVA 
however, these rates were not found to be statistically different to those obtained with no 
added flavin.  
The putative azoreductase PA1225 reduced ANI at rates of 29.6 ±1.4 µM ∙s-1 ∙mg-1 in the 
presence of NADPH and 19.71 ±1.53 µM ∙s-1 ∙mg-1 in the presence of NADH (Figure 4.9 
b). Statistical analysis was performed on these results (unpaired t-test) which confirmed 
NADPH as the preferred electron donor with a significantly higher reaction rate than that 
with NADH.  
When FMN was added to the reaction mix the rate of substrate reduction increased to 42.8 
±2.1 µM ∙s-1 ∙mg-1. A similar trend was apparent with the addition of FAD with this assay 
achieving a rate of 35 ±5.4 µM ∙s-1 ∙mg-1 (Figure 4.9 b). Both of these rates were 
97 
 
statistically different to those obtained in the absence of flavin in the reaction mix (analysis 
performed using one-way ANOVA). Although the rate of reduction is slightly higher with 
the addition of 1 µM FMN when compared to that calculated with 1 µM FAD added, an 
unpaired t-test produced a p value of >0.05 implying that there is no significant preference 
for FMN over FAD.  
PA4975 was found to select for NADPH as the electron donor over NADH with reduction 
of ANI occurring at a rate of 677.4 ±21.5 µM ∙s-1 ∙mg-1 using NADPH and at a rate of 
366.3 ±41 µM ∙s-1 ∙mg-1 with NADH (Figure 4.9 c). Reduction using NADPH as the 
electron donor was significantly more efficient with an unpaired t-test between the two 
data sets producing a p value of <0.002.  
The rates of reduction were decreased slightly in this reaction when 1 µM flavin was 
added. A rate of 642.6 ±24.8 µM ∙s-1 ∙mg-1 was achieved with FMN and 618.8 ±38 µM ∙s-
1 ∙mg-1 with FAD (Figure 4.9 c). Statistical analysis was performed on this data using a 
one-way ANOVA however, and it was found that these rates were not statistically different 
to those obtained in the absence of added flavin.   
  
98 
 
Table 4.3 Enzymatic reaction component combinations used to test protein activity 
and NAD(P)H and flavin selectivity  
A number of combinations of reaction components were used in order to establish the 
protein’s activity in the presence and absence of NAD(P)H and FAD or FMN. Samples 
were prepared using 20 µg of protein, 100 µM of substrate, 500 µM NAD(P)H and 1 µM 
of either flavin in 20 mM Tris HCl 100 mM NaCl pH 8 buffer. 
Enzymatic 
reaction 
Protein Substrate NADH NADPH FMN FAD 
1 X X     
2 X X X    
3 X X  X   
4 X X X  X  
5 X X X   X 
6 X X  X X  
7 X X  X  X 
8  X X    
9  X  X   
10  X X  X  
11  X X   X 
12  X  X X  
13  X  X  X 
 
 
 
Figure 4.8 Rate of ANI reduction by PA1225 with and without NAD(P)H  
Graph showing the ANI absorbance measurements at 660 nm during its reduction catalysed 
by PA1225 in the presence of NADH (red) and NADPH (blue) compared to the negative 
control (black) which included no NAD(P)H. The lack of substrate reduction occurring in 
the negative control confirms that NAD(P)H is essential for the reaction with NADPH 
proving more efficient as an electron donor. 
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Figure 4.9 Nicotinamide and flavin selectivity of P. aeruginosa PAO1 recombinant 
proteins  
Reactions were carried out in 20 mM Tris HCl 100 mM NaCl pH 8 with 100 µM substrate, 
500 µM NAD(P)H, 1 µM flavin and 5-0 µg protein. For PA1224 significantly higher 
reduction (p=0.0006) was apparent when using NADPH (2328.2 ±103.5 µM ∙s-1 ∙mg-1) as 
an electron donor rather than NADH (1386.1 ±81.4 µM ∙s-1 ∙mg-1). When 1 µM flavin was 
added the rates were not significantly different to those that occurred in the absence of 
added flavin (2191.8 ±75.8 µM ∙s-1 ∙mg-1 with FMN and 2167.3 ±168.6 µM ∙s-1 ∙mg-1 with 
FAD) (a). For PA1225 NADPH was confirmed via statistical analysis (p=0.0012) as the 
preferred electron donor (29.6 ±1.4 µM ∙s-1 ∙mg-1) over NADH (19.7 ±1.5 µM ∙s-1 ∙mg-1). 
The reaction rate increased to 42.8 ±2.1 µM ∙s-1 ∙mg-1 in the presence of 1 µM FMN and 
35 ±5.4 µM ∙s-1 ∙mg-1 in the presence of FAD. Although these rates were both statistically 
different to those achieved without flavin they were not statistically different to each other 
(p=0.057) (b). For PA4975 a rate of 677.4 ±21.5 µM ∙s-1 ∙mg-1 was calculated with 
NADPH as electron donor compared to a rate of 366.3 ±41 µM ∙s-1 ∙mg-1 for NADH. These 
rates were significantly different (p=0.0013). Rates were not statistically different upon 
addition of FMN (642.6 ±24.8 µM ∙s-1 ∙mg-1) or FAD (618.8 ±38 µM ∙s-1 ∙mg-1) (c). 
Reduction rates were calculated by fitting the change in OD660 over 300 seconds. Error 
bars represent the standard deviation of replicates (n=3). All statistical analysis was 
performed using Graphpad Prism (version 7). 
 
 
 
 
  
100 
 
To summarise, all three recombinant proteins PA1224, PA1225 and PA4975, were 
identified as quinone reductases that can utilise both NADPH and NADH as electron 
donors, albeit at significantly higher rates using NADPH. The addition of either FMN or 
FAD to the reaction mix did not significantly change the reduction rate of ANI by either 
PA1224 or PA4975. Although it significantly improved the rate of reduction with PA1225, 
the rates calculated for FMN and FAD were not significant to each other. Therefore it was 
not possible to determine the preferred flavin from these datasets alone.  
To further examine the effects of including FMN or FAD in the enzymatic reaction, the 
process was carried out where each recombinant enzyme concentration was kept constant 
for each reaction (0.3 µg for PA1224, 2.5 µg for PA1225 and 0.6 µg for PA4975) but the 
flavin concentration was varied from 0-20 µM. For this experiment ANI was used as the 
substrate and absorbance was measured at 660 nm to avoid interference from absorbance 
of the added flavin. The rates obtained for ANI reduction at each flavin concentration were 
plotted against each other (Figure 4.10). A clear preference for FAD was observed for both 
PA1224 and PA4975 (Figure 4.10 a and c respectively) while no obvious difference was 
seen for PA1225 (Figure 4.10 b).  
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Figure 4.10 Activity assays for PA1224 (a), PA1225 (b) and PA4975 (c) in the presence 
of varying flavin concentrations  
ANI reduction was measured at its specific λmax of 660 nm to compare the effects of 
adding FMN (blue) and FAD (red) to the reaction mix. Enzyme concentration was kept 
constant at 3 µg/mL for PA1224 (a), 25 µg/mL for PA1225 (b) and 6 µg/mL for PA4975 
(c). All reactions were carried out in the presence of 500 µM NADPH and 100 µM ANI in 
20 mM Tris HCl 100 mM NaCl pH 8 buffer. Measurements were performed in triplicate 
and error bars represents ± standard deviation. 
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4.2.2.3 Substrate specificity 
A range of azo and quinone compounds were tested as substrates for each recombinant 
protein using the method described in section 2.6.5. All compounds tested as substrates are 
listed in Table 2.14. Following the collection of data, linear regression analysis was 
performed to determine the rates for reduction of each substrate by each enzyme and 
substrate specificity profiles were established. It is important to note that ANI achieved 
higher reduction rates in this section compared to the previous section where nicotinamide 
and flavin selectivity were determined. This is due to the fact that substrate reduction was 
measured by monitoring NADPH oxidation at 340 nm. This was deemed a more 
appropriate measurement for this section so as to standardise the rates obtained against all 
of the other quinones as the majority tested to do not absorb within the visible spectrum.   
 
  
103 
 
4.2.2.3.1 PA1224 
Upon analysis of the enzymatic activity of PA1224 in reducing the azo compounds, very 
low activity was to be seen (Figure 4.11 a). This enzyme was only effective at reducing 
methyl red with a low reaction rate calculated at 2.9 ±0.2 µM ∙s-1 ∙mg-1. Minimal 
enzymatic activity was observed with some substrates however due to high replicate 
variability or reduction rates below 1 µM ∙s-1 ∙mg-1 these could not be considered as 
examples of proper substrate reduction.  
Reduction of quinone compounds with PA1224 was more effective as reduction was 
apparent with all of the quinones tested with the exception of LAW. Rates of reduction 
varied across a wide range with the highest rate of reduction calculated at 2859.4 ±108.3 
µM ∙s-1 ∙mg-1 with ANI (Figure 4.11 b). The next best substrate found for PA1224 was 
PLU with a rate of 1340 ±11.6 µM ∙s-1 ∙mg-1 determined. This was found to be statistically 
different (unpaired t-test, p value=0.0017) from that obtained for ANI therefore ANI was 
deemed the most suitable substrate for PA1224.  
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Figure 4.11 PA1224 substrate specificity profile   
Reactions were carried out in 20 mM Tris HCl 100 mM NaCl pH 8 with 100 µM substrate, 
500 µM NAD(P)H and 20-0 µg protein for azo compounds and 5-0 µg protein for 
quinones. PA1224 reduction rates of azo compounds: enzyme activity was apparent only 
with methyl red (2.9 ±0.2 µM ∙s-1 ∙mg-1). All other rates were below 1 µM ∙s-1 ∙mg-1 
indicating that there are not substrates for this enzyme (a). PA1224 reduction rates with 
quinones: enzymatic activity obtained with ANI (2859.4 ±108.3 µM ∙s-1 ∙mg-1), PLU (1340 
±11.6 µM ∙s-1 ∙mg-1), MEN (533.9 ±24.8 µM ∙s-1 ∙mg-1), BZQ (470.6 ±30.7 µM ∙s-1 ∙mg-1), 
IBC (424.4 ±33.3 µM ∙s-1 ∙mg-1), UQO (408.5 ±17.9 µM ∙s-1 ∙mg-1), AQS (180.3 ±8.6 
µM ∙s-1 ∙mg-1), DCB (43.3 ±1.7 µM ∙s-1 ∙mg-1), HNQ (25.1 ±1 µM ∙s-1 ∙mg-1), ONO (9.7 
±2 µM ∙s-1 ∙mg-1), LAW (0.7 ±0.5µM ∙s-1 ∙mg-1) (b). Reduction rates were calculated by 
fitting the change in OD over 300 seconds. Error bars represent the standard deviation of 
replicates (n=3). 
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4.2.2.3.2 PA1225  
Virtually no azoreductase activity was observed with PA1225. Methyl red was found to be 
the azo substrate reduced at the highest rate (0.9 ±0.1 µM ∙s-1 ∙mg-1) however with a 
substrate reduction rate of less than 1 µM ∙s-1 ∙mg-, this was not statistically different to the 
reduction rate of methyl red with no enzyme present (unpaired t-test, p value=0.053) 
indicating that PA1225 is not an azoreductase enzyme. 
Quinone reductase activity was confirmed with PA1225 with activity exhibited against all 
substrates tested (Figure 4.12). The highest activity recorded was 296.5 ±3.3 µM ∙s-1 ∙mg-1, 
where ANI was used as a substrate. Relatively high activity was also apparent against BZQ 
(178.4 ±10.7 µM ∙s-1 ∙mg-1), HNQ (175.8 ±8.6 µM ∙s-1 ∙mg-1) and IBC (154 ±7.9 µM ∙s-
1 ∙mg-1). Statistical analysis (one-way ANOVA, p=0.0001) confirmed ANI as the best 
substrate tested for PA1225.  
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Figure 4.12 PA1225 substrate specificity profile   
Reactions were carried out in 20 mM Tris HCl 100 mM NaCl pH 8 with 100 µM substrate, 
500 µM NAD(P)H and 5-0 µg protein. PA1225 reduction rates with quinones: enzymatic 
activity obtained with ANI (296.5 ±3.3 µM ∙s-1 ∙mg-1), BZQ (178.4 ±10.7 µM ∙s-1 ∙mg-1), 
HNQ (175.8 ±8.6 µM ∙s-1 ∙mg-1), IBC (154 ±7.9 µM ∙s-1 ∙mg-1), MEN (132.2 ±9.2 µM ∙s-
1 ∙mg-1), PLU (87.8 ±6.2 µM ∙s-1 ∙mg-1), LAW (70.2 ±1.5 µM ∙s-1 ∙mg-1), ONO (67.4 ±3 
µM ∙s-1 ∙mg-1), UQO (48.1 ±3.2 µM ∙s-1 ∙mg-1), AQS (25.5 ±2.4 µM ∙s-1 ∙mg-1), DCB (4.6 
±0.9 µM ∙s-1 ∙mg-1). Reduction rates were calculated by fitting the change in OD over 300 
seconds. Error bars represent the standard deviation of replicates (n=3). 
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4.2.2.3.3 PA4975 
The azo substrate specificity analysis for the protein PA4975 showed a poor reductive 
capacity against any substrate tested. The highest reduction rates were calculated with the 
substrates ponceau S (1 ±0.5 µM ∙s-1 ∙mg-1) and balsalazide (1 ±0.1 µM ∙s-1 ∙mg-1). Further 
analysis was carried out using unpaired t-tests however these rates were found not to be 
significantly different from those calculated from the reactions carried out in the absence 
of PA4975 (p value=0.4 for ponceau S, p value=0.3 for balsalazide). Thus PA4975 was not 
considered to reduce azo substrates. 
A different situation was evident when quinone compounds were used as substrates. 
Quinone reductase activity was apparent against all the substrates tested (Figure 4.13). 
MEN was the substrate reduced at the highest rate (681 ± 13.4 µM ∙s-1 ∙mg-1) with ANI 
(677.4 ±31.5 µM ∙s-1 ∙mg-1), ONO (644.9 ±41.5 µM ∙s-1 ∙mg-1) and PLU (610.9 ±39.2 
µM ∙s-1 ∙mg-1) following closely behind. These rates were not found to be statistically 
different from one another (one-way ANOVA, p=0.08) meaning that although PA4975 
could be confirmed as a quinone reductase, a single best substrate could not be determined.  
  
108 
 
 
 
Figure 4.13 PA4975 substrate specificity profile   
Reactions were carried out in 20 mM Tris HCl 100 mM NaCl pH 8 with 100 µM substrate, 
500 µM NAD(P)H and 5-0 µg protein. Enzymatic activity obtained with MEN (681 ±13.4 
µM ∙s-1 ∙mg-1), ANI (677.4 ±31.5 µM ∙s-1 ∙mg-1), ONO (644.9 ±41.5 µM ∙s-1 ∙mg-1), PLU 
(610.9 ±39.2 µM ∙s-1 ∙mg-1), BZQ (504.6 ±23.5 µM ∙s-1 ∙mg-1), UQO (316.1 ±8.4 µM ∙s-
1 ∙mg-1), LAW (99.3 ±4.7 µM ∙s-1 ∙mg-1), IBC (77.5 ±5.2 µM ∙s-1 ∙mg-1), AQS (70.6 ±3.7 
µM ∙s-1 ∙mg-1), HNQ (38.6 ±1.6 µM ∙s-1 ∙mg-1), DCB (14.8 ±0.7 µM ∙s-1 ∙mg-1). Reduction 
rates were calculated by fitting the change in OD over 300 seconds. Error bars represent 
the standard deviation of replicates (n=3). 
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4.3 Discussion 
The objectives listed in section 1.3 have been met as follows: 
i. The prosthetic group, flavin cofactor and enzymatic reaction conditions for the 
putative azoreductases from P. aeruginosa PAO1, PA1224, PA1225 and PA4975, 
have been established. 
ii. Substrate specificity profiles have been created for the proteins in question with 
respect to both azo compounds and quinone compounds. 
 
Following the successful biochemical characterisation of PA1224, PA1225 and PA4975, 
all three were confirmed as flavoproteins with NAD(P)H dependent quinone 
oxidoreductase activity. Only PA1224 however, was found to catalyse the reduction of azo 
compounds although as a whole they were not good substrates for this enzyme.  
As these three enzymes produced little or no activity against azo substrates, a quinone 
compound, ANI, was used to determine the nicotinamide and flavin selectivity. The results 
in this chapter have confirmed all three enzymes to be NAD(P)H dependent enzymes with 
a significantly faster reaction occurring with NADPH as the hydride donor. Like other 
NAD(P)H dependent quinone oxidoreductases from P. aeruginosa PAO1 (with the 
exception of PA0949), the three enzymes characterised here can also utilise NADH as an 
electron donor (Ryan et al., 2014, Crescente et al., 2016). The selectivity of PA1224 for 
NADPH seen here is consistent with findings that indicate a preference for NADPH over 
NADH by hNQO1 – the closest homologue of PA1224 (Yang et al., 2005). The structural 
basis for these enzymes being selective for NADPH over NADH remains unclear but it 
could be speculated that charged amino acids on the protein surface may affect this 
preference as research has shown that positively charged residues are frequently involved 
in the specific recognition of the negatively charged phosphate included in NADPH (Singh 
et al., 2015). Structural studies would need to be completed on the enzymes concerned in 
this study however to further examine this idea.  
Considering the data obtained from TLC and DSF analysis along with the enzymatic 
activity, it is clear that FAD is the preferred flavin for PA1224. This is also the case with 
PA1225 as like PA1224, a spot was observed on the TLC plate which had an Rf value 
similar to that calculated for FAD. In addition, although the enzyme activity data would 
suggest otherwise, PA1225 was more effectively stabilised in the presence of FAD over 
FMN. This is consistent with the FAD selectivity for hNQO1 and hNQO2 (Wu et al., 
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1997). PA4975 however, poses more of a conundrum where conflicting results were found 
between DSF analysis and the enzyme assays where DSF indicated a preference for FMN 
but higher rates of enzymatic activity were achieved using FAD. Bearing in mind the fact 
that hNQO2, the closest homologue of PA4975 is selective for FAD over FMN it is likely 
that FAD may also be the preferred flavin in this case (Wu et al., 1997). This could not be 
confirmed via TLC analysis as the yield of protein gained was too low to carry out this 
assay. 
It is important to note that although the addition of exogenous flavin to the enzymatic 
reaction mixture can enhance the reduction rate (McDougall et al., 2017), in this case the 
addition of FMN or FAD did not significantly affect the rate of ANI reduction for PA1224 
and PA4975. This is likely due to the fact that flavin was sufficiently incorporated during 
protein expression. During protein purification (section 3.2.3.1), the protein-containing 
eluates appeared a yellow colour for all three proteins in this study suggesting the presence 
of flavin. In addition, in the absorption spectra for PA1224 and PA1225, two distinct peaks 
were evident at 360 nm and 450 nm indicating the presence of flavin. Calculation of molar 
ratios of protein molecule per flavin molecule found a ratio of 1.9 molecules of protein per 
one molecule of flavin for PA1224 and 2.4 molecules of PA1225 per molecule of flavin. 
The higher number of flavin molecules per protein molecule found with PA1224 over 
PA1225 may explain why a significant difference was seen in the enzymatic rate of 
PA1225 upon addition of flavin but not with PA1224. Also, although this molar ratio could 
not be calculated for PA4975 due to the low protein yield, it is likely that the molar ratio 
was comparable to PA1224 as introduction of flavin to the enzyme reaction did not 
increase the reduction rate significantly. The apparent success of flavin incorporation 
during protein expression perhaps explains why addition of flavin to the expression media 
did not increase the yield of soluble protein in sections 3.2.2.2.1 and 3.2.2.2.2. 
The enzymatic data presented in this chapter indicates a diverse substrate specificity for the 
three proteins characterised. Of the three, azoreductase activity was apparent only with 
PA1224. This enzyme however, was not as effective in azoreduction as others previously 
characterised from P. aeruginosa PAO1, namely pAzoR1-3, PA1204, PA2280 and 
PA2580 (Ryan et al., 2010b, Crescente et al., 2016) with only methyl red reduced out of 
the eleven azo compounds tested. In addition, the rate of reduction against this substrate 
was at least one order of magnitude lower than azoreduction rates obtained from the 
previously characterised azoreductase enzymes (Ryan et al., 2010b, Crescente et al., 
2016).  
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In contrast, all three enzymes characterised in this chapter were effective in the reduction 
of quinone compounds with rates of reduction comparable to those achieved with other 
quinone oxidoreductases from P. aeruginosa PAO1 (paAzoR1-3, PA1204, PA2280, 
PA2580 and PA0949) (Ryan et al., 2010b, Crescente et al., 2016). Also, rates of quinone 
reduction by PA1224 were up to three orders of magnitude higher than that calculated for 
the only azo substrate, methyl red. This data would suggest that quinone compounds are 
the primary physiological substrates of the hNQO1 and hNQO2 homologues examined in 
this chapter. It is interesting to note that the substrates for which each enzyme exhibited the 
highest levels of reductive activity, ANI for PA1224 and PA4975 and BZQ for PA1225, 
both contain only a single aromatic ring. This could suggest that the three proteins of 
concern in this study may possess active sites comparable to those of paAzoR1 and 
PA2280 as these enzymes have been found to have the higher reduction rates against single 
aromatic ringed compounds as opposed to the larger naphthoquinones favoured by 
paAzoR2, paAzoR3, PA2580, PA1204 and PA0949 (Ryan et al., 2010b, Crescente et al., 
2016, Ryan et al., 2014). A comparison of the paAzoR1 structure against homology 
models of paAzoR2 and paAzoR3 confirmed a smaller active site for paAzoR1 than for 
paAzoR2 or paAzoR3, suggesting that this may influence the size of optimum substrates 
(Ryan et al., 2010b, Gonçalves et al., 2013, Ito et al., 2008). It is thus likely that the active 
sites of PA1224, PA1225 and PA4975 are smaller than many of the other quinone 
reductases characterised from P. aeruginosa PAO1.  
The findings in this chapter have confirmed three new quinone oxidoreductases and one 
new azoreductase in the P. aeruginosa PAO1 genome. Quinones are harmful to the 
bacterial cells and used by many plants and invertebrates as a defence mechanism. It is 
therefore likely that the diversity of quinones produced drives bacteria to encompass a 
range of NQOs (Mayer, 2006, Ryan et al., 2014). Also, there is an apparent correlation 
between the size of the host range for bacteria and the number of azoreductases produced. 
P. syringae pv. tomato has two azoreductase genes in its genome and infects only two 
known hosts (Buell et al., 2003, Ryan et al., 2014). With this in consideration, the 
pathogenic promiscuity of P. aeruginosa PAO1, where colonisation of hosts ranging from 
amoebae to humans is common, may be the reason why new azoreductases are being 
identified in the P. aeruginosa PAO1 genome. The next chapter will continue the 
biochemical characterisation of four enzymes from P. aeruginosa PAO1 including three 
quinone oxidoreductases/azoreductases and one quinone oxidoreductase. A structural study 
will also be reported on for one of these proteins.  
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 A continued investigation of azoreductases and NAD(P)H Chapter 5
quinone oxidoreductases from P. aeruginosa PAO1 
 
5.1 Introduction 
The azoreductase family in P. aeruginosa PAO1 has recently been proposed as being 
significantly larger than previously thought. Although it is difficult to identify new 
enzymes in this class due to the large sequence diversity amongst members (Table 5.1), a 
common mechanism for the reduction of azo and quinone compounds, described in 
Chapter 4, has led to the idea that azoreductases and NQOs are members of a single 
superfamily (Ryan et al., 2014, Ryan et al., 2010b). A number of formerly unrelated 
enzyme families including ArsH, MdaB, YieF and WrbA have been implicated as 
encompassing the capacity for azo and quinone reduction (Ryan et al., 2014). 
The gene pa2280 was initially identified as part of the ArsH operon in P. aeruginosa (Cai 
et al., 1998, Mao et al., 2009) and in P. putida is responsible for the detoxification of 
trivalent methylated and aromatic arsenicals by oxidation to pentavalent species (Chen et 
al., 2015). It was suggested to encode an azoreductase as it is a homologue of known 
azoreductases, namely ArsH from both S.meliloti (82% similarity) (Ye et al., 2007) and 
Synechocystis sp. PCC 6803 (78% similarity) (Hervás et al., 2012). In addition, ArsH from 
S. meliloti has the same overall core fold as paAzoR1 (Ryan et al., 2014). 
Homologues of genes encoding known NQOs include pa2580, pa1204 and pa0949 (Ryan 
et al., 2014). Like pa2280, homologues of these three genes encode for proteins which 
possess the same overall fold as paAzoR1 (Ryan et al., 2014, Agarwal et al., 2006, 
Gorman and Shapiro, 2005). There is significant homology between pa2580 and enzymes 
from the MdaB family and NQO activity has been observed in MdaBs from E. coli (75% 
similarity) (Hayashi et al., 1996) and Helicobacter pylori (71% similarity) (Wang and 
Maier, 2004). Similarly, an enzyme from A. thaliana shows NQO activity and is the closest 
homologue of pa1204 that has been characterised (69% similarity) (Sparla et al., 1999). 
Finally, pa0949 forms part of the WrbA family which are known for their strong 
interaction with tryptophan repressor (Yang et al., 1993) and the E. coli homologue of 
WrbA (56% similarity) has NQO activity (Patridge and Ferry, 2006). 
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All four proteins listed above have already been cloned and expressed in E. coli and the 
subsequent characterisation has confirmed all but PA0949 as azoreductase enzymes. 
Quinone reductase activity has been confirmed in all four proteins at a much higher rate 
than that for azoreduction (Crescente et al., 2016). 
 
Table 5.1 Nucleic acid sequence identity between known and putative P. aeruginosa 
PAO1 azoreductase/NQO genes  
Table showing the nucleic acid sequence homology between known (paazor1, paazor2, 
paazor3, pa2280, pa2580, pa1204, pa0949, pa4975) and putative (pa1224, pa1225) 
azoreductase and/or NQO genes from P. aeruginosa PAO1. Values are expressed in 
percentage of homology. Sequences were taken from the Pseudomonas Genome Database 
(Winsor et al., 2016) and identity matrix was generated using a ClustalW alignment in 
Bioedit (Hall, 1999, Thompson et al., 1994). 
 
  
 paazor1 paazor2 paazor3 pa2280 pa2580 pa1204 pa0949 pa4975 pa1224 pa1225 
paazor1 ID 55% 48% 32% 30% 36% 31% 36% 37% 37% 
paazor2 55% ID 50% 33% 29% 33% 31% 35% 33% 37% 
paazor3 48% 50% ID 31% 28% 32% 27% 36% 35% 37% 
pa2280 30% 29% 28% ID 25% 27% 28% 33% 28% 35% 
pa2580 32% 33% 31% 25% ID 33% 28% 32% 32% 32% 
pa1204 36% 33% 32% 33% 27% ID 37% 31% 30% 33% 
pa0949 31% 31% 27% 28% 28% 37% ID 30% 30% 33% 
pa4975 36% 35% 36% 32% 33% 31% 30% ID 56% 37% 
pa1224 37% 33% 35% 32% 28% 30% 30% 56% ID 39% 
pa1225 37% 37% 37% 32% 35% 33% 33% 37% 39% ID 
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The MdaB family of enzymes has been extensively characterised in a range of bacterial 
species and linked to many bacterial physiological functions including virulence, host 
colonisation, survival within macrophages, quorum sensing and antimicrobial 
susceptibility (Sarva et al., 2016, Wang and Maier, 2004, Kraemer et al., 2009, Skurnik et 
al., 2013, Asare et al., 2010, Asare and Abu Kwaik, 2010, Ling et al., 2012, Chen et al., 
2010, Tan et al., 2014). Colonisation of invertebrate and mammalian hosts with 
Francisella sp. has been demonstrated to be significantly impaired upon deletion of mdaB 
(Kraemer et al., 2009, Asare et al., 2010). Francisella novicida mdaB mutants exhibit a 
loss of survival in both the liver and lung of a murine infection model when compared to 
the wild type (Kraemer et al., 2009). In addition, mdaB gene deletion strains of Francisella 
tularensis show decreased proliferation and loss of virulence in the arthropod vector model 
D. melanogaster and the gene deleted strain also has reduced bacterial survival in U937 
derived macrophages (Asare et al., 2010, Asare and Abu Kwaik, 2010). It is likely that this 
phenotype regarding survival within macrophages is attributed to the quinone reductase 
function of MdaB which would protect against ROS damage (Sarva et al., 2016). 
Furthermore, upon comparison of different subspecies of F. tularensis, mdaB is more 
highly expressed (≥5 fold) in the more virulent strain, Schu S4, as opposed to holarctica 
OR960246 (Sarva et al., 2016). 
This apparent role of MdaB in host infection is not exclusive to Francisella sp. however. 
Wang and Maier (2004) noted that mdaB deletion mutants of H. pylori were significantly 
less successful in the colonisation of a mouse stomach than the wild type and Skurnik and 
colleagues (2013) observed that pa2580 (mdaB) mutants of P. aeruginosa P14 were 
unviable in the caecum and spleen of a murine model. As well as survival within a host, 
MdaB in H. pylori has been shown to play a key role in oxidative stress management with 
mdaB mutants unable to survive the same extent of air exposure as the wild type, also the 
gene deleted strains were more sensitive to H2O2, organic hydroperoxides and paraquat 
(Wang and Maier, 2004). A role in quorum sensing in P. aeruginosa was implied by Tan et 
al. (2015) where mdaB was significantly upregulated upon treatment with the QS inhibitor 
Iberin. Finally, MdaB has also been linked to antibiotic sensitivity in P. aeruginosa and E. 
coli and this will be discussed in the next chapter. 
The first azoreductase structure to be solved was that of an enzyme from E. coli (Ito et al., 
2006). Subsequently, several bacterial azoreductase structures have been solved that all 
share a characteristic homodimeric short flavodoxin-like fold, with the active sites formed 
by residues from both monomers and situated at the dimer interface (Wang et al., 2007, 
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Liu et al., 2007b, Binter et al., 2009, Gonçalves et al., 2013, Yu et al., 2014). The substrate 
binding pocket is typically lined by hydrophobic aromatic residues, many of which are part 
of the β-hairpin that forms the active site ‘lid’ and play a role in determining the enzyme’s 
substrate specificity (Wang et al., 2010). Each active site contains one flavin molecule 
which is essential for activity. The ‘flavin binding cradle’, conserved in both bacterial and 
eukaryotic azoreductases, is a structural motif comprising sequence independent hydrogen 
bonds which anchor the FMN or FAD within the active site (Ryan et al., 2010a). The 
azoreductase family has large sequence diversity amongst members resulting in few 
conserved residues between the proteins which indicates a possibility that those that are 
conserved may provide structural stability (Ryan et al., 2014, Ryan et al., 2010a). 
Many structures of azoreductases in complex with substrates such as quinones, azo and 
nitroaromatic compounds have been solved including paAzoR1 with methyl red, 
balsalazide, Coenzyme Q1, anthraquinone-2-sulfonate and nitrofurazone (Wang et al., 
2007, Ryan et al., 2014, Ryan et al., 2011, Ryan et al., 2010a), ppAzoR (from P. putida) 
with anthraquinone-2-sulfonate and reactive black 5 (Gonçalves et al., 2013) and AzrA and 
AzrC (from Bacillus sp.) with acid red 88 and orange I (Yu et al., 2014). All substrates 
bind between the aromatic residues of the β-hairpin and the isoalloxazine rings of the 
flavin, with which they form π-π stacking interactions. 
As of yet, no azoreductase structure has been solved in complex with a nicotinamide 
cofactor. Yu and colleagues (2014) solved the structure of the NAD(P)H competitive 
inhibitor cibacron blue in complex with azoreductases from Bacillus sp. however due to 
structural differences between it and NAD(P)H this does not provide details of the 
nicotinamide binding (Figure 5.1). The structure of MdaB from Streptococcus mutans in 
complex with NADPH has been solved and is the only structural evidence available in the 
literature of nicotinamide binding in this family (Wang et al., 2014). While this may be 
useful, it is important to note that the residues lining the active sites of MdaB enzymes 
from P. aeruginosa, E. coli and Y. pestis are completely conserved with an overall 
sequence identity of ~60%. In contrast, smMdaB shares little sequence similarity with any 
member of this family (21% similarity with paMdaB (Edgar, 2004)). In addition, no 
azoreductase activity has so far been observed with smMdaB so this cannot yet be 
confirmed as an appropriate nicotinamide binding model for an azoreductase enzyme.  
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Figure 5.1 Chemical structures of H2NADPH (a) and cibacron blue (b)  
The chemical structures of H2NADPH (a) and cibacron blue (b) are displayed. Both 
images were generated in ChemSketch (ChemSketch, 2015). 
 
X-ray crystallography is a powerful tool for examining biological function and is based on 
x-ray diffraction datasets obtained from crystals (in this case, protein crystals) grown in a 
supersaturated solution that exhibits conditions that do not significantly perturb the 
molecules natural state (McPherson and Gavira, 2014, Wlodawer et al., 2008). To improve 
understanding of the binding of the nicotinamide cofactor to azoreductase-like enzymes in 
P. aeruginosa, this technique has been employed and is described in this chapter to 
examine the structure of PA2580/paMdaB in complex with a non-reactive form of 
NADPH. In addition, the four proteins, PA2280, PA2580, PA1204 and PA0949, identified 
as putative azoreductases by Ryan et al. (2014) and previously characterised by Crescente 
(2015) are investigated here in order to confirm the flavin selectivity for each enzyme and 
examine their properties in relation to thermostability.  
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5.2 Results 
The continuation of the characterisation of the newly identified azoreductase and NQO 
proteins from P. aeruginosa PAO1, as started by Crescente (2015), is covered in this 
chapter. In order to confirm their flavin selectivity a range of biochemical assays were 
performed. The molecular ratio of flavin molecule per protein monomer was calculated for 
each protein and a structural study of PA2580 was carried out. 
5.2.1 Overexpression and purification of recombinant proteins 
All recombinant proteins used in this section were generated by Dr. Vincenzo Crescente as 
described in Crescente (2015) with the exception of PA2580. The cloned strain, E. coli 
BL21-pET-28b::pa2580 used for the production of PA2580, was also kindly supplied by 
Dr. Vincenzo Crescente. Recombinant PA2580 was overexpressed in two 500 mL culture 
volumes using the method described in section 2.4.1. Following cell lysis and separation, 
the soluble and insoluble fractions along with the whole cell lysate were observed using 
SDS-PAGE (Figure 5.2). For each fraction, distinct bands were seen at approximately 24 
kDa (actual size estimated at 24.1 kDa using ProtParam (Gasteiger E., 2005)) which did 
not appear in the negative control indicating that overexpression had been successful. It 
was clear that soluble protein had been produced with approximately 80% of recombinant 
protein appearing in the soluble fraction. This was then purified via the IMAC method as 
described in section 2.5.1. Samples of the eluates containing purified protein along with the 
flow through and un-purified soluble fraction were examined on SDS-PAGE (Figure 5.3). 
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Figure 5.2 Overexpression of PA2580 recombinant protein in E. coli BL21(DE3)  
Coomassie blue stained SDS-PAGE showing overexpression of PA2580 recombinant 
protein. Large scale protein production in 500 mL culture volumes was compared between 
E. coli BL21(DE3) transformed with pET-28b::pa2580 induced with 0.5 mM IPTG (lanes 
4-6) and a negative control of E. coli BL21(DE3)-pET-28b (lanes 1-3). Overproduction at 
approximately 24 kDa was evident only in the induced azoreductase clone. Lanes depict 
the whole cell lysate (1, 4), insoluble fraction (2, 5) and soluble fraction (3, 6). Lane M 
represents the molecular weight marker. 
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Figure 5.3 Purification of PA2580 recombinant protein using IMAC  
Coomassie blue stained SDS-PAGE showing the purification of the soluble fraction from 
the expression lysate. An Ni-NTA column was loaded with the soluble fractions from 500 
mL cultures and eluted with buffer (20 mM Tris HCl, 100 mM NaCl, pH 8) containing 
increasing concentrations of imidazole (10, 25, 50, 100 and 250 mM). Lanes depict the 
molecular weight marker (M), soluble fraction (1), flow through (2), 0 mM imidazole (3), 
10 mM imidazole (4), 25 mM imidazole (5), 50 mM imidazole (6), 100 mM imidazole (7) 
and 250 mM imidazole (8). Lane M represents the molecular weight marker (NEB broad 
range protein ladder). 
 
 
5.2.2 Dialysis and quantification of PA2580 
Following protein purification, PA2580 was eluted in 20 mM Tris HCl 100 mM NaCl pH 8 
containing 100 mM and 250 mM imidazole. To reduce the amount of imidazole to <1 mM, 
the samples which had been eluted from the IMAC column in 4 mL volumes with 100 mM 
and 250 mM imidazole were added separately to porous tubing with a molecular weight 
cut-off of 12-14 kDa. This tubing was then suspended in 4 L buffer (20 mM Tris HCl 100 
mM NaCl pH 8). Following overnight dialysis, the protein samples were quantified and 
concentrated to 2 mg/mL in 20 mM Tris HCl 100 mM NaCl pH 8 5% v/v glycerol before 
being flash frozen in liquid nitrogen and stored at -80°C. This method resulted in a yield of 
33.3 mg of pure soluble protein from 1 L culture. 
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5.2.3 Characterisation of recombinant azoreductases and quinone 
oxidoreductases 
5.2.3.1 Absorbance spectra of azoreductases and quinone oxidoreductases 
The proteins in this section have already been confirmed as flavoproteins (Crescente, 
2015). Although it is never certain that flavin is incorporated during expression in E. coli it 
was assumed that flavin would indeed be present in PA2280, PA2580 and PA1204 as the 
TLC results (for PA2580 and PA1204 only) and enzymatic activity data from Crescente 
(2015) indicates that flavin is bound. However to quantify the ratio of protein monomers to 
flavin molecules, absorbance readings were taken between 300 and 600 nm. The 
absorbance spectra for FMN and FAD obtained in section 4.2.1.2 were used as a means of 
comparison. The spectra obtained for PA2280, PA2580 and PA1204 displayed the 
characteristic flavin absorption peaks (Figure 5.4). No flavin absorption peaks were 
apparent for PA0949. To determine the ratio of protein monomer to flavin molecule the 
absorbance measurements at 280 and 450 nm were examined. The molar ratios for each 
protein to flavin were as follows, 4.3:1 for PA2280, 2.5:1 for PA2580, 3.4:1 for PA1204 
and 6.2:1 for PA0949. 
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Figure 5.4 Absorption spectra for PA2280 (a), PA2580 (b), PA1204 (c) and PA0949 (d) 
Absorbance spectra of the purified recombinant proteins PA2280 (a), PA2580 (b), PA1204 
(c) and PA0949 (d) compared with FMN and FAD absorption spectra, showing two 
absorption shoulders for the free flavin molecules (λmax 360 and 450 nm). 400 µg/mL 
protein solutions were prepared in 20 mM Tris HCl 100 mM NaCl pH 8 and placed in UV 
transparent cuvettes for the spectra determination. 20 µM FMN and FAD solutions were 
prepared in the same buffer and analysed via the same method as the protein solutions. 
Absorption spectra were generated in three replicates (n=3) using Infinite M200 PRO plate 
reader between 300 and 600 nm. 
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5.2.3.2 Confirming flavin selectivity 
The characterisation of PA2280, PA2580, PA1204 and PA0949 carried out in Crescente 
(2015) followed a similar process to that described in section 4.2.2.2 where a series of 
activity assays were performed and the rates compared to establish the preferred electron 
donor and flavin cofactor. For all four proteins, NADPH was confirmed as the preferred 
electron donor over NADH with significantly higher activity rates achieved with the 
former. Regarding flavin selectivity, Crescente (2015) observed that PA2280 and PA0949 
reduced their substrate more efficiently in the presence of FMN over FAD while PA2580 
and PA1204 achieved higher reduction rates with FAD as the cofactor. The flavin 
selectivity was confirmed for PA2580 and PA1204 only via TLC analysis where a spot 
was observed for both proteins with an Rf similar to that of FAD. As mentioned in the 
previous section, no spot was observed for either PA2280 or PA0949 thus the flavin 
selectivity in this case could not be confirmed (Crescente, 2015). 
To further investigate the flavin selectivity of these proteins, the reduction of ANI by each 
enzyme was monitored in the presence of increasing concentrations of each flavin. ANI 
was selected as the substrate in this case as it is a universal substrate for these enzymes 
(Crescente et al., 2016) and the λmax of 660 nm would not be interfered with by the 
presence of either flavin. Consistent with the findings of Crescente (2015), FMN appears 
to be the preferred flavin for PA2280 and PA0949. For PA2280, a much steeper increase in 
reduction rates was apparent with FMN over FAD (Figure 5.5 a) while PA0949 showed no 
reductive capacity in the presence of FAD at any concentration but as FMN concentration 
increased so did the rate of activity (Figure 5.5 d). A preference for FMN over FAD was 
also evident with PA1204 (Figure 5.5 c). Regarding PA2580, it was not possible to 
determine flavin selectivity via this method as both sets of reduction rates were similar 
(Figure 5.5 b). 
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Figure 5.5 Activity assays for PA2280 (a), PA2580 (b), PA1204 (c) and PA0949 (d) in 
the presence of varying flavin concentrations   
ANI reduction was measured at its specific λmax of 660 nm to compare the effects of 
adding FMN (blue) and FAD (red) to the reaction mix. Enzyme concentration was kept 
constant at 0.2 µg/mL for PA2280 (a), 5 µg/mL for PA2580 (b), 1 µg/mL for PA1204 (c) 
and 10 µg/mL for PA0949 (d). All reactions were carried out in the presence of 500 µM 
NADPH and 100 µM ANI in 20 mM Tris HCl 100 mM NaCl pH 8 buffer. Measurements 
were performed in triplicate and error bars represents ± standard deviation. 
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To provide further evidence of the flavin selectivity of these proteins, the effects on protein 
stability upon addition of FMN and/or FAD were monitored using DSF. The TM of each 
protein was calculated in the presence and absence of flavin. An increase in TM upon 
addition of flavin would indicate the binding of flavin to the protein. For PA2280, a small 
but significant thermal shift was observed in the presence of 1 µM FMN while no change 
was evident with 1 µM FAD. Upon addition of 1 µM of either flavin to PA2580 a 
significant thermal shift was noted, however the shift was much greater at 16°C with FAD 
as opposed to 5°C with FMN. Regarding PA1204 and PA0949, no significant difference 
was apparent upon addition of either 1 or 5 µM flavin however when the FMN 
concentration was increased to 20 µM, PA1204 was destabilised. In contrast, addition of 
20 µM FAD significantly increased the TM of this protein by 6°C. The addition of 20 µM 
or either flavin stabilised PA0949 with a much larger increase in thermostability evident 
with FMN compared to FAD (12°C and 2°C respectively). All DSF results are listed in 
Table 5.2. 
 
 
Table 5.2 Binding of flavin cofactors to azoreductase and NQO enzymes  
Changes in protein thermostability were measured in response to addition of either FMN 
or FAD. *20 µM or †1 µM flavin was added to the mixture. Thermostability was 
measured for 64 µg/mL enzyme in 20 mM Tris HCl pH 8 and 100 mM NaCl. All 
measurements were performed in triplicate. Fitting of the melting curve was performed 
using Graphpad Prism (version 7) to a Boltzman sigmoidal distribution. 
Azoreductase TM/°C TM + FMN/°C TM + FAD/°C 
PA2280
†
 47.3 ± 0.1 49.1 ± 0.7 47.4 ± 0.2 
PA2580
†
 47.1 ± 0.1 52.6 ± 0.2 63.5 ± 0.1 
PA1204
*
 71.1 ± 0.6 49.2 ± 2.0 77.3 ± 0.5 
PA0949
*
 55.7 ± 0.3 64.4 ± 0.8 57.7 ± 0.3 
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5.2.4 Crystallisation and structural determination of PA2580 
5.2.4.1 Crystallisation of PA2580 with H2NADPH 
The purified protein PA2580 was concentrated via an ultracentrifugation concentrator to 
10 mg/mL and washed in 20 mM Tris HCl 500 µM FAD 2 mM H2NADPH. Initial small 
scale crystal trials (0.2 µL protein solution) were set down using a Mosquito crystallisation 
robot (TTP Labtech). Screens were performed in sitting drop 96-well plates and the buffer 
conditions trialled were PACT premier HT-96, JCSG-plus and Morpheus (Molecular 
Dimensions). The conditions which grew crystals are listed in Table 5.3. Typical protein 
crystals of approximately 93 µm across were obtained within 3 to 4 days (Figure 5.6). 
Although crystals were obtained in some PACT premier conditions, the scaling up 
procedure (2 µL of protein solution) was only performed for the successful Morpheus 
screens, B6 (0.09 M Halogens, 0.1 M Sodium HEPES, 0.1 M MOPS, 20% v/v ethylene 
glycol, 10% w/v polyethylene glycol (PEG) 8000 pH 7.5) and F10 (0.12 M 
Monosaccharides, 0.1 M Bicine, 0.1 M Tris, 20% v/v ethylene glycol, 10% w/v PEG 8000 
pH 8.5). This was due to the fact that these particular Morpheus screens contain 20% 
ethylene glycol and 10% w/v PEG 8000 thus an extra soaking stage in cryoprotectant 
prior to freezing could be omitted (Gorrec, 2009). Crystals from both sets of conditions 
were picked and soaked overnight in 4 µL 10 mM H2NADPH prepared in the appropriate 
Morpheus buffer prior to snap freezing in liquid nitrogen. 
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Table 5.3 Successful crystallisation conditions for PA2580 
Conditions 
Screen Well Additives Buffer pH Precipitant 
PACT 
premier 
HT-96 
F6 
0.2 M sodium formate 
0.1 M 
Bis Tris 
propane 
6.5 
20% w/v PEG 3350 
G6 
7.5 
G2 0.2 M Sodium bromide 
G3 0.2 M Sodium iodide 
G7 
0.2 M Sodium acetate trihydrate 
F7 6.5 
Morpheus 
B6 
0.09 M Sodium fluoride; 
0.09 M Sodium bromide; 
0.9 M Sodium iodide; 
0.1 M 
HEPES 
0.1 M 
MOPS 
7.5 
20% v/v Ethylene 
glycol 
10% w/v PEG 8000 
F10 
0.12 M D-Glucose; 
0.12 M D-Mannose; 
0.12 M D-Galactose; 
0.12 M L-Fructose; 
0.12 M D-Xylose; 
0.12 M N-Acetyl-D-Glucosamine 
0.1 M 
Bicine Tris 
8.5 
 
 
 
 
Figure 5.6 Crystals of PA2580  
Crystals of PA2580 in mother liquor 0.1 M HEPES 0.1 M MOPS pH 7.5 and 20% v/v 
ethylene glycol 10% w/v PEG 8000. These crystals were grown by the sitting drop vapour 
diffusion method in 48-well Maxi plates. These crystals were imaged using Xli Cap.  
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5.2.4.2 Structure determination of PA2580 with bound H2NADPH 
The frozen mounted crystals were transported to the Diamond light source by Dr. Edward 
Lowe (Oxford University). The gathering of data and subsequent molecular replacement is 
described in section 2.7.4. The structure of PA2580 obtained from crystals grown in 2 mM 
H2NADPH was solved at 1.29 Å with good stereochemistry and Rfree and Rwork values of 
15.7% and 13.9% respectively. Two PA2580 monomers each with the same flavodoxin 
fold found in other MdaB structures were evident in the asymmetric unit of the crystal. 
There was strong density in both active sites obtained after molecular replacement for the 
expected bound FAD which allowed unambiguous building of the complete FAD molecule 
(Figure 5.7). Subsequent rounds of refinement which included the addition of water 
molecules revealed density in the active site pocket consistent with the binding of MOPS 
(one of the buffer components in the crystallisation solution) (Figure 5.8 a). 
The crystals which had been soaked overnight in H2NADPH were used as an attempt to 
overcome the binding of MOPS in the active site. A second dataset was collected using the 
same method as used above and the structure solved at 1.35 Å. The structure of PA2580 
solved above was stripped of its ligands and used to phase the new structure via molecular 
replacement. In this case, refinement resulted in a density consistent with the nicotinamide 
group of H2NADPH and this was subsequently refined in place (Figure 5.8 b). All 
processing and refinement statistics are available in Table 5.4. 
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Figure 5.7 Crystal structure of the PA2580 homodimer 
Each monomer (represented in pink and blue) is shown with the FAD cofactor bound 
(yellow). This image was generated and manipulated in CCP4MG (McNicholas et al., 
2011). 
 
 
 
 
 
Figure 5.8 Binding of compounds in the active site of PA2580  
Electron density consistent with MOPS is displayed bound to the FAD cofactor of PA2580 
(a). Following overnight soaking of preformed crystals in 10 mM H2NADPH, electron 
density consistent with the nicotinamide group of H2NADPH was present bound to the 
FAD cofactor of PA2580 (b). These images were generated using CCP4MG (McNicholas 
et al., 2011).   
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Table 5.4 Processing and refinement statistics for PA2580 and PA2580-nicotinamide 
Structure PA2580 PA2580-nicotinamide 
Space Group P21 21 21 P21 21 21 
α, β,  (°) 90, 90, 90 90, 90, 90 
a, b, c (Å) 61.47, 64.01, 99.59 61.58, 63.84, 99.57 
Processing Statistics 
Resolution Range (Å) 53.85-1.29 49.78-1.35 
Unique reflections 96132 (5516) 85976 (7704) 
Rmerge 0.067 (0.612) 0.078 (0.880) 
<I/σ(I)> 13.5 (2.3) 13.0 (1.7) 
Completeness % 96.6 (75.9) 99.1 (92.1) 
Multiplicity
 a
 5.4 (2.3) 6.3 (4.4) 
Refinement Statistics 
Rwork % 15.7 15.7 
Rfree
 
%
 c
 13.9 13.2 
RMSD bond angle (°) 1.09 1.03 
RMSD bond length (Å) 0.008 0.008 
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5.3 Discussion 
The aims of this chapter as laid out in section 1.3 have been completed as follows: 
i. Characterisation of the enzymes PA2280, PA2580, PA1204 and PA0949 from P. 
aeruginosa PAO1 (including flavin cofactor selectivity and thermostability 
analysis) has been completed. 
ii. The crystal structure of PA2580 in complex with the non-reactive H2NADPH has 
been solved at a resolution of 1.3 Å. 
 
In agreement with the biochemical and enzymatic analysis carried out by Crescente (2015), 
the four proteins PA2280, PA2580, PA1204 and PA0949 have different cofactor and 
substrate preferences. They have also been noted here to encompass different 
thermostability profiles. 
All proteins were expected to be flavin dependent enzymes and this was confirmed by 
Crescente (2015). However, the level of flavin incorporation during recombinant protein 
expression in E. coli was unclear. A low flavin to protein ratio could also occur as a result 
of dissociation of flavin from the enzyme during overnight dialysis as the flavin is not 
covalently bound to the enzyme (Ryan et al., 2010a). How much flavin will dissociate is 
dependent on the affinity of the protein for the flavin. Upon collection of UV-visible 
spectra for each protein it was evident that flavin was present in a different molar ratio for 
each enzyme. The data obtained here was consistent with that the TLC results gathered by 
Crescente (2015) where a spot was visible for PA1204 and PA2580 (flavin to protein ratios 
of 3.4:1 and 2.5:1 respectively) but not for PA2280 or PA0949 (flavin to protein ratios of 
4.3:1 and 6.2:1 respectively) thus confirming that there is less incorporation or increased 
loss of flavin in the latter two proteins. Also, neither PA2280 nor PA0949 displayed 
reductive activity against ANI without the addition of flavin to the reaction mix. It is 
therefore not surprising that these were the two enzymes with the lowest flavin to protein 
ratio. 
Regarding flavin selectivity, PA2280 has shown a clear preference for FMN over FAD in 
both DSF analysis and the activity assays which included increasing concentrations of 
FMN and FAD. This data is consistent with the findings of Crescente (2015) where 
reduction of methyl red was significantly higher with FMN included the reaction mix. 
Also, ArsH from S. meliloti has been confirmed via TLC analysis to select for FMN (Ye et 
al., 2007). Although the activity assays completed here for PA2580 failed to show any 
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obvious preference for either flavin, previous work has shown that methyl red is reduced at 
a higher rate upon inclusion of FAD (Crescente, 2015). In addition, TLC analysis 
completed by Crescente (2015) yielded an obvious FAD spot for this protein. The DSF 
data compiled here has also confirmed FAD as the cofactor with a higher thermal shift 
apparent with FAD as opposed to FMN indicating selective binding of FAD to the protein. 
This result is consistent with data from a study on MdaB from E. coli (75% sequence 
similarity) that showed that the enzyme was selective for FAD when reducing quinones 
(Hayashi et al., 1996). PA1204 presents a more confusing result however with the DSF 
data showing selectivity for FAD while the activity assays including increasing flavin 
concentrations imply a clear preference for FMN. The FMN selectivity is supported by 
Agarwal et al. (2006) where the crystal structure of PA1204 was solved with FMN bound. 
It is important to note however that no experimental evidence was suggested in this study 
for introduction of FMN over FAD. Considering the findings in Crescente (2015), it is 
likely that FAD is the preferred cofactor as a weak TLC spot was observed for FAD and 
MEN was reduced at a significantly higher rate with FAD over FMN. Finally, PA0949 
appears to select for FMN over FAD. No reduction of ANI occurs upon addition of 5-20 
µM FAD in the reaction mix while when FMN is included the reaction rate increases 
steadily with FMN concentration. A similar result was obtained by Crescente (2015) where 
reduction of MEN only occurred in the presence of FMN. The DSF results gathered here 
also indicate FMN as the more suitable cofactor with a larger increase in thermostability 
evident when FMN was included compared to FAD. This is consistent with literature that 
has demonstrated FMN being selectively incorporated into WrbA from E. coli by means of 
activity assays and structural analysis (Kishko et al., 2013). 
The unusually high thermostability of PA1204 coupled with its ability to reduce azo 
compounds, as demonstrated by Crescente (2015), is likely to be of particular use in 
bioremediation as high thermostability implies a longer lifetime and higher tolerance to 
extreme pH values, high salt concentration, elevated pressure and the presence of organic 
co-solvents (Brissos et al., 2014). In addition, previous research has shown the capacity of 
YieF from E. coli in reducing heavy metal ions such as Cr
6+
 and U
6+
 to the less water 
soluble Cr
3+ 
and U
3+ 
(Ackerley et al., 2004). In aquatic environments these heavy metals 
can be absorbed by living organisms and enter into the food chain which can result in the 
accumulation of large concentrations within the human body and serious health disorders 
thus decreasing water solubility of these ions is essential (Babel and Kurniawan, 2004). 
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With this in mind, it is possible that engineered members of the YieF family could prove 
highly beneficial in bioremediation of both heavy metals and azo dyes. 
Structural analysis of PA2580 was carried out by means of x-ray crystallography. This 
protein was selected for structural studies as a high yield of pure protein was easily and 
reproducibly obtained from recombinant expression. This protein has previously been 
demonstrated to preferentially utilise NADPH over NADH during reduction reactions thus 
it was decided to co-crystallise the protein with the chemically reduced non-oxidisable 
form of NADPH, H2NADPH. The structure was solved and displayed two PA2580 
monomers which form a homodimer with one molecule of FAD bound to each monomer. 
The active site, similar to other solved azoreductases sits at the interface between the two 
monomers. 
The overall fold of PA2580 was found to be the same short flavodoxin-like fold as 
previously described for other enzymes of the MdaB family from E. coli and Y. pestis 
(Adams and Jia, 2006, Minasov et al., 2011) (Figure 5.9 a). Similar to other azoreductase 
enzymes from P. aeruginosa such as paAzoR1, the active site is lined with predominantly 
hydrophobic and aromatic amino acids which assist in the binding of substrates, the 
majority of which are hydrophobic (Ryan et al., 2010a). Interestingly, these residues in the 
substrate binding pocket are highly conserved between MdaB from E. coli and PA2580 
indicating that these two enzymes would have similar substrate specificity profiles and 
possibly interchangeable primary functions (Adams and Jia, 2006) (Figure 5.9 b). PISA 
analysis (Krissinel and Henrick, 2007) identified that PA2580 is likely to exist as a 
homodimer in solution, as is MdaB from E. coli (Adams and Jia, 2006). The Gibbs free 
energy of dissociation (ΔGdiss) for dimeric association of PA2580 is calculated as 24.5 kcal 
mol
-1
 suggesting that the homodimer is likely to be stable in solution. 
As expected, FAD is accommodated into the active site of each monomer. Like other 
known azoreductases including paAzoR1-3 from P. aeruginosa, the amino acid sequence 
in the flavin binding cradle of PA2580 bears no similarity to other known azoreductases 
(Ryan et al., 2010a). Similar to other azoreductases, the binding occurs via hydrogen bonds 
formed between the flavin and the peptide backbone which are sequence independent 
(Figure 5.10). As the enzymatic reaction occurs via the bound flavin, this explains why 
such high sequence diversity is possible amongst the azoreductase-like enzymes (Ryan et 
al., 2014). 
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Figure 5.9 Structural comparison of PA2580 and ecMdaB 
Crystal structure of PA2580 (represented in blue) and ecMdaB (represented in gold) shown 
with FAD cofactor bound (yellow). The structure of ecMdaB is from PDB 2B3D (Adams 
and Jia, 2006). The two structures align with an RMSD value of 0.6. The image was 
generated and manipulated in CCP4MG (McNicholas et al., 2011) and compared using the 
superpose secondary structure matching tool in CCP4MG (Krissinel and Henrick, 2004). 
The overall structure of both proteins overlaid is displayed (a). The amino acids labelled in 
the substrate binding pocket are conserved across the two proteins (b). 
 
 
 
Figure 5.10 Hydrogen bonds are formed between PA2580 and FAD 
The FAD (represented in yellow) is anchored in place via hydrogen bonds (depicted in red) 
formed with the sequence independent peptide backbone. The image was generated and 
manipulated in CCP4MG (McNicholas et al., 2011).  
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As mentioned in section 5.1, the structure of smMdaB in complex with NADPH, solved by 
Wang and colleagues (2014), is unlikely to be representative of paMdaB/PA2580 due to 
the low level of conservation of residues in the active site compared to other MdaB 
members. This was confirmed upon comparison of the smMdaB structure to that of 
PA2580. After 3D structural alignment using secondary structure matching of Cα atoms 
(Krissinel and Henrick, 2004), a high RMSD value of 1.8 was obtained for PA2580 
superposed against smMdaB (compared to a value of 0.6 for PA2580 and ecMdaB). A 
visual representation of the surfaces smMdaB and PA2580 (Figure 5.11 a) and of ecMdaB 
and PA2580 (Figure 5.11 b) further proves the difference in structure of smMdaB and the 
protein of interest in this study. Thus the structure of NADPH bound to smMdaB is not a 
useful tool in examining nicotinamide binding to the azoreductase-like enzymes in P. 
aeruginosa. 
 
 
Figure 5.11 Surface comparison of PA2580 against other MdaB structures 
Surface comparison of PA2580 (represented in orange) and smMdaB (represented in blue). 
A high RMSD value of 1.8 was obtained indicating that these are not closely related 
molecules. The structure of smMdaB is from PDB 3LCM (Wang et al., 2014) (a). Surface 
comparison of PA2580 (represented in orange) and ecMdaB (represented in blue). 
Superposing the two structures yielded an RMSD value of 0.6. The structure of ecMdaB is 
from PDB 2B3D (Adams and Jia, 2006) (b). Both models display bound FAD (shown in 
yellow). The images were generated and manipulated in CCP4MG (McNicholas et al., 
2011) and compared using the superpose tool in CCP4MG (Krissinel and Henrick, 2007). 
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Due to the occupation of the protein’s active site with MOPS, the decision was made to 
gather diffraction data from crystals soaked overnight in concentrated H2NADPH, a non-
reactive analogue of NADPH. Refinement from this second dataset resulted in unbiased 
difference density consistent with the nicotinamide group of H2NADPH. Following 
subsequent refinement with this in place it was clear to see that the nicotinamide binds co-
planar with the ring system of FAD, with the C4 atom of the nicotinamide from which the 
hydride is transferred, approximately 3.8 Å from the N5 acceptor of FAD (Figure 5.12 a). 
The amide group of the nicotinamide makes hydrogen bonds with the side chains of both 
Tyr108 and Asn126. Although the 3.6 Å distance from C4 → N5 is similar to that 
observed in the structure of nicotinamide in complex with smMdaB (Figure 5.12 b), the 
binding orientation of nicotinamide within the active site is rotated approximately 75° 
between the two structures which is likely due to the amide group interacting with 
hydrogen bonding groups (Arg55 and Tyr106) in a radically different part of the active site 
(Figure 5.12 c). As previously mentioned, the residues lining the active sites of MdaB 
enzymes from P. aeruginosa, E. coli and Y. pestis are completely conserved, it is therefore 
likely that the nicotinamide binding to PA2580 observed in this study is likely to be 
representative of the other MdaB family members. 
 
Figure 5.12 Comparison of nicotinamide binding to PA2580 and smMdaB 
Nicotinamide is displayed bound within PA2580. Unbiased positive density consistent with 
the nicotinamide group of H2NADPH is shown as green mesh (a). The nicotinamide group 
is depicted bound to smMdaB in a different orientation to that observed for PA2580 (b). 
The overlaid structures of nicotinamide binding to PA2580 and smMdaB are displayed. 
RMSD from secondary structure matching gave a value of 1.8 (c). The structure of 
smMdaB is from PDB 3LCM (Wang et al., 2014). The images were generated and 
manipulated in CCP4MG (McNicholas et al., 2011) and compared using the superpose tool 
in CCP4MG (Krissinel and Henrick, 2007). 
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The structure of PA2580 bound to nicotinamide solved here highlights the importance of 
hydrogen bonding in the determination of binding orientation of the cofactor. It also serves 
to highlight the limitations of using cibacron blue to predict NAD(P)H interactions (as 
carried out by Yu and colleagues (2014)) as this compound lacks equivalent hydrogen 
bonding groups. The continuation of the work initiated by Crescente (2015) presented here 
confirms the azoreductase-like proteins in P. aeruginosa as flavin dependent enzymes with 
differing cofactor selectivity. The primary physiological role of these enzymes in P. 
aeruginosa still remains unclear. The physiological role of the azoreductases and 
azoreductases–like enzymes in P. aeruginosa will be examined in the next chapter. 
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 Phenotypic analysis of P. aeruginosa wild type and Chapter 6
azoreductase-like gene deletion strains 
 
6.1 Introduction 
P. aeruginosa is a prevalent microbe in the natural environment which can colonise and 
invade many hosts, including humans, to cause serious and potentially life threatening 
infections (Mena and Gerba, 2009). Predominantly an opportunistic pathogen, it is the 
most prevalent gram-negative bacteria to cause infection in intensive care units worldwide 
and in the ICU it is independently affiliated with increased mortality rates, an issue 
exacerbated by its intrinsic and acquired resistance to many antimicrobial agents 
(Rosenthal et al., 2012, Nathwani et al., 2014). The intrinsic resistance of P. aeruginosa to 
many antibiotics has been attributed mainly to the nature of its hydrophilic 
lipopolysaccharide outer membrane which forms a barrier against numerous toxic agents 
(Nikaido and Vaara, 1985). It is, however, the astounding capacity of P. aeruginosa to 
demonstrate many enzymatic and mutational mechanisms of bacterial resistance that has 
led to the emergence of MDR strains unsusceptible to aminoglycosides, cephalosporins, 
fluoroquinolones and carbapenems (Pechère and Köhler, 1999, CDC, 2013). Thus, the 
identification of genes in the P. aeruginosa genome that may influence this resistance is 
essential and could subsequently lead to the development of novel targets for antimicrobial 
chemotherapy.  
Although azoreductases are predominantly associated with their ability to cleave the azo 
bond found in azo dyes and azo pro-drugs it is unlikely that the breakdown of these 
synthetic substances is the primary physiological role of this class of enzyme (Wang et al., 
2007). As previously mentioned in Chapter 4, many azoreductases including those 
produced by P. aeruginosa, are capable of reducing quinone compounds, with much higher 
rates achieved in this case than for the reduction of azo substrates which indicates that this 
may be their principal function (Ryan et al., 2010b, Ryan et al., 2014, Crescente et al., 
2016). In addition to this, recent publications have suggested that they may also be 
involved in antimicrobial sensitivity (Table 6.1). 
Resistance in P. aeruginosa is complex and can be attributed to many mechanisms 
including lipopolysaccharide modification of the outer membrane, alteration of outer 
membrane porins, target protein mutations, expression of modifying enzymes such as β-
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lactamases and multi-drug efflux pumps (Moskowitz et al., 2004, Redgrave et al., 2014, 
Aldred et al., 2014). The potential role that azoreductases may play in any of these systems 
remains unclear however there is evidence to suggest that they are somehow involved. For 
instance, paAzoR3 (pa3223) mutants of P. aeruginosa PAO1 are up to two fold more 
susceptible to carbapenems, specifically meropenem, than the wild type (Wang et al., 
2016). It has also been found that sub inhibitory levels of tetracycline, chloramphenicol 
and spectinomycin induce upregulation of pa2580 in P. aeruginosa PAO1 and that mutants 
lacking this gene are more sensitive to treatment with carbenicillin, chloramphenicol, 
ciprofloxacin and hydrogen peroxide, also, these traits are reversed in the complemented 
strain (Chen et al., 2010). In contrast, expression of another azoreductase homologue, 
pa0949, is downregulated up to three fold upon exposure of P. aeruginosa PAO1 to 
tobramycin and ciprofloxacin but upregulated (1.5 fold) in the presence of tetracycline 
(Linares et al., 2006). Downregulation of this gene has also been reported in E. coli 
following gentamicin treatment (Al-Majdoub et al., 2013). Finally in P. aeruginosa PAO1, 
pa1224 harbours a mutation of alanine (position 251 on the protein surface) to valine when 
resistance to the polymyxin colistin occurs however the significance of this remains 
unclear as this modification is conserved when the resistance is lost (Lee et al., 2016).  
This apparent involvement of azoreductases and their homologues in the response to 
antibiotics is not specific to P. aeruginosa PAO1 and is also observed in other 
microorganisms. For example, plasmid derived overexpression of azoreductases azoR and 
mdaB in E. coli leads to increased MICs for aminoglycosides streptomycin and kanamycin 
compared to the wild type strain. Confusingly, the same result is unexpectedly seen upon 
deletion of azoR therefore it is decidedly unclear what effect the azoreductases actually 
have regarding aminoglycoside susceptibility in E. coli (Ling et al., 2012). Nonetheless, 
this data indicates some involvement of the azoreductases in antibiotic sensitivity. In 
addition, quinolone resistant S. typhimurium display 1-3 fold upregulation of the 
azoreductase homologues mdaB and wrbA in comparison to non-resistant strains, again 
suggesting that these enzymes play a role in antibiotic sensitivity (Correia et al., 2016). 
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Table 6.1 Azoreductase and azoreductase-like genes implicated in antimicrobial 
susceptibility 
Overview of the azoreductase and azoreductase-like genes and their associations in 
antibiotic sensitivity in different bacterial strains.  
 
 
 
  
Gene Bacterium Phenotype 
paAzoR3 
P. aeruginosa 
PAO1 
Transposon insertion mutants more susceptible to meropenem 
(Wang et al., 2016) 
pa2580 
Upregulated in response to tetracycline, chloramphenicol and 
spectinomycin, transposon insertion mutants more susceptible 
to carbenicillin, chloramphenicol and ciprofloxacin (Chen et 
al., 2010) 
pa0949 
Upregulated in response to tetracycline, downregulated in 
response to tobramycin and ciprofloxacin (Linares et al., 2006) 
pa1224 Mutation observed in colistin resistant strains (Lee et al., 2016) 
azoR 
E. coli 
Overexpression and gene deletion results in higher tolerance to 
streptomycin and kanamycin (Ling et al., 2012) 
mdaB 
Overexpression results in greater tolerance to streptomycin and 
kanamycin (Ling et al., 2012) 
wrbA 
Downregulated in response to treatment with gentamicin (Al-
Majdoub et al., 2013) 
mdaB 
S. typhimurium 
Upregulated in quinolone-resistant strains when compared to 
the wild type (Correia et al., 2016) wrbA 
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The three major classes of antibiotics; β-lactams, aminoglycosides and fluoroquinolones, 
have all been reported to generate ROS, specifically hydroxyl radicals, in bacteria which 
contribute to the killing efficiency of these chemotherapeutic agents. These antimicrobials 
use internal iron to promote Fenton-mediated hydroxyl radical formation which is 
mediated by the tricarboxylic acid cycle and depletion of NADH (Dwyer et al., 2007, 
Kohanski et al., 2007). It has been suggested that although different antibiotic classes have 
specific targets upon which they exert their mechanism of action (for example β-lactams 
target penicillin binding proteins, fluoroquinolones target DNA gyrase), antimicrobial 
treatment also sets off a complex series of metabolic changes within the cell, downstream 
of their direct point of interaction which results in the production of ROS and the 
subsequent breakage of double stranded DNA and protein mistranslation (Belenky et al., 
2015). Treatment of bacterial cells with natural antioxidants such as glutathione and 
ascorbic acid increases cell survival following exposure to the major classes of antibiotics, 
supporting this hypothesis that ROS are generated by antimicrobials and are involved in 
their bactericidal action (Dwyer et al., 2014). As discussed in section 1.2.2, azoreductases 
and quinone reductases can act as defence mechanisms during oxidative stress, with this in 
mind it is possible that this may be the mechanism by which these enzymes influence the 
susceptibility of bacteria to antimicrobial treatment.  
With a pool of literature, touched upon above, linking azoreductases and azoreductase 
homologues to antibiotic susceptibility across bacterial strains, a library of azoreductase-
like gene deletion mutants were obtained from the Manoil laboratory, University of 
Washington (Jacobs et al., 2003). A series of phenotypic experiments including antibiotic 
sensitivity assays were carried out by Dr. Vincenzo Crecente (Crescente, 2015). It was 
observed that the strains lacking the azoreductase-like genes had altered susceptibility to 
numerous antibiotics including fluoroquinolones and aminoglycosides by up to ten fold 
(Table 6.2), reinforcing the suggestion that azoreductases in P. aeruginosa play a role in 
antimicrobial sensitivity. In order to confirm this finding however, it is essential to 
complement each transposon mutant with the relevant knocked out gene and witness 
reversion, if, any, to the wild type phenotype.  
So far, the primary focus of this thesis has been describing the characterisation of the gene 
products of azoreductase-like genes in P. aeruginosa PAO1. This chapter will report on the 
phenotypic effects of these genes in relation to antibiotic susceptibility, while also 
examining if the findings are consistent in another P. aeruginosa strain, specifically the 
clinical strain P. aeruginosa TBCF 10839. The aim of this chapter is to generate a library 
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of complemented strains of the azoreductase-like gene deletion mutants and subsequently 
investigate the effects that the azoreductase-like genes may have on sensitivity to different 
classes of antibiotics.  
 
  
 
Table 6.2 Minimum inhibitory concentration of P. aeruginosa PAO1 wild type and the azoreductase-like gene transposon mutants for 
a range of antibiotics  
MIC values in µg/mL for a range of antibiotics tested against P. aeruginosa PAO1 wild type (WT) and the gene deletion mutants are listed. 
Antibiotics tested included fluoroquinolones, β-lactams, aminoglycosides and polymyxins. A difference in sensitivity is observed between the 
wild type and the knockout strains. This table was adapted from Crescente (2015). 
  
 
Antibiotic Class Antibiotic WT Δpa0785 Δpa1962 Δpa3223 Δpa2280 Δpa2580 Δpa1204 Δpa0949 Δpa4975 
Fluoroquinolones 
Ciprofloxacin 1 0.13 0.06 0.25 0.06 0.03 0.06 0.5 0.06 
Levofloxacin 4 0.13 0.06 0.25 0.06 0.03 0.06 0.5 0.06 
Naladixic acid 500 250 250 250 250 250 250 250 500 
β-lactams Ceftiazidime 2 4 4 4 4 4 8 4 4 
Aminoglycosides 
Gentamicin 0.47 0.94 0.94 1.88 0.94 0.94 7.5 0.94 1.88 
Tobramycin 1 1 1 1 2 2 2 1 2 
Polymyxins Colistin 8 2 2 2 2 2 2 2 2 
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6.2 Results 
It has previously been shown that single gene transposon mutants of P. aeruginosa PAO1 
are more susceptible to certain antibiotics, specifically fluoroquinolones and colistin 
(Crescente, 2015). To prove this effect however, it was essential to reintroduce the gene of 
interest into either the chromosomal or extra chromosomal DNA of the mutated strain. 
Following this, antibiotic sensitivity assays were carried out to observe whether the 
microorganism would revert to the phenotype of the wild type strain, thus confirming 
whether or not it was the gene of interest responsible for the change in sensitivity.  
The results listed below include the generation of the P. aeruginosa PAO1 transposon 
insertion mutant strains complemented with the relevant gene, RNA extraction followed by 
cDNA synthesis and PCR to confirm expression of the gene of interest followed by MIC 
assays to observe the effects of this gene on antimicrobial sensitivity. MIC assays were 
also carried out for P. aeruginosa TBCF 10839, P. aeruginosa TBCF 10839 Δpa0785, P. 
aeruginosa TBCF 10839 Δpa0785-pUCP20::pa0785 and P. aeruginosa TBCF 10839 
Δpa0785-pUCP20::pa0785-0787 so as to compare the effects of an azoreductase gene 
deletion on a clinical strain.  
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6.2.1 Generation of complemented strains for the azoreductase-like gene 
deletion mutants  
6.2.1.1 Preparation of genes of interest 
The DNA sequences of pa0785, pa1962, pa3223, pa2280, pa2580, pa1204, pa0949 and 
pa4975 were obtained from The Pseudomonas Genome Database (Winsor et al., 2016). 
The genes of interest were prepared for cloning into pUCP24 in the same manner described 
for the cloning of pa1224 and pa1225 in section 3.2.1.1. Gene specific primers were 
designed to incorporate BamHI and SalI restriction sites into the forward and reverse 
primers respectively and were chosen to correspond with restriction sites present in 
pUCP24 (Figure 6.1). Following PCR, products estimated at the correct size for each gene 
cloned were to be seen on 1% w/v agarose gel (Figure 6.2, Table 6.3). PCR product sizes 
were estimated using the molecular weight analysis tool in Image Lab 5.2.1 (BIO-RAD). 
The PCR products were purified and quantified before a double restriction digest with 
BamHI and SalI restriction enzymes. Following this, the samples were purified and 
quantified once more, ready for ligation into the cloning vector. 
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Figure 6.1 pUCP24 vector map 
pUCP24 vector map showing the area of multiple restriction sites (MRS) with BamHI and 
SalI labelled along with the annealing sites of M13 forward and reverse primers. This 
figure was adapted from the Addgene website and the vector map generated using BVTech 
Plasmid.  
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Figure 6.2 PCR amplification of azoreductases and azoreductase-like genes from P. 
aeruginosa PAO1 for cloning into pUCP24  
1% w/v agarose gel showing the azoreductases and azoreductase-like genes amplified from 
total P. aeruginosa PAO1 genomic DNA using HiFidelity Taq polymerase. Samples shown 
are 1 Kb Plus DNA ladder (lanes M), pa3223 (lane 1), pa1204 (lane 2), pa0949 (lane 3), 
pa0785 (lane 4), pa1962 (lane 5), pa2280 (lane 6) pa2580 (lane 7) and pa4975 (lane 8). 
 
 
 
 
Table 6.3 Estimated size of amplified putative azoreductase genes compared to actual 
size of PCR product sizes  
These estimations are based on the migration of the band compared to the migration of 
bands of known sizes and they correspond to the actual expected gene sizes as predicted 
using the Pseudomonas Genome Database. All estimations were calculated using the 
molecular weight analysis tool in Image Lab 5.2.1 
  
PCR product 
Estimated size of PCR 
product (bp) 
Actual size of 
amplified DNA (bp) 
Percentage 
error 
pa3223 705 695 1.4% 
pa1204 611 599 2% 
pa0949 709 676 4.9% 
pa0785 703 671 4.8% 
pa1962 761 722 5.4% 
pa2280 755 722 4.6% 
pa2580 608 622 2.3% 
pa4975 771 753 2.4% 
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6.2.1.2 Preparation of the cloning vector 
Plasmid pUCP24 was extracted from E. coli JM109 and quantified. The vector was then 
prepared for ligation with the genes of interest in the same manner as described for pET-
28b in section 3.2.1.2 with the exception being the use of restriction enzymes BamHI and 
SalI for the double restriction digest. As before, a sample of the digested plasmid was ran 
alongside undigested plasmid on 1% w/v agarose gel (Figure 6.1). A typical band of 
supercoiled circular plasmid was evident for the undigested plasmid while a defined single 
band appeared for the digested sample.  
 
Figure 6.3 Endonuclease restriction digest of pUCP24   
1% w/v agarose gel showing the pUCP24 plasmid before and after endonuclease digestion 
with restriction enzymes BamHI and SalI. Digested samples (lanes 2, 3 and 4) display a 
linearised plasmid while the undigested sample (lane 1) shows the supercoiled plasmid 
form. Thermo Scientific 100 bp Plus DNA ladder (lane M) was used as standard. 
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6.2.1.3 Obtaining and screening successful clones 
The plasmids and PCR products for each gene of interest were ligated and transformed into 
E. coli JM109 in the same manner as described for the cloning of the azoreductase-like 
genes into pET-28b (section 3.2.1.3). This same procedure was also used to select for and 
screen for positive clones with the exception being that pUCP24 confers gentamicin 
resistance, thus in this case LB agar was supplemented with gentamicin rather than 
kanamycin. PCR was carried out on each positive clone using M13 primers which are 
designed to anneal to pUCP24 in sections upstream and downstream of the inserted gene 
sequence. PCR products were analysed on 1% w/v agarose gel. Bands of expected sizes 
ranging between approximately 600 and 750 bp were observed for the potential clones 
representing insertion of gene of interest (Figure 6.4). Should ligation have been 
unsuccessful, the M13 primers would have amplified a sequence comprising of only 114 
bp. PCR product sizes were estimated using the molecular weight analysis tool in Image 
Lab 5.2.1 (BIO-RAD). Following the sequencing of potential clones and alignment of 
results with the appropriate sequences from the Pseudomonas Genome Database it was 
clear that no point mutations had occurred during the cloning process and successful clones 
had been obtained (data shown in APPENDIX VII).  
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Figure 6.4 E. coli JM109 transformed with pUCP24 ligated with the azoreductase-like 
genes   
1% w/v agarose gels showing the PCR products from transformant colonies amplified 
using M13 primers. PCR products displayed represent the negative control pUCP24 (lane 
1), pUCP24::pa0785 (lanes 2-4), pUCP24::pa3223 (lanes 5-7) and pUCP24::pa0949 (lanes 
8-11). 1 Kb plus DNA ladder was used as standard (lane M). 
  
150 
 
6.2.1.4 Transformation into P. aeruginosa PAO1 transposon insertion mutant 
strains 
Following confirmation of successful cloning by PCR and sequencing, plasmid extractions 
were performed on overnight cultures of positive clones for each strain. Following the 
preparation of chemically competent cells for each P. aeruginosa PAO1 gene deletion 
mutant, PCR was carried out on each strain using the appropriate primers for each gene 
deletion (Table 2.16) to confirm the presence of the transposon insertion. The same 
reactions were also carried out on the wild type strain to confirm amplification of the genes 
of interest and thus compare the wild type vs. the knockout. Upon analysis on 1% w/v 
agarose gel it was clear that the transposon insertion was present in each competent gene 
deletion mutant (Figure 6.5). Following this confirmation, heat shock transformations were 
carried out to insert pUCP24 containing each azoreductase-like sequence into the 
appropriate mutant strain. Empty pUCP24 was also transformed into each mutant strain so 
as to create a negative control to be used later in the MIC assays. PCR was carried out on 
each transformant using the M13 primers. This would enable screening for strains 
containing both the cloned plasmids and the empty plasmids. Upon observation on 1% w/v 
agarose gel, bands of appropriate sizes were to be seen for each transformant confirming 
successful generation of complemented strains for each azoreductase-like gene deletion 
mutant (Figure 6.6 a and b, APPENDIX III). PCR product sizes were estimated using the 
molecular weight analysis tool in Image Lab 5.2.1 (BIO-RAD). 
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Figure 6.5 P. aeruginosa PAO1 single gene transposon insertion mutants confirmation 
in competent cells  
1% w/v agarose gels showing the azoreductase-like genes amplified from colonies of 
chemically competent P. aeruginosa PAO1 WT and the single gene transposon mutants 
(TrM). Amplification of the azoreductase-like genes is only apparent in the reactions 
performed on the WT strain. Lanes displayed represent 1 Kb Plus DNA ladder (lanes M), 
pa0785 WT (lane 1), pa0785 TrM (lane 2), pa1962 WT (lane 3), pa1962 TrM (lane 4), 
pa3223 WT (lane 5), pa3223 TrM (lane 6), pa2280 WT (lane 7), pa2280 TrM (lane 8), 
pa2580 WT (lane 9), pa2580 TrM (lane 10), pa1204 WT (lane 11), pa1204 TrM (lane 12), 
pa0949 WT (lane 13), pa0949 TrM (lane 14), pa4975 WT (lane 15) and pa4975 TrM (lane 
16). 
 
Figure 6.6 P. aeruginosa PAO1 single gene transposon insertion mutants transformed 
with pUCP24   
1% w/v agarose gels showing the PCR products for pUCP24 amplified using M13 primers. 
PCR products are displayed representing pUCP24::pa2280 (lanes 1-3) and pUCP24 (lanes 
4-6) transformed into P. aeruginosa PAO1 Δ2280. PCR products were estimated at 804 bp 
for pUCP24::pa2280 (869 bp actual size) and 142 bp for pUCP24 (114 bp actual size) (a). 
PCR products are displayed representing pUCP24 (lanes 1-3) and pUCP24::pa2580 (lanes 
4-6) transformed into P. aeruginosa PAO1 Δ2580. PCR products were estimated at 802 bp 
for pUCP24::pa2580 (736 bp actual size) and 120 bp for pUCP24 (114 bp actual size) (b). 
1 Kb plus DNA ladder was used as standard for each gel (lane M).  
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6.2.2 Confirmation of gene expression in the complemented strains 
To confirm the expression of the gene of interest in each complemented strain, and also the 
lack of gene expression in the controls containing the empty vector, RNA extraction was 
performed on cultures in the exponential phase of each gene deletion mutant containing 
empty pUCP24 and its corresponding complemented strain. On column DNase digestion 
was carried out and was essential so as to remove any residual genomic DNA which would 
interfere with the results of the RT-PCR. RNA extraction was deemed successful by 
examination on 1% w/v agarose gel when a characteristic double band was to be seen 
(Figure 6.7, APPENDIX IV). Following cDNA synthesis, PCR was carried out on each 
sample using the appropriate primers designed to amplify within the coding region of the 
gene in question. Upon observation on 1% w/v agarose gel it was apparent that the relevant 
genes were being expressed in the complemented strains but not in the negative controls 
(Figure 6.8). The single band representing the positive control, housekeeping gene rpoD 
(APPENDIX V), confirmed that RNA extraction and cDNA synthesis had been successful 
thus the data here verifies that the complemented strains generated in this chapter were a 
reliable means to examine the phenotypic effects of the gene in question in relation to 
antibiotic susceptibility. 
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Figure 6.7 Total RNA extracted from P. aeruginosa PAO1 strains  
1% w/v agarose gels showing the RNA extracted from P. aeruginosa PAO1 WT, knockout 
strains containing empty pUCP24 (KO) and complemented strains (Comp). Extraction was 
performed on liquid cultures in the exponential phase using the RNeasy Mini Kit (Qiagen). 
Bands displayed depict RNA from PAO1 WT (lane 1), pa1962 KO (lane 2), pa1962 Comp 
(lane 3), pa2580 KO (lane 4) and pa2580 Comp (lane 6). 1 Kb plus DNA ladder was used 
as standard for each gel (lanes M). 
  
154 
 
 
Figure 6.8 Gene expression of P. aeruginosa PAO1 WT, gene deletion mutants 
transformed with pUCP24 and the complemented strains  
1% w/v agarose gels showing PCR products where cDNA synthesised from extracted total 
RNA was used as a template. PCR was performed on cDNA from P. aeruginosa PAO1 
WT, each knockout strain containing empty pUCP24 (KO) and each complemented strain 
using primers specific for the coding region of each azoreductase-like gene (Comp). 
Products displayed are 1 Kb Plus DNA ladder (lanes M), pa1962 WT (lane 1), pa1962 KO 
(lane 2), pa1962 Comp (lane 3), pa3223 WT (lane 4), pa3223 KO (lane 5), pa3223 Comp 
(lane 6), pa2580 WT (lane 7), pa2580 KO (lane 8), pa2580 Comp (lane 9), pa1204 WT 
(lane 10), pa1204 KO (lane 11), pa1204 Comp (lane 12), pa0949 WT (lane 13), pa0949 
KO (lane 14), pa0949 Comp (lane 15), pa0785 WT (lane 16), pa0785 KO (lane 17), 
pa0785 Comp (lane 18), pa2280 WT (lane 19), pa2280 KO (lane 20), pa2280 Comp (lane 
21), pa4975 WT (lane 22), pa4975 KO (lane 23) and pa4975 Comp (lane 24). 
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6.2.3 Phenotypic analysis of P. aeruginosa PAO1 and TBCF 10839 strains  
For convenience, ‘P. aeruginosa PAO1 strains’ refers to wild type P. aeruginosa PAO1, 
each azoreductase-like gene transposon mutant obtained from the Manoil laboratory 
transformed with the pUCP24 vector and each transposon mutant complemented with the 
pUCP24 vector containing the knocked out gene. ‘P. aeruginosa TBCF 10839 strains’ 
refers to wild type P. aeruginosa TBCF 10839, P. aeruginosa TBCF 10839 Δpa0785, P. 
aeruginosa TBCF 10839 Δpa0785-pUCP20::pa0785 and P. aeruginosa TBCF 10839 
Δpa0785-pUCP20::pa0785-0787. 
 
6.2.3.1 Growth analysis of P. aeruginosa PAO1 strains along with P. aeruginosa 
TBCF 10839 strains  
Analysis of planktonic growth was performed on all P. aeruginosa PAO1 strains (Figure 
6.9). The results show that no significant growth difference compared to the wild type was 
apparent after a period of 20 hours (p>0.05). After seven hours of growth, all strains, with 
the exception of the wild type and the transposon insertion mutant transformed with 
pUCP24::pa1204, had entered the stationary phase with the other two entering the 
stationary phase at the eight hour time point. There was no significant difference in cell 
density amongst strains after seven or eight hours of growth (p>0.05). This data indicates 
that the transposon insertion along with the inclusion of the pUCP24 vector does not affect 
the growth of P. aeruginosa PAO1.  
For all P. aeruginosa TBCF 10839 strains the cultures reached the stationary phase after 6 
hours (Figure 6.10). There was no significant difference between the wild type and the 
genetically modified strains (p>0.05) indicating that the genetic adaptions do not alter 
bacterial growth rate.  
All of the statistical analysis presented here was carried out using a one-way ANOVA. 
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Figure 6.9 Growth analysis P. aeruginosa PAO1 strains     
Graph showing the growth curves of all P. aeruginosa PAO1 strains at 37°C in MH broth 
(supplemented with 10 µg/mL gentamicin for all samples with the exception of the WT). 
Strains tested include the wild type (WT), the transposon insertion mutants containing 
pUCP24 (ΔpaAzoR) and the complemented strains (ΔpaAzoR Comp). There was no 
significant difference observed in the growth rates between strains. All strains were grown 
in triplicate in 96-well plates for 18 hours in an Infinite M200 PRO plate reader. 
Uninoculated broth was used as a negative control. Error bars represent standard deviation 
(n=3). 
  
 
Figure 6.10 Growth analysis P. aeruginosa TBCF 10839 strains     
Graph showing the growth curves of all P. aeruginosa TBCF 10839 strains at 37°C in MH 
broth. There was no significant difference observed in the growth rates between strains. All 
strains were grown in triplicate in 96-well plates for 18 hours in an Infinite M200 PRO 
plate reader. Uninoculated broth was used as a negative control Error bars represent 
standard deviation (n=3). 
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6.2.3.2 Comparison of CFU/mL of all P. aeruginosa PAO1 strains and all P. 
aeruginosa TBCF strains 
The value for CFU/mL for P. aeruginosa PAO1 was calculated and compared against the 
values found for all of the knockout strains containing pUCP24 and their corresponding 
complemented strains. The same process was executed for all P. aeruginosa TBCF 10839 
strains. All values are listed in Table 6.4. These results indicate that cell size is not greatly 
affected by the genetic modifications across strains and obtaining readings at OD600 is an 
accurate way to compare cell density.  
 
Table 6.4 CFU/mL for all P. aeruginosa strains     
Overnight liquid cultures of all P. aeruginosa strains were standardised to OD600 0.02 and 
serial dilutions ranging from 10-1 to 10-7 were prepared for each sample. 5 µL of each 
dilution was dropped onto LB agar. Drops containing 20-200 colonies were counted and 
used to determine CFU/mL for each strain. The results listed here indicate that cell size is 
not greatly affected by the genetic modifications. All experiments were performed in 
triplicate. 
Strain Modification CFU/ mL 
P. aeruginosa PAO1 
Wild Type 6.4±0.7 × 10 7 
Δpa0785-pUCP24 5.3±0.2 × 10 7 
Δpa0785-pUCP24::pa0785 6.1±0.4 × 10 7 
Δpa1962-pUCP24 6.6±0.5 × 10 7 
Δpa1962-pUCP24::pa1962 7.5±0.2 × 10 7 
Δpa3223-pUCP24 7.2±0.3 × 10 7 
Δpa3223-pUCP24::pa3223 5.6±0.3 × 10 7 
Δpa2280-pUCP24 6.5±0.3 × 10 7 
Δpa2280-pUCP24::pa2280 7.3±0.7 × 10 7 
Δpa2580-pUCP24 6.1±0.4 × 10 7 
Δpa2580-pUCP24::pa2580 7.5±0.3 × 10 7 
Δpa1204-pUCP24 6.2±0.6 × 10 7 
Δpa1204-pUCP24::pa1204 6.4±0.2 × 10 7 
Δpa0949-pUCP24 6.2±0.2 × 10 7 
Δpa0949-pUCP24::pa0949 7.3±0.3 × 10 7 
Δpa4975-pUCP24 6.5±0.5 × 10 7 
Δpa4975-pUCP24::pa4975 6.9±0.3 × 10 7 
P. aeruginosa TBCF 10839 
Wild Type 7.1±0.8 × 10 7 
Δpa0785 7.4±0.6 × 10 7 
Δpa0785-pUCP20::pa0785 7.3±0.8 × 10 7 
Δpa0785-pUCP20::pa0785-0787 6.5±0.2 × 10 7 
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6.2.3.3 Minimum Inhibitory Concentration 
The antibiotic sensitivity was tested for all P. aeruginosa PAO1 strains and all P. 
aeruginosa TBCF 10839 strains by determining the MIC for each strain against a range of 
antibiotics. The antibiotics trialled in this section were selected based on previous data 
(Crescente, 2015) where it was noted that the MIC of azoreductase-like gene deletion 
mutants tended to differ from that of the wild type, thus indicating that these genes may be 
involved in antibiotic susceptibility. To confirm this idea, it was necessary to examine 
whether the addition of the knocked out gene back into the bacteria would result in 
reversion to the wild type phenotype.  
The results gathered show that in most cases different MIC values were obtained for the 
wild type strains compared to their genetically modified counterparts and are listed in 
Table 6.5 and 6.6. In the presence of the fluoroquinolones (ciprofloxacin, levofloxacin, 
sparfloxacin and prulifloxacin) and naladixic acid, the wild type for both P. aeruginosa 
PAO1 and P. aeruginosa TBCF 10839 were more resistant to the antibiotics than any of 
the genetically manipulated strains. It is important to note however, that the complemented 
strains exhibited an MIC value comparable to that of the relevant knock outs rather than 
the wild type. For the P. aeruginosa TBCF 10839 strains, the MIC result for ceftiazidime 
and amikacin were constant at 8 µg/mL and 2 µg/mL respectively. For P. aeruginosa 
PAO1 strains, the MIC of amikacin was either the same as that for the wild type or two 
fold higher with the exception of P. aeruginosa PAO1 Δpa0785-pUCP24::pa0785 where 
the MIC was half that of the wild type. With ceftiazidime, a similar trend was seen where 
all strains containing the pUCP24 plasmid had a lower sensitivity to the antibiotic than the 
wild type. Upon culturing of the P. aeruginosa PAO1 strains in colistin, the majority had 
the same MIC as the wild type. Of those that did not, the MIC was lower but no pattern 
regarding whether the strains included the azoreductase gene or not was apparent. 
Regarding growth inhibition of the P. aeruginosa TBCF 10839 strains with colistin, the 
paAzoR1 knockout had a MIC four fold lower than that of the wild type while the strain 
complemented with the paAzoR1 gene did indeed mirror that of the wild type. The strain 
complemented with the full operon, pa0785-0787, had a two fold higher MIC than the 
paAzoR1 knock out however it still remained lower than that of the wild type.  
  
Table 6.5 Minimum inhibitory concentration values (in µg/mL) for a range of antimicrobial agents against P. aeruginosa PAO1 strains 
Table showing the MIC values for all antibiotics tested against P. aeruginosa PAO1 wild type (WT), the transposon insertion mutants 
containing pUCP24 (ΔpaAzoR) and the complemented strains (ΔpaAzoR Comp). Although differences in sensitivity were seen when the 
azoreductase-like gene deletion mutants were compared to the wild type, reversion to the wild type phenotype was not apparent upon 
complementation with the gene of interest. MICs were determined using the microdilution method in 96-well plates. Each experiment was 
carried out in triplicate. 
 
 
 
Antibiotic Class Antibiotic WT Δpa0785 Δpa0785 Comp Δpa1962 Δpa1962 Comp Δpa3223 Δpa3223 Comp Δpa2280 Δpa2280 Comp 
Fluoroquinolones 
Ciprofloxacin 1 0.125 0.0625 0.125 0.125 0.125 0.25 0.125 0.125 
Levofloxacin 8 1 0.5 1 1 1 1 1 1 
Naladixic Acid 1000 125 125 250 250 500 250 250 250 
Sparfloxacin 8 2 1 2 2 2 2 2 2 
Prulifloxacin 4 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 
β-lactams Ceftiazidime 2 4 4 4 4 8 8 4 4 
Aminoglycosides Amikacin 2 4 1 4 4 4 4 2 2 
Polymyxins Colistin 4 4 2 4 4 2 4 4 2 
Antibiotic Class Antibiotic WT Δpa2580 Δpa2580 Comp Δpa1204 Δpa1204 Comp Δpa0949 Δpa0949 Comp Δpa4975 Δpa4975 Comp 
Fluoroquinolones 
Ciprofloxacin 1 0.125 0.125 0.25 0.125 0.125 0.125 0.25 0.125 
Levofloxacin 8 1 0.5 1 0.5 1 1 1 1 
Naladixic Acid 1000 125 500 250 250 125 125 125 125 
Sparfloxacin 8 2 2 4 2 2 2 2 2 
Prulifloxacin 4 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.25 
β-lactams Ceftiazidime 2 4 4 8 8 4 4 4 4 
Aminoglycosides Amikacin 2 4 4 4 4 2 2 4 4 
Polymyxins Colistin 4 4 4 2 4 4 2 4 4 
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Table 6.6 Minimum inhibitory concentration values (in µg/mL) for a range of 
antimicrobial agents against P. aeruginosa TBCF 10839 strains     
Table showing the MIC values for all antibiotics tested against P. aeruginosa TBCF 10839 
wild type (WT), the azoreductase knockout (Δ0785) and the strains complemented with the 
gene of interest (Δpa0785-pUCP20::pa0785) and the operon containing the gene of interest 
(Δpa0785-pUCP20::pa0785-0787). Although differences in sensitivity were seen when the 
pa0785 mutants were compared to the wild type, reversion to the wild type phenotype was 
not apparent upon complementation with the gene of interest or with the full operon 
encoding the gene of interest. MICs were determined using the microdilution method in 
96-well plates. Each experiment was carried out in triplicate. 
 
  
Antibiotic Class Antibiotic WT Δpa0785 
Δpa0785-
pUCP20::pa0785 
Δpa0785-
pUCP20::pa0785-
0787 
Fluoroquinolones 
Ciprofloxacin 1 0.5 0.25 0.5 
Levofloxacin 4 2 1 2 
Naladixic Acid 500 250 250 500 
Sparfloxacin 4 4 2 4 
Prulifloxacin 8 1 2 2 
β-lactams Ceftiazidime 8 8 8 8 
Aminoglycosides Amikacin 2 2 2 2 
Polymyxins Colistin 32 8 32 16 
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6.3 Discussion 
The aims of this chapter as laid out in section 1.3 have been met as follows: 
i. Complemented strains of P. aeruginosa PAO1 azoreductase-like gene deletion 
mutants were generated and the gene insertion confirmed via PCR and DNA 
sequencing. 
ii. The relevant genes were successfully expressed in all of the complemented strains. 
This was confirmed by RT-PCR. The same method was also used to observe non-
expression of the knocked out gene in the appropriate strains.  
iii. Any relevant difference in cell size amongst all strains in question including the P. 
aeruginosa PAO1 strains and P. aeruginosa TBCF 10839 strains was ruled out by 
determining CFU/mL. This ensured that the OD600 reading was a suitable method of 
standardising bacterial concentration.  
iv. Growth rate analysis of all P. aeruginosa PAO1 strains and all P. aeruginosa 
TBCF 10839 strains confirmed that there was no significant effect on growth of the 
genetically modified strains meaning that MIC assays could be carried out without 
having to alter incubation times for particular strains.  
v. MICs for all P. aeruginosa PAO1 and P. aeruginosa TBCF 10839 strains were 
determined for a range of antibiotics so antibiotic susceptibility between the wild 
type and the knock out and complemented strains could be compared. While 
differences in susceptibility were noted between the azoreductase–like gene 
deletion mutants and the wild type strains, they did not revert to the wild type 
phenotype upon reintroduction of the gene of interest. 
 
P. aeruginosa, specifically MDR strains, have been labelled a ‘serious threat’ by the 
Centre for Disease Control with approximately 13% of severe healthcare-associated 
infections unsusceptible to several classes of antibiotics (CDC, 2013). Recent trends have 
shown an increase in strains resistant to aminoglycosides, β-lactams and fluoroquinolones 
as the cause of nosocomial pneumonia (Zilberberg and Shorr, 2013, Sievert et al., 2013). 
With the current therapeutics increasingly less effective, there is an urgent need for novel 
targets for antimicrobial chemotherapy.  
To further expand the study of the physiological role of azoreductases and azoreductase-
like genes in P. aeruginosa PAO1, a library of knockout strains complemented with the 
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appropriate gene was successfully generated using molecular cloning. The gene of interest 
was inserted under control of the lacUV5 promoter. As neither P. aeruginosa nor the 
cloning vector possess a lacI repressor, the gene of interest was constitutively expressed 
without any need for induction (Winsor et al., 2016, Olsen et al., 1982, Bagdasarian, 
1983). This was confirmed with RT-PCR, a method by which total RNA is extracted from 
bacterial cultures in the log phase and used as a template for cDNA synthesis upon which 
PCR is performed using gene-specific primers. Total RNA is a reliable means for 
monitoring protein expression as it is produced when genes are transcribed from DNA as 
complementary base pairs which are then transferred to a ribosome for translation to a 
protein (Clancy, 2008). This procedure proved that the complemented strains were 
expressing the genes of interest while the knockout strains transformed with the empty 
vector were not.  
The MIC results showed that the transformants containing empty pUCP24 retained the 
same phenotype of altered sensitivity to the antibiotics tested as the gene deletion mutants 
lacking the plasmid, indicating that the vector alone was not affecting susceptibility to 
antibiotics. The absence of any significant changes in growth rates or values for CFU/mL 
assured that any changes in growth or cell size were not limiting factors in the MIC assays. 
Upon addition of the plasmids for complementation, the phenotype remained the same as 
that for the corresponding knockout with no reversion to the wild type apparent 
whatsoever. Unfortunately this result means that it cannot be said with confidence that it is 
any of the genes in question specifically that are causing this altered susceptibility.  
Unlike the laboratory strain P. aeruginosa PAO1, P. aeruginosa TBCF 10839 is a clinical 
isolate which has caused numerous nosocomial outbreaks (Klockgether et al., 2013). 
Originally detected in a CF lung at a point of critical illness (Tümmler et al., 1991), it is 
phenotypically different from P. aeruginosa PAO1 in relation to quorum sensing, 
virulence effector protein production and biofilm formation (Rakhimova et al., 2008, 
Cullen et al., 2015). It is interesting to note is that this current study has shown that this 
clinical strain has greatly reduced sensitivity to colistin when compared to PAO1 (8 fold 
increase in MIC). As polymyxins are reserved as a treatment of last resort for MDR gram-
negative bacteria, this result further highlights the need for the development of new 
antibiotics (Lee et al., 2016). The P. aeruginosa TBCF 10839 paAzoR1 knockout strain 
used in this study was generated by insertion of a pTnMOD-OGM mini-Tn5 plasposon and 
the complemented strains were constructed by addition of an episomal pUCP20 vector 
cloned with the gene(s) of interest (Rakhimova et al., 2008). Although this gene deletion 
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and subsequent complementation along with the gene expression were not confirmed in 
this pilot study, these strains were included here so as to monitor whether the phenotype 
regarding antibiotic susceptibility was consistent across two different P. aeruginosa 
strains. In addition, it was a means to observe whether the effects of azoreductase gene 
deletion stayed the same when a different method of knocking out the gene(s) of interest 
was implemented. Interestingly, like the P. aeruginosa PAO1 strains, the antimicrobial 
sensitivity was altered upon deletion of the azoreductase genes and the phenotype for the 
most part remained unchanged upon complementation with the knocked out gene. This 
similarity amongst strains is indicative that although we do not see reversion to the wild 
type upon complementation, it is important not to rule out these genes as participants in the 
determination of antimicrobial susceptibility.  
The results obtained in this chapter where almost identical antibiotic susceptibility patterns 
for the gene deletion and complemented strains (in both P. aeruginosa PAO1 and P. 
aeruginosa TBCF 10839) are seen correlate to the findings of Ling et al. (2012) where 
overexpression and deletion of azoR in E. coli exhibited the same result of decreased 
sensitivity to aminoglycosides. This effect was not exclusive to azoR and was also noted in 
other unrelated genes including hyfA (probable electron transfer protein), lpdA (a 
lipoamide dehydrogenase), paaD (putative phenylacetate-CoA oxygenase subunit) and 
yejG (hypothetical protein) (Andrews et al., 1997, Stephens et al., 1983, Karp et al., 2014).  
Overexpression of a wild type gene product can sometimes cause a mutant phenotype 
(Prelich, 2012). Evidences of such an effect have been documented in the yeast 
Saccharomyces cerevisiae where overexpression of regulatory proteins mirrors the 
phenotype of the strain when the gene encoding for the protein in question is knocked out. 
For example, overexpression of MIF1, implicated in mitotic chromosome transmission, 
results in increased frequency of chromosome loss, a consequence also apparent in the 
MIF1 mutant strain (Meeks-Wagner et al., 1986). Another regulatory protein in the same 
species encoded by SPT5, when overexpressed or indeed under expressed, exhibits the 
same altered transcription of several genes as the SPT5 deletion mutant (Swanson et al., 
1991). These genes all function as part of multiprotein complexes insinuating that this 
phenomenon may be due to disrupting protein stoichiometry which subsequently interferes 
with the overall function. It could thus be tempting to suggest that the observed phenotypic 
effects of gene deletion and subsequent complementation in this current study may be 
attributed to a precise level of gene expression which is crucial to gene function whereby 
any deviation from this may have a detrimental effect on the overall role. It is important to 
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note however, that the aforementioned evidence is derived from eukaryotic cells and thus 
cannot be directly applied to bacteria so without extensive further research into this idea, it 
must remain simply as speculation. 
In order to control the expression levels of the complemented genes so that they replicate 
those of the wild type a different method of complementation could be applied. As 
previously stated, all complemented genes were expressed under control of the lacUV5 
promoter (Olsen et al., 1982). As this is a promoter derived from the lac promoter native to 
E. coli and is often used in expression systems in molecular biology it is highly likely that 
the genes of interest are not being expressed at identical rates as they would be under the 
control of their native promoter (Rosano and Ceccarelli, 2014). Also, as pUCP24 is a high 
copy number plasmid with 500-700 copies per cell, overexpression of the gene(s) of 
interest is most probable (Minton, 1984). A means of troubleshooting this would be to 
reinsert the gene of interest back into the chromosome. This could be achieved by using a 
mini-Tn7 system whereby the appropriate gene sequence would be cloned into a mini-Tn7 
vector. When transformed along with a helper plasmid encoding the Tn7 site-specific 
transposition pathway the gene of interest would be successfully integrated back into the 
chromosomal genome and expression levels should simulate those of the wild type (Choi 
and Schweizer, 2006). It is important to note however that this system would not 
circumvent the issue of the lost native promotor. Ideally the gene of interest would be 
cloned into the mini-Tn7 vector along with its native promotor however identification of 
each specific promotor sequence would require an extensive bioinformatics study beyond 
the scope of this investigation. Following utilisation of the mini-Tn7 system, quantitative 
real time-PCR could be performed on the wild type and the complemented strain. 
Assuming expression levels were interchangeable, MIC results obtained from this method 
could give definitive answers as to whether or not these genes play a role in antibiotic 
sensitivity.  
The process applied by the Manoil laboratory to knock out the azoreductase-like genes 
involves adding a tetracycline resistance (tet) cassette so as to select for the transposon 
insertion mutants (Jacobs et al., 2003). As the resistance conferred here involves efflux 
pump activity (Allard and Bertrand, 1992, de Lorenzo et al., 1990), there is a possibility 
that this may affect the MIC data gathered for these strains, although debatable given that 
the P. aeruginosa TBCF 10839 paAzoR1 knockout was created using a different method 
and no resistance cassette is left in the mutant strain (Rakhimova et al., 2008), yet the same 
result was still apparent. The pCRE vector, a derivative of pUT which carries the cre gene 
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from pRH133, can excise the sequences situated between the loxP sites in the transposon 
(which includes tet) via cre-mediated recombination (Jacobs et al., 2003, Manoil, 2000). 
Thus, transformation of these strains with the pCRE vector prior to complementation 
would remove this resistance cassette and eliminate any possible likelihood that this 
resistance determinant is altering the MIC results.  
The data presented in this chapter presents more questions as opposed to answers. From 
these pilot results alone a conclusive result cannot be derived concerning whether or not 
the azoreductases and azoreductase-like genes play a key role in antibiotic sensitivity in P. 
aeruginosa. However based on previous literature and the fact that the phenotype observed 
here is conserved across two strains it would be beneficial to conduct a further extensive 
study involving the approaches listed above in order to further investigate this potential 
involvement.   
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 Conclusions Chapter 7
 
The aims of the work presented in this thesis were developed to improve understanding of 
azoreductases and NQOs in P. aeruginosa PAO1. Investigating the role of these genes and 
their products was in turn, directed towards gaining insight as to whether these genes may 
serve as suitable novel targets for antimicrobial chemotherapy. In the following sections, 
each aim as stated in section 1.3 will be addressed. 
7.1 Cloning of putative P. aeruginosa PAO1 azoreductase genes 
The cloning of two putative azoreductase genes is described in Chapter 3. Ryan et 
al. (2014) proposed that azoreductases and NQOs in P. aeruginosa form a 
superfamily which is more extensive than previously thought with that particular 
study suggesting there are at least ten in the P. aeruginosa PAO1 genome (pa0785, 
pa1962, pa3223, pa2280, pa2580, pa1204, pa0949, pa4975, pa1224, pa1225). 
Eight of these have previously been cloned by Wang et al. (2007), Ryan et al. 
(2010b) and Crescente (2015). The cloning of the final two, pa1224 and pa1225 is 
discussed in Chapter 3. Briefly, these genes were cloned into pET-28b and the 
constructs transformed into E. coli JM109 and BL21 strains. Positive clones were 
screened via PCR of individual colonies and confirmed by sequencing. The cloned 
genes were shown to correspond precisely with the published gene sequences as 
listed on the Pseudomonas Genome Database (Winsor et al., 2011). 
7.2 Production and purification of suspected P. aeruginosa PAO1 
azoreductase enzymes as recombinant proteins 
The expression and purification of PA1224, PA1225 and PA4975 is described in 
Chapter 3. Production and purification of the other seven azoreductases and NQOs 
from P. aeruginosa PAO1 has previously been completed by Wang et al. (2007), 
Ryan et al. (2010b) and Crescente et al. (2016). Overexpression of pa1224, pa1225 
and pa4975 was achieved by inducing the lacUV5 promotor with IPTG.  
Following expression, proteins were extracted and purified using Ni-NTA (IMAC). 
The expression method required adaption for each protein implying that, unlike 
other azoreductase-like enzymes in P. aeruginosa, they are not all expressed by E. 
coli in the same way. Adding to this, a relatively large range in the amount of 
soluble protein gained was apparent (4–25 mg/L of culture compared to 30–40 
mg/L for the other azoreductases).  
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7.3 Biochemical and enzymatic analysis of proposed P. aeruginosa PAO1 
azoreductase and NQO recombinant proteins 
In chapter 4, biochemical and enzymatic characterisation of PA1224, PA1225 and 
PA4975 is described. The presence of flavin molecules, selectivity for NAD(P)H 
and flavin and substrate specificity profiles are determined.  
Analysis of the presence of flavin molecules shows that they can be detected via 
absorption spectra and TLC for PA1224 and PA1225 (FAD in both cases). The 
purification of PA4975 did not yield adequate soluble protein for these procedures 
to be completed however it is assumed FAD was incorporated during expression as 
addition to the enzymatic assays did not significantly affect reduction of ANI. DSF 
analysis suggested FAD as the cofactor for all three however PA4975 showed 
higher enzymatic reduction rates with FMN. Due to DSF and evidence in the 
literature it is likely that FAD is the preferred cofactor.  
All enzymes were biochemically active and NADPH was indicated as the preferred 
reductant for all three enzymes.   
Substrate specificity was assessed using a range of azo and quinone compounds. 
The data obtained showed that all three were capable of catalysing reduction of 
quinones with the rates comparable to other NQOs from P. aeruginosa PAO1. 
PA1224 was the only enzyme with which azo reduction was observed. The rates of 
quinone reduction calculated for PA1224 were an order of magnitude higher than 
those gathered for PA1225 and PA4975 which corresponds with previous 
azoreductase enzymatic data where evidence of azo reduction is only seen in those 
with higher rates of quinone reduction (Wang et al., 2007, Crescente, 2015). In this 
study, the characterisation of PA4975 as initiated by Green et al. (2014) has been 
expanded upon and PA1224 and PA1225 have been characterised for the first time 
and confirmed as NAD(P)H dependent quinone reductases.  
Chapter 5 describes the continued characterisation of PA2280, PA2580, PA1204 
and PA0949 as initiated by Crescente (2015) and published in Crescente et al. 
(2016). The TLC analysis completed by Crescente (2015) confirmed FAD as the 
flavin for which PA2580 and PA1204 are selective and this was reiterated here 
using DSF analysis. Through enzymatic assays and DSF, FMN was identified as 
the preferred flavin for PA2280 and PA0949, consistent with the preliminary 
enzymatic data gathered by Crescente (2015).  
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The work presented in chapters 3, 4 and 5 paves the way for investigating the 
effects of inhibitors on this family of enzymes in P. aeruginosa. Inhibitors such as 
β-sultams (Kolb et al., 2014), resveratrol and quercetin have been identified and 
could be used to further examine these enzymes both biochemically and 
phenotypically in a bid to gain increased understanding of their biological function.  
 
7.4 Structural determination and analysis of P. aeruginosa PAO1 
azoreductase and NQO, PA2580 
Chapter 5 describes how the crystal structure of PA2580 was solved at 1.3 Å and 
confirmed as two monomers which form a homodimer with one molecule of FAD 
bound to each monomer. The active site sits between the two monomers and is 
similar to other solved azoreductases with the same short flavodoxin-like fold as 
previously described for other enzymes of the MdaB family. It was found that the 
nicotinamide binds co-planar with the ring system of FAD in a position which 
would allow electron transfer to the N5 atom of FAD. This is the first time this 
structure has been solved and the first time an azoreductase protein structure has 
been solved with nicotinamide bound thus presenting an opportunity for further 
expansion on the binding properties of NAD(P)H to azoreductases. 
 
7.5 Analysis of P. aeruginosa PAO1 antibiotic resistance using azoreductase 
and NQO single gene transposon mutants and corresponding 
complemented strains 
Chapter 6 describes the generation of complemented strains of P. aeruginosa PAO1 
using molecular cloning. The individual knockout strains were confirmed via PCR 
and the gene insertions of the complemented strains were confirmed via 
sequencing. All sequences corresponded exactly with those published on the 
Pseudomonas Genome Database (Winsor et al., 2011). Transcription of inserted 
genes was observed using RT-PCR and this approach was also implemented to 
ensure that none of the gene deletion strains were expressing the gene of interest. 
Although the initial knockout results looked promising with isolates showing 
increased sensitivity to fluoroquinolones, the complemented strains failed to revert 
to the wild type. Interesting results were observed by Crescente (2015) where the 
azoreductase gene deletion mutants appeared to have an involvement in biofilm 
formation and motility. Now that complemented strains have been generated and 
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gene transcription has been confirmed, this is currently being further examined by 
Greg Cooper at Kingston University.  
The aims of this thesis have been met as discussed above. The findings presented 
here add to the current body of knowledge surrounding the extensive and complex 
genome of P. aeruginosa and generates a platform for continued exploration of the 
physiological role of these enzymes.  
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APPENDIX I 
 
Azo compound structures 
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APPENDIX II 
Quinone compound structures 
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APPENDIX III 
 
  
P. aeruginosa PAO1 single gene transposon insertion mutants 
transformed with pUCP24   
1% w/v agarose gels showing the PCR products for pUCP24 amplified using 
M13 primers. PCR products are displayed representing PAO1 Δpa0785-
pUCP24::pa0785 (lane 1), PAO1 Δpa0785-pUCP24 (lane 2), PAO1 
Δpa1204-pUCP24::pa1204 (lane 3), PAO1 Δpa1204-pUCP24 (lane 4), 
PAO1 Δpa0949-pUCP24::pa0949 (lane 5), PAO1 Δpa0949-pUCP24 (lane 6) 
(a), PAO1 Δpa3223-pUCP24::pa3223 (lane 1), PAO1 Δpa3223-pUCP24 
(lane 2) (b), PAO1 Δpa4975-pUCP24 (lane 1), PAO1 Δpa4975-
pUCP24::pa4975 (lanes 2 and 3) (c), PAO1 Δpa1962-pUCP24::pa1962 (lane 
s 1-4), PAO1 Δpa1962-pUCP24 (lanes 5-8) (d). 1 Kb plus DNA ladder was 
used as standard for each gel (lanes M). 
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APPENDIX IV 
 
  Total RNA extracted from P. aeruginosa PAO1 strains.  
1% w/v agarose gels showing the total RNA extracted from P. aeruginosa PAO1 
knockout strains containing empty pUCP24 (KO) and complemented strains 
(Comp). Extraction was performed on liquid cultures in the exponential phase 
using the RNeasy Mini Kit (Qiagen). Bands displayed depict RNA from PAO1 
pa0785 KO (lane 1), pa0785 Comp (lane 2), pa3223 KO (lane 3), pa3223 Comp 
(lane 4) (a), pa1204 Comp (lane 1) pa0949 KO (lane 2), pa0949 Comp (lane 3) 
(b), pa1204 KO (lane 1), pa2280 KO (lane 2), pa2280 Comp (lane 3), pa4975 KO 
(lane 4), pa4975 Comp (lane 5) (c). 1 Kb plus DNA ladder was used as standard 
for each gel (lanes M). 
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APPENDIX V 
 
  
Positive control for RNA extraction and cDNA synthesis    
1% w/v agarose gels showing PCR products where cDNA synthesised 
from extracted total RNA was used as a template. PCR was performed on 
cDNA from P. aeruginosa PAO1 WT, each knockout strain containing 
empty pUCP24 (KO) and each complemented strain using primers 
specific for the house keeping gene, rpoD. PCR products displayed are 
from PAO1 WT (lane 1), pa1962 KO (lane 2), pa1962 Comp (lane 3), 
pa2580 KO (lane 4), pa2580 Comp (lane 5) (a), pa1204 Comp (lane 1) 
pa0949 KO (lane 2), pa0949 Comp (lane 3) (b), pa1204 KO (lane 1), 
pa2280 KO (lane 2), pa2280 Comp (lane 3), pa4975 KO (lane 4), pa4975 
Comp (lane 5) (c), pa0785 KO (lane 1), pa0785 Comp (lane 2), pa3223 
KO (lane 3), pa3223 Comp (lane 4) (d). 1 Kb plus DNA ladder was used 
as standard for each gel (lanes M). 
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APPENDIX VI 
 
Alignment of pa1224 sequence in pET-28b in E. coli JM109 (FWD and REV) against 
pa1224 sequence from P. aeruginosa PAO1 in the Pseudomonas Genome Database  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                 5          15         25         35         45                   
pa1224       ---------- ---------- ---------- ---------- ----------  
FWD          ---------- ---------- ---------- ---------- ----------  
REV          AATTGTGAGC GGATAACAAT TCCCCTCTAG AAATAATTTT GTTTAACTTT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                 55         65         75         85         95                   
pa1224       ---------- ---------- ---------- ---------- ----------  
FWD          ---------- ---------- ---------- ---------- ----------  
REV          AAGAAGGAGA TATACCATGG GCAGCAGCCA TCATCATCAT CATCACAGCA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                105        115        125        135        145              
pa1224       ---------- ---------- ------ATGA ACGTACTCAT CGTCTATGCC  
FWD          ---------- ---------- ----ATATGA -CGTACTCAT CGTCTATGCC  
REV          GCGGCCTGGT GCCGCGCGGC AGCCATATGA ACGTACTCAT CGTCTATGCC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                155        165        175        185        195              
pa1224       CATCCCGAGC CGCGCTCCCT CAACGGTGCG CTCAAGGACT TCGCGGTCGC  
FWD          CATCCCGAGC CGCGCTCCCT CAACGGTGCG CTCAAGGACT TCGCGGTCGC  
REV          CATCCCGAGC CGCGCTCCCT CAACGGTGCG CTCAAGGACT TCGCGGTCGC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                205        215        225        235        245              
pa1224       CCGCCTCGAG GCGGCCGGCC ATGCGGTGCA GGTTTCGGAC CTCTACGCGA  
FWD          CCGCCTCGAG GCGGCCGGCC ATGCGGTGCA GGTTTCGGAC CTCTACGCGA  
REV          CCGCCTCGAG GCGGCCGGCC ATGCGGTGCA GGTTTCGGAC CTCTACGCGA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                255        265        275        285        295              
pa1224       TGGGCTGGAA GGCCGTGCTC GATGCCGGCG ACAGCCTCGA GCGCGAGGCC  
FWD          TGGGCTGGAA GGCCGTGCTC GATGCCGGCG ACAGCCTCGA GCGCGAGGCC  
REV          TGGGCTGGAA GGCCGTGCTC GATGCCGGCG ACAGCCTCGA GCGCGAGGCC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                305        315        325        335        345              
pa1224       AGCGAACGCT TCGATCCTTC CGCAACTTCC CTGCGCGCCT TCGAGAACGG  
FWD          AGCGAACGCT TCGATCCTTC CGCAACTTCC CTGCGCGCCT TCGAGAACGG  
REV          AGCGAACGCT TCGATCCTTC CGCAACTTCC CTGCGCGCCT TCGAGAACGG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                355        365        375        385        395              
pa1224       TTGGCAGAGC GTCGACATCG CCGGTGAGCA GGACAAGCTG CGCTGGGCCG  
FWD          TTGGCAGAGC GTCGACATCG CCGGTGAGCA GGACAAGCTG CGCTGGGCCG  
REV          TTGGCAGAGC GTCGACATCG CCGGTGAGCA GGACAAGCTG CGCTGGGCCG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                405        415        425        435        445              
pa1224       ATACGCTGAT CCTGCAATTC CCGCTCTGGT GGTTCAGCAT GCCGGCGATC  
FWD          ATACGCTGAT CCTGCAATTC CCGCTCTGGT GGTTCAGCAT GCCGGCGATC  
REV          ATACGCTGAT CCTGCAATTC CCGCTCTGGT GGTTCAGCAT GCCGGCGATC  
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             ....|....| ....|....| ....|....| ....|....| ....|....|  
                455        465        475        485        495              
pa1224       CTCAAGGGTT GGATCGATCG CGTCTATGCC TGCGGCTTCG CCTACGGGGT  
FWD          CTCAAGGGTT GGATCGATCG CGTCTATGCC TGCGGCTTCG CCTACGGGGT  
REV          CTCAAGGGTT GGATCGATCG CGTCTATGCC TGCGGCTTCG CCTACGGGGT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                505        515        525        535        545              
pa1224       CGGCGAACAT TCCGACAGCC ACTGGGGCGA CCGCTACGGC GAGGGCCGGA  
FWD          CGGCGAACAT TCCGACAGCC ACTGGGGCGA CCGCTACGGC GAGGGCCGGA  
REV          CGGCGAACAT TCCGACAGCC ACTGGGGCGA CCGCTACGGC GAGGGCCGGA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                555        565        575        585        595              
pa1224       TGCAGGGCAA GCGGGCGATG CTGGTAGTCA CCGCCGGCGG CTGGGAGTCG  
FWD          TGCAGGGCAA GCGGGCGATG CTGGTAGTCA CCGCCGGCGG CTGGGAGTCG  
REV          TGCAGGGCAA GCGGGCGATG CTGGTAGTCA CCGCCGGCGG CTGGGAGTCG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                605        615        625        635        645              
pa1224       CACTACGCCG CGCGCGGTAT CAACGGACCG ATGGACGACC TGCTGTTCCC  
FWD          CACTACGCCG CGCGCGGTAT CAACGGACCG ATGGACGACC TGCTGTTCCC  
REV          CACTACGCCG CGCGCGGTAT CAACGGACCG ATGGACGACC TGCTGTTCCC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                655        665        675        685        695              
pa1224       CATCCACCAC GGCATCCTGC ATTACCCCGG CTTCGAGGTA TTGCCGCCGT  
FWD          CATCCACCAC GGCATCCTGC ATTACCCCGG CTTCGAGGTA TTGCCGCCGT  
REV          CATCCACCAC GGCATCCTGC ATTACCCCGG CTTCGAGGTA TTGCCGCCGT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                705        715        725        735        745              
pa1224       TCGTCGTCTA TCGCAGCGGC CGGATCGACG CGGAGCGTTT CGCCGCGCTG  
FWD          TCGTCGTCTA TCGCAGCGGC CGGATCGACG CGGAGCGTTT CGCCGCGCTG  
REV          TCGTCGTCTA TCGCAGCGGC CGGATCGACG CGGAGCGTTT CGCCGCGCTG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                755        765        775        785        795              
pa1224       AGCGAGCAGT TGGGCCGGCG CCTCGATGAC CTGCAGCGCG CTGCGCCGAT  
FWD          AGCGAGCAGT TGGGCCGGCG CCTCGATGAC CTGCAGCGCG CTGCGCCGAT  
REV          AGCGAGCAGT TGGGCCGGCG CCTCGATGAC CTGCAGCGCG CTGCGCCGAT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                805        815        825        835        845              
pa1224       CCCGTTCCGC CGGCAGAACG GCGGCGACTA CCTGATCCCG GCGCTGACCC  
FWD          CCCGTTCCGC CGGCAGAACG GCGGCGACTA CCTGATCCCG GCGCTGACCC  
REV          CCCGTTCCGC CGGCAGAACG GCGGCGACTA CCTGATCCCG GCGCTGACCC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                855        865        875        885        895              
pa1224       TGCGCGACGA ACTTGCCCCG CAGCGGGCCG GTTTCGCCAT GCACCTGGCC  
FWD          TGCGCGACGA ACTTGCCCCG CAGCGGGCCG GTTTCGCCAT GCACCTGGCC  
REV          TGCGCGACGA ACTTGCCCCG CAGCGGGCCG GTTTCGCCAT GCACCTGGCC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                905        915        925        935        945              
pa1224       GAATGA---- ---------- ---------- ---------- ----------  
FWD          GAATGACCCC GGAGCTCCGT CGACAAGCTT GCGGCCGCAC TCGAGCACCA  
REV          GAATGACCCC GGAGCTCCGT CGACAAGCTT GCGGCCGCAC TCGAGCACC-  
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             ....|....| ....|....| ....|....| ....|....| ....|....|  
                955        965        975        985        995              
pa1224       ---------- ---------- ---------- ---------- ----------  
FWD          CCACCACCAC CACTGAGATC CGGCTGCTAA CAAAGCCCGA AAGGAAGCTG  
REV          ---------- ---------- ---------- ---------- ----------  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                1005       1015       1025       1035       1045             
pa1224       ---------- ---------- ---------- ---------- ----------  
FWD          AGTTGGCTGC TGCCACCGCT GAGCAATAAC TAGCATAACC CCTTGGGGCC  
REV          ---------- ---------- ---------- ---------- ----------  
 
             ....|....| ....|....| ....|....| ....| 
                1055       1065       1075       1085     
pa1224       ---------- ---------- ---------- ----- 
FWD          TCTAAACGGG TCTTGAGGGG TTTTTGCTGA AGGAG 
REV          ---------- ---------- ---------- ----- 
 
 
 
 
 
Alignment of pa1225 sequence in pET-28b in E. coli JM109 (FWD and REV) against 
pa1225 sequence from P. aeruginosa PAO1 in the Pseudomonas Genome Database  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                 5          15         25         35         45                   
pa1225       ---------- ---------- ---------- ---------- ----------  
FWD          ---------- ---------- ---------- ---------- ----------  
REV          CTGCCACCAT ACCCACGCCG AAACAAGCGC TCATGAGCCC GAAGTGGCGA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                 55         65         75         85         95                   
pa1225       ---------- ---------- ---------- ---------- ----------  
FWD          ---------- ---------- ---------- ---------- ----------  
REV          GCCCGATCTT CCCCATCGGT GATGTCGGCG ATATAGGCGC CAGCAACCCG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                105        115        125        135        145              
pa1225       ---------- ---------- ---------- ---------- ----------  
FWD          ---------- ---------- ---------- ---------- ----------  
REV          CACCTGTGGC GCCGGTGATG CCGGGCCACG ATGCGTCCGG CGTAGAGGAT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                155        165        175        185        195              
pa1225       ---------- ---------- ---------- ---------- ----------  
FWD          ---------- ---------- ---------- ---------- ----------  
REV          CGAGATCTCG ATCCCGCGAA ATTAATACGA CTCACTATAG GGGAATTGTG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                205        215        225        235        245              
pa1225       ---------- ---------- ---------- ---------- ----------  
FWD          ---------- ---------- ---------- ---------- ----------  
REV          AGCGGATAAC AATTCCCCTC TAGAAATAAT TTTGTTTAAC TTTAAGAAGG  
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             ....|....| ....|....| ....|....| ....|....| ....|....|  
                255        265        275        285        295              
pa1225       ---------- ---------- ---------- ---------- ----------  
FWD          ---------- ---------- ---------- ---------- ----------  
REV          AGATATACCA TGGGCAGCAG CCATCATCAT CATCATCACA GCAGCGGCCT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                305        315        325        335        345              
pa1225       ---------- ---------A TGCATGCCCT GATCGTCGTC GCTCATCATC  
FWD          ---------- ---------- ---------- ---------- --TCATCATC  
REV          GGTGCCGCGC GGCAGCCATA TGCATGCCCT GATCGTCGTC GCTCATCATC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                355        365        375        385        395              
pa1225       ATCCCCGCTC TCTCACCCAC GCCCTCGCCG CGCGCATCGC CGAAGGCGTG  
FWD          ATCCCCGCTC TCTCACCCAC GCCCTCGCCG CGCGCATCGC CGAAGGCGTG  
REV          ATCCCCGCTC TCTCACCCAC GCCCTCGCCG CGCGCATCGC CGAAGGCGTG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                405        415        425        435        445              
pa1225       GTCCGCGCCG GTCATTCCGC GGAAACCGCC GACCTGGCGG CGGAAGGCTT  
FWD          GTCCGCGCCG GTCATTCCGC GGAAACCGCC GACCTGGCGG CGGAAGGCTT  
REV          GTCCGCGCCG GTCATTCCGC GGAAACCGCC GACCTGGCGG CGGAAGGCTT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                455        465        475        485        495              
pa1225       CGAGCCGCGC TTCGGCCTGG CCGACCACGC CGTGCATCGC GGCCAGGCGT  
FWD          CGAGCCGCGC TTCGGCCTGG CCGACCACGC CGTGCATCGC GGCCAGGCGT  
REV          CGAGCCGCGC TTCGGCCTGG CCGACCACGC CGTGCATCGC GGCCAGGCGT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                505        515        525        535        545              
pa1225       CGCCTCCCGC CGACGTCCTC GCCGAGCAGG CGCGCATCGA TCGCGCCGAT  
FWD          CGCCTCCCGC CGACGTCCTC GCCGAGCAGG CGCGCATCGA TCGCGCCGAT  
REV          CGCCTCCCGC CGACGTCCTC GCCGAGCAGG CGCGCATCGA TCGCGCCGAT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                555        565        575        585        595              
pa1225       ACCCTGGTGC TGGTCTACCC GATCTACTGG TGGTCGATGC CGGCCCTGCT  
FWD          ACCCTGGTGC TGGTCTACCC GATCTACTGG TGGTCGATGC CGGCCCTGCT  
REV          ACCCTGGTGC TGGTCTACCC GATCTACTGG TGGTCGATGC CGGCCCTGCT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                605        615        625        635        645              
pa1225       CAAGGGCTGG ATCGATCGCG TGTTCTCCAA TGGCTGGGCC TTCGACTACA  
FWD          CAAGGGCTGG ATCGATCGCG TGTTCTCCAA TGGCTGGGCC TTCGACTACA  
REV          CAAGGGCTGG ATCGATCGCG TGTTCTCCAA TGGCTGGGCC TTCGACTACA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                655        665        675        685        695              
pa1225       GCATCGGCGG CGACCTGCGG AAAAAGCTGC AGCGCCTGCG CGTGGTGCTG  
FWD          GCATCGGCGG CGACCTGCGG AAAAAGCTGC AGCGCCTGCG CGTGGTGCTG  
REV          GCATCGGCGG CGACCTGCGG AAAAAGCTGC AGCGCCTGCG CGTGGTGCTG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                705        715        725        735        745              
pa1225       GTCGGTGTCG GCGGCGCCGA TGCCGGCACC TTCGAGCGGC ACGGCTACGC  
FWD          GTCGGTGTCG GCGGCGCCGA TGCCGGCACC TTCGAGCGGC ACGGCTACGC  
REV          GTCGGTGTCG GCGGCGCCGA TGCCGGCACC TTCGAGCGGC ACGGCTACGC  
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             ....|....| ....|....| ....|....| ....|....| ....|....|  
                755        765        775        785        795              
pa1225       CGGGGCGATG CGCACCCAGA TCGACCATGG CATCTTCGAT TACTGCGGCG  
FWD          CGGGGCGATG CGCACCCAGA TCGACCATGG CATCTTCGAT TACTGCGGCG  
REV          CGGGGCGATG CGCACCCAGA TCGACCATGG CATCTTCGAT TACTGCGGCG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                805        815        825        835        845              
pa1225       CACGGGTGGT CCGTTCCGAA CTGTTGCTGG AGTCGGAGAG CGCCGATCCG  
FWD          CACGGGTGGT CCGTTCCGAA CTGTTGCTGG AGTCGGAGAG CGCCGATCCG  
REV          CACGGGTGGT CCGTTCCGAA CTGTTGCTGG AGTCGGAGAG CGCCGATCCG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                855        865        875        885        895              
pa1225       ATCCGGCATC TGGACCAGGC CCTGCACATC GGCAGCCAGC TCTTCGCCGC  
FWD          ATCCGGCATC TGGACCAGGC CCTGCACATC GGCAGCCAGC TCTTCGCCGC  
REV          ATCCGGCATC TGGACCAGGC CCTGCACATC GGCAGCCAGC TCTTCGCCGC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                905        915        925        935        945              
pa1225       ACGCGGCGCG CAGGGGGCCG CCCAGGCGCA GCCGCTGGAG GCCTGA----  
FWD          ACGCGGCGCG CAGGGGGCCG CCCAGGCGCA GCCGCTGGAG GCGTGACCCC  
REV          ACGCGGCGCG CAGGGGGCCG CCCAGGCGCA GCCGCTGGAG GCGTGACCCC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                955        965        975        985        995              
pa1225       ---------- ---------- ---------- ---------- ----------  
FWD          CGAGCTCCGT CGACAAGCTT GCGGCCGCAC TCGAGCACCA CCACCACCAC  
REV          CGAGCTCCGT CGACAAGCTT GCGGCCGCAC TCGAGCAC-- ----------  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                1005       1015       1025       1035       1045             
pa1225       ---------- ---------- ---------- ---------- ----------  
FWD          CACTGAGATC CGGCTGCTAA CAAAGCCCGA AAGGAAGCTG AGTTGGCTGC  
REV          ---------- ---------- ---------- ---------- ----------  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                1055       1065       1075       1085       1095             
pa1225       ---------- ---------- ---------- ---------- ----------  
FWD          TGCCACCGCT GAGCAATAAC TAGCATAACC CCTTGGGGCC TCTAAACGGG  
REV          ---------- ---------- ---------- ---------- ----------  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                1105       1115       1125       1135       1145             
pa1225       ---------- ---------- ---------- ---------- ----------  
FWD          TCTTGAGGGG TTTTTTGCTG AAAGGAGGAA CTATATCCGG ATTGGCGAAT  
REV          ---------- ---------- ---------- ---------- ----------  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                1155       1165       1175       1185       1195             
pa1225       ---------- ---------- ---------- ---------- ----------  
FWD          GGGACGCGCC CTGTAGCGGC GCATTAAGCG CGGCGGGTGT GGTGGTTACG  
REV          ---------- ---------- ---------- ---------- ----------  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                1205       1215       1225       1235       1245             
pa1225       ---------- ---------- ---------- ---------- ----------  
FWD          CGCAGCGTGA CCGCTACACT TGCCAGCGCC CTAGCGCCCG CTCCTTTCGC  
REV          ---------- ---------- ---------- ---------- ----------  
 
180 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                1255       1265       1275       1285       1295             
pa1225       ---------- ---------- ---------- ---------- ----------  
FWD          TTTCTTCCCT TCCTTTCTCG CCACGTTCGC CGGCTTTCCC CGTCAAGCTC  
REV          ---------- ---------- ---------- ---------- ----------  
 
             ....|....| ....|....| ....|....| ....|. 
                1305       1315       1325       1335     
pa1225       ---------- ---------- ---------- ------ 
FWD          TAATCGGGGG CTCCCTTTAG GGTTCCGATT TAGTGC 
REV          ---------- ---------- ---------- ------ 
 
Alignment of pa4975 sequence in pET-28b in E. coli JM109 (FWD and REV) against 
pa4975 sequence from P. aeruginosa PAO1 in the Pseudomonas Genome Database  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                 5          15         25         35         45                   
pa4975       ---------- ---------- ---------- ---------- ----------  
FWD          TGCGCCGGAC GGCGGCATGT TCGTGATGGT CGACATCCGT CCCACCGGAC  
REV          ---------- ---------- ---------- ---------- ----------  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                 55         65         75         85         95                   
pa4975       ---------- ---------- ---------- ---------- ----------  
FWD          TTTCCGCCCA GGCCTTCGCC GACCGCCTGC TGGACCGCCA TGGCGTATCG  
REV          ---------- ---------- ---------- ---------- ----------  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                105        115        125        135        145              
pa4975       ---------- ---------- ---------- ---------- ----------  
FWD          GTGCTCGCCG GCGAAGCCTT CGGCCCGAGC GCCGCCGGTC ACATCCGCCT  
REV          ---------- ---------- ---ATCCCGC GAAATTAATA CGACTCACTA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                155        165        175        185        195              
pa4975       ---------- ---------- ---------- ---------- ----------  
FWD          CGGCCTGGTG TTGGGCGCCG AACCGCTGCG CGAAGCCTGT CGGCGCATTG  
REV          TAGGGGAATT GTGAGCGGAT AACAATTCCC CTCTAGAAAT AATTTTGTT-  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                205        215        225        235        245              
pa4975       ---------- ---------- ---------- ---------- ----------  
FWD          CGGCTGTGCG CCGCCGAGTT GCT-CGGCCA GGCCTGAACC CCTCGGCCGC  
REV          TAACTTTAAG AAGGAGATAT ACCATGGGCA GCAGCCATCA TCATCATCAT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                255        265        275        285        295              
pa4975       ---------- ---------- ---------- -------ATG AACGTACTGA  
FWD          GAGCGATGCG GCCGGTCACC ACGATTCGGA AACCACGATG AACGTACTGA  
REV          CACAGCAGCG GCCTGGTGCC GCG---CGGC AGCCAT-ATG AACGTACTGA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                305        315        325        335        345              
pa4975       TCGTCCACGC CCACAACGAA CCGCAATCCT TCACCCGCGC GCTCTGTGAC  
FWD          TCGTCCACGC CCACAACGAA CCGCAATCCT TCACCCGCGC GCTCTGTGAC  
REV          TCGTCCACGC CCACAACGAA CCGCAATCCT TCACCCGCGC GCTCTGTGAC  
181 
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                355        365        375        385        395              
pa4975       CAGGCATGCG AGACCCTGGC AGGCCAGGGC CACGCGGTGC AGGTCTCGGA  
FWD          CAGGCATGCG AGACCCTGGC AGGCCAGGGC CACGCGGTGC AGGTCTCGGA  
REV          CAGGCATGCG AGACCCTGGC AGGCCAGGGC CACGCGGTGC AGGTCTCGGA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                405        415        425        435        445              
pa4975       TCTCTACGCG ATGAACTGGA ATCCGGTGGC CAGTGCCGCC GACTTCGCCG  
FWD          TCTCTACGCG ATGAACTGGA ATCCGGTGGC CAGTGCCGCC GACTTCGCCG  
REV          TCTCTACGCG ATGAACTGGA ATCCGGTGGC CAGTGCCGCC GACTTCGCCG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                455        465        475        485        495              
pa4975       AGCGCGCCGA TCCCGACTAC CTGGTGTACG CCCTGGAGCA GCGCGAGAGC  
FWD          AGCGCGCCGA TCCCGACTAC CTGGTGTACG CCCTGGAGCA GCGCGAGAGC  
REV          AGCGCGCCGA TCCCGACTAC CTGGTGTACG CCCTGGAGCA GCGCGAGAGC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                505        515        525        535        545              
pa4975       GTCAAGCGCC AGAGCCTGGC CGCCGACATC CAGGCCGAGC TGGACAAGCT  
FWD          GTCAAGCGCC AGAGCCTGGC CGCCGACATC CAGGCCGAGC TGGACAAGCT  
REV          GTCAAGCGCC AGAGCCTGGC CGCCGACATC CAGGCCGAGC TGGACAAGCT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                555        565        575        585        595              
pa4975       GCTGTGGGCC GACCTGCTGA TCCTCAACTT TCCGATCTAC TGGTTCTCGG  
FWD          GCTGTGGGCC GACCTGCTGA TCCTCAACTT TCCGATCTAC TGGTTCTCGG  
REV          GCTGTGGGCC GACCTGCTGA TCCTCAACTT TCCGATCTAC TGGTTCTCGG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                605        615        625        635        645              
pa4975       TGCCGGCGAT CCTCAAGGGG TGGTTCGACC GGGTACTGGT GTCCGGGGTC  
FWD          TGCCGGCGAT CCTCAAGGGG TGGTTCGACC GGGTACTGGT GTCCGGGGTC  
REV          TGCCGGCGAT CCTCAAGGGG TGGTTCGACC GGGTACTGGT GTCCGGGGTC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                655        665        675        685        695              
pa4975       TGCTATGGCG GCAAGCGCTT CTACGACCAG GGTGGCCTGG CCGGCAAGAA  
FWD          TGCTATGGCG GCAAGCGCTT CTACGACCAG GGTGGCCTGG CCGGCAAGAA  
REV          TGCTATGGCG GCAAGCGCTT CTACGACCAG GGTGGCCTGG CCGGCAAGAA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                705        715        725        735        745              
pa4975       GGCGCTGGTC AGCCTGACCC TGGGCGGGCG CCAGCACATG TTCGGCGAGG  
FWD          GGCGCTGGTC AGCCTGACCC TGGGCGGGCG CCAGCACATG TTCGGCGAGG  
REV          GGCGCTGGTC AGCCTGACCC TGGGCGGGCG CCAGCACATG TTCGGCGAGG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                755        765        775        785        795              
pa4975       GTGCCATCCA CGGACCGCTG GAGGACATGC TGCGGCCGAT CCTGCGCGGC  
FWD          GTGCCATCCA CGGACCGCTG GAGGACATGC TGCGGCCGAT CCTGCGCGGC  
REV          GTGCCATCCA CGGACCGCTG GAGGACATGC TGCGGCCGAT CCTGCGCGGC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                805        815        825        835        845              
pa4975       ACCCTGGCCT ATGTCGGCAT GCAGGTGCTG GAGCCCTTCG TCGCCTGGCA  
FWD          ACCCTGGCCT ATGTCGGCAT GCAGGTGCTG GAGCCCTTCG TCGCC-----  
REV          ACCCTGGCCT ATGTCGGCAT GCAGGTGCTG GAGCCCTTCG TCGCCTGGCA  
182 
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                855        865        875        885        895              
pa4975       CGTGCCATAC ATCAGCGAGG AAGCGCGCGG CAACTTCCTG CGCGCCTACC  
FWD          ---------- ---------- ---------- ---------- ----------  
REV          CGTGCCATAC ATCAGCGAGG AAGCGCGCGG CAACTTCCTG CGCGCCTACC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                905        915        925        935        945              
pa4975       GGGCGCGGCT GGAAAATCTC GAGCAGGATG TACCCCTGCG GTTCCCGCGG  
FWD          ---------- ---------- ---------- ---------- ----------  
REV          GGGCGCGGCT GGAAAATCTC GAGCAGGATG TACCCCTGCG GTTCCCGCGG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                955        965        975        985        995              
pa4975       CTGGAGCAGT TCGACGCGCT GCTCCAGCCG CTGGCGCGCT GA--------  
FWD          ---------- ---------- ---------- ---------- ----------  
REV          CTGGAGCAGT TCGACGCGCT GCTCCAGCCG CTGGCGCGCT GAGCTCCGTC  
 
             ....|....| .. 
                1005       
pa4975       ---------- -- 
FWD          ---------- -- 
REV          GACAAGCTTG CG 
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APPENDIX VII 
 
 
Alignment of pa0785 sequence in pUCP24 in P. aeruginosa PAO1 Δpa0785 (FWD) 
against pa0785 sequence from P. aeruginosa PAO1 in the Pseudomonas Genome 
Database  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                 5          15         25         35         45                   
pa0785       ---------- ---------- ---------- ---------- ----------  
FWD          AGTCAGTGAG CGAGGAAGCG GAAGAGCGCC CAATACGCAA ACCGCCTCTC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                 55         65         75         85         95                   
pa0785       ---------- ---------- ---------- ---------- ----------  
FWD          CCCGCGCGTT GGCCGATTCA TTAATGCAGC TGGCACGACA GGTTTCCCGA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                105        115        125        135        145              
pa0785       ---------- ---------- ---------- ---------- ----------  
FWD          CTGGAAAGCG GGCAGTGAGC GCAACGCAAT TAATGTGAGT TAGCTCACTC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                155        165        175        185        195              
pa0785       ---------- ---------- ---------- ---------- ----------  
FWD          ATTAGGCACC CCAGGCTTTA CACTTTATGC TTCCGGCTCG TATGTTGTGT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                205        215        225        235        245              
pa0785       ---------- ---------- ---------- ---------- ----------  
FWD          GGAATTGTGA GCGGATAACA ATTTCACACA GGAAACAGCT ATGACATGAT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                255        265        275        285        295              
pa0785       ---------- ---------- ---------- --ATGAGTAG AATTCTTGCA  
FWD          TACGAATTCG AGCTCGGTAC CCGGGGATCC AGATGAGTAG AATTCTTGCA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                305        315        325        335        345              
pa0785       GTGCATGCCA GTCCGCGAGG CGAGCGCTCG CAGTCCCGGC GTCTCGCCGA  
FWD          GTGCATGCCA GTCCGCGAGG CGAGCGCTCG CAGTCCCGGC GTCTCGCCGA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                355        365        375        385        395              
pa0785       GGTTTTCCTG GCGGCCTATC GCGAAGCCCA TCCGCAGGCC CGCGTGGCTC  
FWD          GGTTTTCCTG GCGGCCTATC GCGAAGCCCA TCCGCAGGCC CGCGTGGCTC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                405        415        425        435        445              
pa0785       GCCGCGAAGT CGGCCGGGTA CCGCTTCCGG CGGTCACCGA GGCCTTCGTC  
FWD          GCCGCGAAGT CGGCCGGGTA CCGCTTCCGG CGGTCACCGA GGCCTTCGTC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                455        465        475        485        495              
pa0785       GCCGCCGCCT TCCATCCCCA GCCGGAACAG CGTTCGCTGG CGATGCAGGC  
FWD          GCCGCCGCCT TCCATCCCCA GCCGGAACAG CGTTCGCTGG CGATGCAGGC  
 
184 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                505        515        525        535        545              
pa0785       CGACCTGGCG CTGAGCGACC AACTGGTCGG CGAACTGTTC GACAGCGACC  
FWD          CGACCTGGCG CTGAGCGACC AACTGGTCGG CGAACTGTTC GACAGCGACC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                555        565        575        585        595              
pa0785       TGCTGGTGAT CTCCACGCCG ATGTACAACT TCAGCGTGCC CAGCGGCCTG  
FWD          TGCTGGTGAT CTCCACGCCG ATGTACAACT TCAGCGTGCC CAGCGGCCTG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                605        615        625        635        645              
pa0785       AAGGCCTGGA TCGACCAGAT CGTGCGCCTC GGGGTGACCT TCGATTTCGT  
FWD          AAGGCCTGGA TCGACCAGAT CGTGCGCCTC GGGGTGACCT TCGATTTCGT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                655        665        675        685        695              
pa0785       CCTCGACAAT GGCGTCGCCC AGTACCGGCC GCTGCTGCGT GGCAAGCGTG  
FWD          CCTCGACAAT GGCGTCGCCC AGTACCGGCC GCTGCTGCGT GGCAAGCGTG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                705        715        725        735        745              
pa0785       CGCTGATCGT CACCAGTCGC GGTGGCCATG GCTTCGGCCC GGGCGGCGAG  
FWD          CGCTGATCGT CACCAGTCGC GGTGGCCATG GCTTCGGCCC GGGCGGCGAG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                755        765        775        785        795              
pa0785       AACCAGGCGA TGAACCACGC CGATCCCTGG TTGCGCACCG CGCTGGGTTT  
FWD          AACCAGGCGA TGAACCATGC CGATCCCTGG TTGCGCACCG CGCTGGGTTT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                805        815        825        835        845              
pa0785       CATCGGCATC GACGAGGTCA CGGTGGTCGC GGCGGAAGGC GAGGAATCCG  
FWD          CATCGGCATC GACGAGGTCA CGGTGGTCGC GGCGGAAGGC GAGGAATCCG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                855        865        875        885        895              
pa0785       GCGGCAGGTC CTTCGAGGAC TCCTGCGACG AGGCGGAACA GCGCCTGCTG  
FWD          GCGGCAGGTC CTTCGAGGAC TCCTGCGACG AGGCGGAACA GCGCCTGCTG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                905        915        925        935        945              
pa0785       GCGCTGGCGC GGTCGGCCTG A--------- ---------- ----------  
FWD          GCGCTGGCGC GGTCGGCCTG AGGAGTCGAC CTGCAGGCAT GCAAGCTGGC  
 
             .. 
              
pa0785       -- 
FWD          AC 
 
Alignment of pa1962 sequence in pUCP24 in P. aeruginosa PAO1 Δpa1962 (FWD) 
against pa1962 sequence from P. aeruginosa PAO1 in the Pseudomonas Genome 
Database  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                 5          15         25         35         45                   
pa1962       ---------- ---------- ---------- ---------- ----------  
FWD          GTCAGTGAGC GAGGAAGCGG AAGAGCGCCC AATACGCAAA CCGCCTCTCC  
185 
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                 55         65         75         85         95                   
pa1962       ---------- ---------- ---------- ---------- ----------  
FWD          CCGCGCGTTG GCCGATTCAT TAATGCAGCT GGCACGACAG GTTTCCCGAC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                105        115        125        135        145              
pa1962       ---------- ---------- ---------- ---------- ----------  
FWD          TGGAAAGCGG GCAGTGAGCG CAACGCAATT AATGTGAGTT AGCTCACTCA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                155        165        175        185        195              
pa1962       ---------- ---------- ---------- ---------- ----------  
FWD          TTAGGCACCC CAGGCTTTAC ACTTTATGCT TCCGGCTCGT ATGTTGTGTG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                205        215        225        235        245              
pa1962       ---------- ---------- ---------- ---------- ----------  
FWD          GAATTGTGAG CGGATAACAA TTTCACACAG GAAACAGCTA TGACATGATT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                255        265        275        285        295              
pa1962       ---------- ---------- ---------- ---------- ---------A  
FWD          ACGAATTCGA GCTCGGTACC CGGGGATCCC GCACTTTCAG GAGCGAGACA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                305        315        325        335        345              
pa1962       TGAAACTTTT GCATATCGAT TCCAGCATCC TCGGCGACGC CTCCGCTTCC  
FWD          TGAAACTTTT GCATATCGAT TCCAGCATCC TCGGCGACGC CTCCGCTTCC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                355        365        375        385        395              
pa1962       CGCCAACTGA GCGCCGAGCT GGTCCAGGCC TGGCGGCAGA ACGAAGACGG  
FWD          CGCCAACTGA GCGCCGAGCT GGTCCAGGCC TGGCGGCAGA ACGAAGACGG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                405        415        425        435        445              
pa1962       GCTTGACGTC ACCTACCGCG ACCTGGCCGC CGACGCGGTG GCGCATTTCT  
FWD          GCTTGACGTC ACCTACCGCG ACCTGGCCGC CGACGCGGTG GCGCATTTCT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                455        465        475        485        495              
pa1962       CCGCCCTGAC CCTGGCCGCC GGCAGCACCC CGGCGGAGCT GCGCGATGCC  
FWD          CCGCCCTGAC CCTGGCCGCC GGCAGCACCC CGGCGGAGCT GCGCGATGCC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                505        515        525        535        545              
pa1962       GCGCTGAAGC ATGAAGTCGC GGTGGGTGAA GAAGTGCTGG AAGAGTTCCT  
FWD          GCGCTGAAGC ATGAAGTCGC GGTGGGTGAA GAAGTGCTGG AAGAGTTCCT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                555        565        575        585        595              
pa1962       CGCCGCCGAC GTCGTGGTAA TCGGCGCGCC GATGTACAAC TTCACCATCT  
FWD          CGCCGCCGAC GTCGTGGTAA TCGGCGCGCC GATGTACAAC TTCACCATCT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                605        615        625        635        645              
pa1962       CCAGCCAGCT CAAGGCCTGG ATCGATCGCA TCGCGGTCGC CGGCAAGACC  
FWD          CCAGCCAGCT CAAGGCCTGG ATCGATCGCA TCGCGGTCGC CGGCAAGACC  
186 
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                655        665        675        685        695              
pa1962       TTCCGCTACA CCGAGAACGG CCCGGTTGGC CTGGCCGGCG ACAAGAAAGT  
FWD          TTCCGCTACA CCGAGAACGG CCCGGTTGGC CTGGCCGGCG ACAAGAAAGT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                705        715        725        735        745              
pa1962       GGTGATCGTC TCCACCGCCG GTGGCGTGCA TGCCGGCCAG CCGACCGGCG  
FWD          GGTGATCGTC TCCACCGCCG GTGGCGTGCA TGCCGGCCAG CCGACCGGCG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                755        765        775        785        795              
pa1962       CGGCCCACGA AGGCTACCTG CGCACCGTGC TGGGTTTCTT CGGCATCACC  
FWD          CGGCCCACGA AGGCTACCTG CGCACCGTGC TGGGTTTCTT CGGCATCACC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                805        815        825        835        845              
pa1962       GATATCGAAG TGGTTCGCGC CGAAGGCCTG GCCTATGGCG AGGAGCCCCG  
FWD          GATATCGAAG TGGTTCGCGC CGAAGGCCTG GCCTATGGCG AGGAGCCCCG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                855        865        875        885        895              
pa1962       CACCCAGGCC ATCGCCGCCG CCCGCCGGCA GATCGCCGGG CAGTTCGCCG  
FWD          CACCCAGGCC ATCGCCGCCG CCCGCCGGCA GATCGCCGGG CAGTTCGCCG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                905        915        925        935        945              
pa1962       CGGCCTG--- ---------- ---------- ---------- ----------  
FWD          CGGCCTGATC CCCGCGTCAT CGGAAAACCC CGCTTCGGCG GGTTTTTCGC  
 
             ....|....| ....|....| ....|....| ....|....|  
                955        965        975        985            
pa1962       ---------- ---------- ---------- ----------  
FWD          GTTGTGCGCA GCGGCGCGCT GCGTGTCGAC CTGCAGGCAG  
 
 
 
 
Alignment of pa3223 sequence in pUCP24 in P. aeruginosa PAO1 Δpa3223 (FWD) 
against pa3223 sequence from P. aeruginosa PAO1 in the Pseudomonas Genome 
Database  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                 5          15         25         35         45                   
pa3223       ---------- ---------- ---------- ---------- ----------  
FWD          TCCCCGCGCG TTGGCCGATT CATTAATGCA GCTGGCACGA CAGGTTTCCC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                 55         65         75         85         95                   
pa3223       ---------- ---------- ---------- ---------- ----------  
FWD          GACTGGAAAG CGGGCAGTGA GCGCAACGCA ATTAATGTGA GTTAGCTCAC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                105        115        125        135        145              
pa3223       ---------- ---------- ---------- ---------- ----------  
FWD          TCATTAGGCA CCCCAGGCTT TACACTTTAT GCTTCCGGCT CGTATGTTGT  
187 
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                155        165        175        185        195              
pa3223       ---------- ---------- ---------- ---------- ----------  
FWD          GTGGAATTGT GAGCGGATAA CAATTTCACA CAGGAAACAG CTATGACATG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                205        215        225        235        245              
pa3223       ---------- ---------- ---------- ---------- --ATGTCCCG  
FWD          ATTACGAATT CGAGCTCGGT ACCCGGGGAT CCAGGTCGAG TCATGTCCCG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                255        265        275        285        295              
pa3223       TGTCCTGGTT ATCGAGAGCA GTGCCCGCCA ACGGGGCTCG GTTTCCCGCC  
FWD          TGTCCTGGTT ATCGAGAGCA GTGCCCGCCA ACGGGGCTCG GTTTCCCGCC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                305        315        325        335        345              
pa3223       TGCTGACGGC GGAATTCATC TCCCACTGGA AAATCGCGCA TCCCGCTGAT  
FWD          TGCTGACGGC GGAATTCATC TCCCACTGGA AAATCGCGCA TCCCGCTGAT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                355        365        375        385        395              
pa3223       CGCTTCCAGG TTCGCGACCT GGCGCGCGAG CCGCTGCCGC ACCTCGATGA  
FWD          CGCTTCCAGG TTCGCGACCT GGCGCGCGAG CCGCTGCCGC ACCTCGATGA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                405        415        425        435        445              
pa3223       ATTATTGCTG GGAGCCTGGA CCACCCCCTG TGATGGCCAT AGCGCTGCGG  
FWD          ATTATTGCTG GGAGCCTGGA CCACCCCCTG TGATGGCCAT AGCGCTGCGG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                455        465        475        485        495              
pa3223       AAAGGCGCGC CCTCGAGCGT TCCAATCGCC TGACCGAGGA GTTGCGGATG  
FWD          AAAGGCGCGC CCTCGAGCGT TCCAATCGCC TGACCGAGGA GTTGCGGATG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                505        515        525        535        545              
pa3223       GCGGACGTGC TGGTGCTGGC GGCACCGATG TACAACTTCG CCATTCCCAG  
FWD          GCGGACGTGC TGGTGCTGGC GGCACCGATG TACAACTTCG CCATTCCCAG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                555        565        575        585        595              
pa3223       CAGCCTGAAG AGCTGGTTCG ACCATGTGCT GCGCGCCGGC CTGACCTTCC  
FWD          CAGCCTGAAG AGCTGGTTCG ACCATGTGCT GCGCGCCGGC CTGACCTTCC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                605        615        625        635        645              
pa3223       GTTACGCCGA GCAGGGGCCG GAAGGCCTGC TACAGGGCAA GCGCGCCTTC  
FWD          GTTACGCCGA GCAGGGGCCG GAAGGCCTGC TACAGGGCAA GCGCGCCTTC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                655        665        675        685        695              
pa3223       GTTCTCACCG CCCGCGGCGG GATCTACGCC GGCGGTGGTC TCGATCACCA  
FWD          GTTCTCACCG CCCGCGGCGG GATCTACGCC GGCGGTGGTC TCGATCACCA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                705        715        725        735        745              
pa3223       GGAACCCTAT CTGCGCCAGG TGCTGGGCTT CGTCGGCATC CACGACGTCA  
FWD          GGAACCCTAT CTGCGCCAGG TGCTGGGCTT CGTCGGCATC CACGACGTCA  
188 
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                755        765        775        785        795              
pa3223       CCTTCATCCA CGCGGAGGGC ATGAACATGG GCCCGGAATT CCGTGAGAAA  
FWD          CCTTCATCCA CGCGGAGGGC ATGAACATGG GCCCGGAATT CCGTGAGAAA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                805        815        825        835        845              
pa3223       GGCCTGGCGC GAGCCCGTGA GCGGATGCGG CAGGCGCTGG AAACCGACAC  
FWD          GGCCTGGCGC GAGCCCGTGA GCGGATGCGG CAGGCGCTGG AAACCGACAC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                855        865        875        885        895              
pa3223       CTCCCTTTGC GTCCCTCTGC CAACGCTCCG GTGA------ ----------  
FWD          CTCCCTTTGC GTCCCTCTGC CAACGCTCCG GTGATTGGAC GCAGCACCCG  
 
             ....|....| ....|....| ....|.. 
                905        915        925    
pa3223       ---------- ---------- ------- 
FWD          GTCGACCTGC AGGCATGCAA GCTGCAC 
 
 
 
 
Alignment of pa2280 sequence in pUCP24 in P. aeruginosa PAO1 Δpa2280 (FWD) 
against pa2280 sequence from P. aeruginosa PAO1 in the Pseudomonas Genome 
Database  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                 5          15         25         35         45                   
pa2280       ---------- ---------- ---------- ---------- ----------  
FWD          CCGCCTCTCC CCGCGCGTTG GCCGATTCAT TAATGCAGCT GGCACGACAG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                 55         65         75         85         95                   
pa2280       ---------- ---------- ---------- ---------- ----------  
FWD          GTTTCCCGAC TGGAAAGCGG GCAGTGAGCG CAACGCAATT AATGTGAGTT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                105        115        125        135        145              
pa2280       ---------- ---------- ---------- ---------- ----------  
FWD          AGCTCACTCA TTAGGCACCC CAGGCTTTAC ACTTTATGCT TCCGGCTCGT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                155        165        175        185        195              
pa2280       ---------- ---------- ---------- ---------- ----------  
FWD          ATGTTGTGTG GAATTGTGAG CGGATAACAA TTTCACACAG GAAACAGCTA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                205        215        225        235        245              
pa2280       ---------- ---------- ---------- ---------A TGTCCGAACA  
FWD          TGACATGATT ACGAATTCGA GCTCGGTACC CGGGGATCCA TGTCCGAACA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                255        265        275        285        295              
pa2280       ACTACCCAAC CTCGATCCCG CGCTGCTCGG CGACCCGCCC CCCGTCTCCG  
FWD          ACTACCCAAC CTCGATCCCG CGCTGCTCGG CGACCCGCCC CCCGTCTCCG  
189 
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                305        315        325        335        345              
pa2280       GGCACAGGCC GCGCATCCTC CTGCTCTACG GCTCGACCCG CGAGCGCTCC  
FWD          GGCACAGGCC GCGCATCCTC CTGCTCTACG GCTCGACCCG CGAGCGCTCC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                355        365        375        385        395              
pa2280       TTCAGCCGCC TGCTGGTGCT GGAGGCCGCA CGCCTGCTCG AACGCTTCGG  
FWD          TTCAGCCGCC TGCTGGTGCT GGAGGCCGCA CGCCTGCTCG AACGCTTCGG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                405        415        425        435        445              
pa2280       TGCCGAAACG CGGATTTTCG ACCCTTCCGG GCTGCCATTG CCCGATGATG  
FWD          TGCCGAAACG CGGATTTTCG ACCCTTCCGG GCTGCCATTG CCCGATGATG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                455        465        475        485        495              
pa2280       CACCGGTGGA GCATCCCAAG GTCCGCGAGT TGCGCGACCT GGTGCAGTGG  
FWD          CACCGGTGGA GCATCCCAAG GTCCGCGAGT TGCGCGACCT GGTGCAGTGG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                505        515        525        535        545              
pa2280       TCGGAAGGCC AGGTCTGGTG CTCGCCCGAG CGCCACGGTG CGCTGTCCGC  
FWD          TCGGAAGGCC AGGTCTGGTG CTCGCCCGAG CGCCACGGTG CGCTGTCCGC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                555        565        575        585        595              
pa2280       GGTATTCAAG GCGCAGATCG ACTGGATTCC CCTGGCACTC GGGGCGGTGC  
FWD          GGTATTCAAG GCGCAGATCG ACTGGATTCC CCTGGCACTC GGGGCGGTGC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                605        615        625        635        645              
pa2280       GCCCGACCCA GGGCAAGACC CTGGCGCTGA TGCAGGTCTG CGGCGGCTCG  
FWD          GCCCGACCCA GGGCAAGACC CTGGCGCTGA TGCAGGTCTG CGGCGGCTCG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                655        665        675        685        695              
pa2280       CAGTCGTTCA ACGTGGTCAA CCAGTTGCGC GTGCTGGGTC GCTGGATGCG  
FWD          CAGTCGTTCA ACGTGGTCAA CCAGTTGCGC GTGCTGGGTC GCTGGATGCG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                705        715        725        735        745              
pa2280       CATGTTCACC ATCCCCAACC AGTCCTCGGT TCCCAAGGCC TACCTGGAGT  
FWD          CATGTTCACC ATCCCCAACC AGTCCTCGGT TCCCAAGGCC TACCTGGAGT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                755        765        775        785        795              
pa2280       TCGACGAAGC GGGCCGGATG AAGCCATCGC CCTACTACGA CCGGGTGGTC  
FWD          TCGACGAAGC GGGCCGGATG AAGCCATCGC CCTACTACGA CCGGGTGGTC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                805        815        825        835        845              
pa2280       GACGTGATGG AGGAGTTGTT CAAGTTCACC CTGCTCCTGC GCGAGCGCAC  
FWD          GACGTGATGG AGGAGTTGTT CAAGTTCACC CTGCTCCTGC GCGAGCGCAC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                855        865        875        885        895              
pa2280       GGACTTCCTG GTGGACCGCT ATTCGGAGCG CAAGGAAAGC GCCGAGCAGC  
FWD          GGACTTCCTG GTGGACCGCT ATTCGGAGCG CAAGGAAAGC GCCGAGCAGC  
190 
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                905        915        925        935        945              
pa2280       TTTCCGCGCG GGTCGACCAG CGTTCGCTCT GA-------- ----------  
FWD          TTTCCGCGCG GGTCGACCAG CGTTCGCTCT GAACCGCGTC GACCTGCAGG  
 
             ....|....| . 
                955        
pa2280       ---------- - 
FWD          CATGCAAGCT G 
 
Alignment of pa2580 sequence in pUCP24 in P. aeruginosa PAO1 Δpa2580 (FWD) 
against pa2580 sequence from P. aeruginosa PAO1 in the Pseudomonas Genome 
Database  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                 5          15         25         35         45                   
pa2580       ---------- ---------- ---------- ---------- ----------  
FWD          ACATGTTCTT TCCTGCGTTA TCCCCTGATT CTGTGGATAA CCGTATTACC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                 55         65         75         85         95                   
pa2580       ---------- ---------- ---------- ---------- ----------  
FWD          GCCTTTGAGT GAGCTGATAC CGCTCGCCGC AGCCGAACGA CCGAGCGCAG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                105        115        125        135        145              
pa2580       ---------- ---------- ---------- ---------- ----------  
FWD          CGAGTCAGTG AGCGAGGAAG CGGAAGAGCG CCCAATACGC AAACCGCCTC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                155        165        175        185        195              
pa2580       ---------- ---------- ---------- ---------- ----------  
FWD          TCCCCGCGCG TTGGCCGATT CATTAATGCA GCTGGCACGA CAGGTTTCCC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                205        215        225        235        245              
pa2580       ---------- ---------- ---------- ---------- ----------  
FWD          GACTGGAAAG CGGGCAGTGA GCGCAACGCA ATTAATGTGA GTTAGCTCAC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                255        265        275        285        295              
pa2580       ---------- ---------- ---------- ---------- ----------  
FWD          TCATTAGGCA CCCCAGGCTT TACACTTTAT GCTTCCGGCT CGTATGTTGT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                305        315        325        335        345              
pa2580       ---------- ---------- ---------- ---------- ----------  
FWD          GTGGAATTGT GAGCGGATAA CAATTTCACA CAGGAAACAG CTATGACATG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                355        365        375        385        395              
pa2580       ---------- ---------- ---------- ----ATGAAA AACATTCTCC  
FWD          ATTACGAATT CGAGCTCGGT ACCCGGGGAT CCCCATGAAA AACATTCTCC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                405        415        425        435        445              
pa2580       TGCTCAACGG CGGAAAGCGT TTCGCCCATT CCGACGGTCG CCTCAACCAG  
FWD          TGCTCAACGG CGGAAAGCGT TTCGCCCATT CCGACGGTCG CCTCAACCAG  
 
191 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                455        465        475        485        495              
pa2580       ACCCTGCACG AAACCGCCCT GGCCCATCTG GACCGCCGTG GCTTCGACCT  
FWD          ACCCTGCACG AAACCGCCCT GGCCCATCTG GACCGCCGTG GCTTCGACCT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                505        515        525        535        545              
pa2580       GCGCCAGACC TTCATCGACG GTGGCTATGA TATCCCGACG GAGGTGGACA  
FWD          GCGCCAGACC TTCATCGACG GTGGCTATGA TATCCCGACG GAGGTGGACA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                555        565        575        585        595              
pa2580       AGTTCCTCTG GGCCGACGTG GTGATCTACC AGATGCCCGG CTGGTGGATG  
FWD          AGTTCCTCTG GGCCGACGTG GTGATCTACC AGATGCCCGG CTGGTGGATG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                605        615        625        635        645              
pa2580       GGCGCCCCGT GGACAGTGAA GCGCTACATC GACGAAGTCT TCACGGCCGG  
FWD          GGCGCCCCGT GGACAGTGAA GCGCTACATC GACGAAGTCT TCACGGCCGG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                655        665        675        685        695              
pa2580       ACACGGCAGC CTCTATGCCA ACGACGGTCG TACCCGCTCC GACAGCACGC  
FWD          ACACGGCAGC CTCTATGCCA ACGACGGTCG TACCCGCTCC GACAGCACGC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                705        715        725        735        745              
pa2580       AGAAATATGG CAGCGGCGGT CTGGTGCAGG GCAAGCGCTA CATGATCTCG  
FWD          AGAAATATGG CAGCGGCGGT CTGGTGCAGG GCAAGCGCTA CATGATCTCG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                755        765        775        785        795              
pa2580       GCGACCTGGA ATGCACCACG GCAGGCGTTC GACGATCCGA GCGACTTCTT  
FWD          GCGACCTGGA ATGCACCACG GCAGGCGTTC GACGATCCGA GCGACTTCTT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                805        815        825        835        845              
pa2580       CGAAGGAAAA GGCGTGGATG CGGTGTATTT CCCCTTCCAC AAGGCCAACC  
FWD          CGAAGGAAAA GGCGTGGATG CGGTGTATTT CCCCTTCCAC AAGGCCAACC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                855        865        875        885        895              
pa2580       AGTTCCTCGG CATGTCCGGC CTGCCGACGT TCCTCGCGGT GGATGTGATG  
FWD          AGTTCCTCGG CATGTCCGGC CTGCCGACGT TCCTCGCGGT GGATGTGATG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                905        915        925        935        945              
pa2580       AAGCGCCCGG ACGTCCCGGC TACCGTCGCT GCCTACCAGG CGCACCTGGA  
FWD          AAGCGCCCGG ACGTCCCGGC TACCGTCGCT GCCTACCAGG CGCACCTGGA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                955        965        975        985        995              
pa2580       CAGGGTGTTC GGGCGCGCCG GCTGA----- ---------- ----------  
FWD          CAGGGTGTTC GGGCGCGCCG GCTGAGTTCG TCGACCTGCA GGCATGCAAG  
 
             .. 
              
pa2580       -- 
FWD          CT 
 
192 
 
Alignment of pa1204 sequence in pUCP24 in P. aeruginosa PAO1 Δpa1204 (FWD) 
against pa1204 sequence from P. aeruginosa PAO1 in the Pseudomonas Genome 
Database  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                 5          15         25         35         45                   
pa1204       ---------- ---------- ---------- ---------- ----------  
FWD          CATGTTCTTT CCTGCGTTAT CCCCTGATTC TGTGGATAAC CGTATTACCG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                 55         65         75         85         95                   
pa1204       ---------- ---------- ---------- ---------- ----------  
FWD          CCTTTGAGTG AGCTGATACC GCTCGCCGCA GCCGAACGAC CGAGCGCAGC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                105        115        125        135        145              
pa1204       ---------- ---------- ---------- ---------- ----------  
FWD          GAGTCAGTGA GCGAGGAAGC GGAAGAGCGC CCAATACGCA AACCGCCTCT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                155        165        175        185        195              
pa1204       ---------- ---------- ---------- ---------- ----------  
FWD          CCCCGCGCGT TGGCCGATTC ATTAATGCAG CTGGCACGAC AGGTTTCCCG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                205        215        225        235        245              
pa1204       ---------- ---------- ---------- ---------- ----------  
FWD          ACTGGAAAGC GGGCAGTGAG CGCAACGCAA TTAATGTGAG TTAGCTCACT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                255        265        275        285        295              
pa1204       ---------- ---------- ---------- ---------- ----------  
FWD          CATTAGGCAC CCCAGGCTTT ACACTTTATG CTTCCGGCTC GTATGTTGTG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                305        315        325        335        345              
pa1204       ---------- ---------- ---------- ---------- ----------  
FWD          TGGAATTGTG AGCGGATAAC AATTTCACAC AGGAAACAGC TATGACATGA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                355        365        375        385        395              
pa1204       ---------- ---------- ---------- -----ATGAG CGACGACATC  
FWD          TTACGAATTC GAGCTCGGTA CCCGGGGATC CCGGCATGAG CGACGACATC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                405        415        425        435        445              
pa1204       AAGGTATTGG GCATTTCCGG CAGCCTGCGC AGCGGCTCCT ACAACAGCGC  
FWD          AAGGTATTGG GCATTTCCGG CAGCCTGCGC AGCGGCTCCT ACAACAGCGC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                455        465        475        485        495              
pa1204       GGCGCTGCAG GAGGCGATTG GCCTGGTCCC GCCGGGCATG AGCATCGAGC  
FWD          GGCGCTGCAG GAGGCGATTG GCCTGGTCCC GCCGGGCATG AGCATCGAGC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                505        515        525        535        545              
pa1204       TGGCGGACAT CTCCGGCATC CCGCTGTACA ACGAGGACGT CTACGCCCTC  
FWD          TGGCGGACAT CTCCGGCATC CCGCTGTACA ACGAGGACGT CTACGCCCTC  
 
193 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                555        565        575        585        595              
pa1204       GGCTTCCCGC CCGCGGTGGA ACGCTTCCGC GAGCAGATTC GCGCGGCGGA  
FWD          GGCTTCCCGC CCGCGGTGGA ACGCTTCCGC GAGCAGATTC GCGCGGCGGA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                605        615        625        635        645              
pa1204       CGCGCTGCTG TTCGCCACCC CGGAATACAA CTATTCGATG GCCGGGGTGC  
FWD          CGCGCTGCTG TTCGCCACCC CGGAATACAA CTATTCGATG GCCGGGGTGC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                655        665        675        685        695              
pa1204       TGAAGAATGC CATCGACTGG GCCTCGCGGC CGCCGGAGCA GCCGTTCTCC  
FWD          TGAAGAATGC CATCGACTGG GCCTCGCGGC CGCCGGAGCA GCCGTTCTCC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                705        715        725        735        745              
pa1204       GGCAAGCCGG CGGCGATCCT CGGCGCCAGC GCCGGGCGTT TCGGCACCGC  
FWD          GGCAAGCCGG CGGCGATCCT CGGCGCCAGC GCCGGGCGTT TCGGCACCGC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                755        765        775        785        795              
pa1204       GCGGGCGCAG TATCACTTGC GCCAGACGCT GGTGTTCCTC GACGTTCATC  
FWD          GCGGGCGCAG TATCACTTGC GCCAGACGCT GGTGTTCCTC GACGTTCATC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                805        815        825        835        845              
pa1204       CGCTGAACAA GCCGGAAGTG ATGATCTCCA GCGCGCAGAA CGCCTTCGAT  
FWD          CGCTGAACAA GCCGGAAGTG ATGATCTCCA GCGCGCAGAA CGCCTTCGAT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                855        865        875        885        895              
pa1204       GCCCAGGGCC GGCTGCTCGA CGACAAGGCG CGCGAGCTGA TCCAGCAGCA  
FWD          GCCCAGGGCC GGCTGCTCGA CGACAAGGCG CGCGAGCTGA TCCAGCAGCA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                905        915        925        935        945              
pa1204       GTTGCAGGCC CTGCAGCTAT GGGTGCGCCG CCTGCGCGGT TGA-------  
FWD          GTTGCAGGCC CTGCAGCTAT GGGTGCGCCG CCTGCGCGGT TGAATGCCTC  
 
             ....|....| ....|....| ....| 
                955        965        975    
pa1204       ---------- ---------- ----- 
FWD          GTCGACCTGC AGGCATGCAA GCTGC 
 
 
 
Alignment of pa0949 sequence in pUCP24 in P. aeruginosa PAO1 Δpa0949 (FWD) 
against pa0949 sequence from P. aeruginosa PAO1 in the Pseudomonas Genome 
Database  
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                 5          15         25         35         45                   
pa0949       ---------- ---------- ---------- ---------- ----------  
fwd          ACCGCTTGCC GCAGCCGAAC GACCGAGCGC AGCGAGTCAG TGAGCGAGGA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                 55         65         75         85         95                   
pa0949       ---------- ---------- ---------- ---------- ----------  
fwd          AGCGGAAGAG CGCCCAATAC GCAAACCGCC TCTCCCCGCG CGTTGGCCGA  
194 
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                105        115        125        135        145              
pa0949       ---------- ---------- ---------- ---------- ----------  
fwd          TTCATTAATG CAGCTGGCAC GACAGGTTTC CCGACTGGAA AGCGGGCAGT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                155        165        175        185        195              
pa0949       ---------- ---------- ---------- ---------- ----------  
fwd          GAGCGCAACG CAATTAATGT GAGTTAGCTC ACTCATTAGG CACCCCAGGC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                205        215        225        235        245              
pa0949       ---------- ---------- ---------- ---------- ----------  
fwd          TTTACACTTT ATGCTTCCGG CTCGTATGTT GTGTGGAATT GTGAGCGGAT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                255        265        275        285        295              
pa0949       ---------- ---------- ---------- ---------- ----------  
fwd          AACAATTTCA CACAGGAAAC AGCTATGACA TGATTACGAA TTCGAGCTCG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                305        315        325        335        345              
pa0949       ---------- --------TT GAGCAGTCCC TACATCCTGG TGCTGTACTA  
fwd          GTACCCGGGG ATCCTCGCTT GAGCAGTCCC TACATCCTGG TGCTGTACTA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                355        365        375        385        395              
pa0949       CAGTCGCCAT GGCGCTACCG CGGAAATGGC CCGGCAGATC GCCCGTGGCG  
fwd          CAGTCGCCAT GGCGCTACCG CGGAAATGGC CCGGCAGATC GCCCGTGGCG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                405        415        425        435        445              
pa0949       TCGAACAGGG CGGCTTCGAG GCGCGTGTAC GCACGGTTCC CGCGGTATCC  
fwd          TCGAACAGGG CGGCTTCGAG GCGCGTGTAC GCACGGTTCC CGCGGTATCC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                455        465        475        485        495              
pa0949       ACCGAATGCG AAGCGGTCGC CCCCGACATC CCCGCGGAGG GGGCGCTGTA  
fwd          ACCGAATGCG AAGCGGTCGC CCCCGACATC CCCGCGGAGG GGGCGCTGTA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                505        515        525        535        545              
pa0949       CGCAACCCTG GAGGACCTGA AGAACTGCGC GGGCCTGGCC CTCGGCAGCC  
fwd          CGCAACCCTG GAGGACCTGA AGAACTGCGC GGGCCTGGCC CTCGGCAGCC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                555        565        575        585        595              
pa0949       CGACCCGCTT CGGCAACATG GCTTCCCCGC TGAAATACTT CCTCGACGGT  
fwd          CGACCCGCTT CGGCAACATG GCTTCCCCGC TGAAATACTT CCTCGACGGT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                605        615        625        635        645              
pa0949       ACCAGCAGCC TGTGGCTGAC CGGCAGCCTG GTCGGCAAGC CGGCAGCGGT  
fwd          ACCAGCAGCC TGTGGCTGAC CGGCAGCCTG GTCGGCAAGC CGGCAGCGGT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                655        665        675        685        695              
pa0949       CTTCACCTCC ACCGCCAGCC TGCACGGCGG CCAGGAGACC ACTCAGTTAT  
fwd          CTTCACCTCC ACCGCCAGCC TGCACGGCGG CCAGGAGACC ACTCAGTTAT  
195 
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                705        715        725        735        745              
pa0949       CGATGCTGTT GCCATTGCTG CACCACGGCA TGCTGGTCCT GGGCATTCCC  
fwd          CGATGCTGTT GCCATTGCTG CACCACGGCA TGCTGGTCCT GGGCATTCCC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                755        765        775        785        795              
pa0949       TACAGCGAAC CCGCCCTGCT GGAAACCCGC GGCGGCGGCA CGCCTTACGG  
fwd          TACAGCGAAC CCGCCCTGCT GGAAACCCGC GGCGGCGGCA CGCCTTACGG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                805        815        825        835        845              
pa0949       CGCCAGCCAC TTCGCCGGCG CCGATGGCAA GCGCAGCCTC GATGAGCACG  
fwd          CGCCAGCCAC TTCGCCGGCG CCGATGGCAA GCGCAGCCTC GATGAGCACG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                855        865        875        885        895              
pa0949       AACTGACCCT GTGTCGCGCG CTGGGCAAAC GCCTGGCGGA AACCGCCGGC  
fwd          AACTGACCCT GTGTCGCGCG CTGGGCAAAC GCCTGGCGGA AACCGCCGGC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                905        915        925        935        945              
pa0949       AAGCTGGGGA GTTGA----- ---------- ---------- ----------  
fwd          AAGCTGGGGA GTTGAAATGG CCCGCAAGAA CAAACCGCCT GCAGGCATGC  
 
             ....|....| ....|....| ....|....| ....|.... 
                955        965        975        985      
pa0949       ---------- ---------- ---------- --------- 
fwd          AAGCTGGCAC G--------- ---------- --------- 
 
 
Alignment of pa4975 sequence in pUCP24 in P. aeruginosa PAO1 Δpa4975 (FWD) 
against pa4975 sequence from P. aeruginosa PAO1 in the Pseudomonas Genome 
Database  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                 5          15         25         35         45                   
pa4975       ---------- ---------- ---------- ---------- ----------  
FWD          TTGACCGAGG AAGCGGAAGA GCGCCCAATA CGCAAACCGC CTCTCCCCGC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                 55         65         75         85         95                   
pa4975       ---------- ---------- ---------- ---------- ----------  
FWD          GCGTTGGCCG ATTCATTAAT GCAGCTGGCA CGACAGGTTT CCCGACTGGA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                105        115        125        135        145              
pa4975       ---------- ---------- ---------- ---------- ----------  
FWD          AAGCGGGCAG TGAGCGCAAC GCAATTAATG TGAGTTAGCT CACTCATTAG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                155        165        175        185        195              
pa4975       ---------- ---------- ---------- ---------- ----------  
FWD          GCACCCCAGG CTTTACACTT TATGCTTCCG GCTCGTATGT TGTGTGGAAT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                205        215        225        235        245              
pa4975       ---------- ---------- ---------- ---------- ----------  
FWD          TGTGAGCGGA TAACAATTTC ACACAGGAAA CAGCTATGAC ATGATTACGA  
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             ....|....| ....|....| ....|....| ....|....| ....|....|  
                255        265        275        285        295              
pa4975       ---------- ---------- ---------A TGAACGTACT GATCGTCCAC  
FWD          ATTCGAGCTC GGTACCCGGG GATCCCACGA TGAACGTACT GATCGTCCAC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                305        315        325        335        345              
pa4975       GCCCACAACG AACCGCAATC CTTCACCCGC GCGCTCTGTG ACCAGGCATG  
FWD          GCCCACAACG AACCGCAATC CTTCACCCGC GCGCTCTGTG ACCAGGCATG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                355        365        375        385        395              
pa4975       CGAGACCCTG GCAGGCCAGG GCCACGCGGT GCAGGTCTCG GATCTCTACG  
FWD          CGAGACCCTG GCAGGCCAGG GCCACGCGGT GCAGGTCTCG GATCTCTACG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                405        415        425        435        445              
pa4975       CGATGAACTG GAATCCGGTG GCCAGTGCCG CCGACTTCGC CGAGCGCGCC  
FWD          CGATGAACTG GAATCCGGTG GCCAGTGCCG CCGACTTCGC CGAGCGCGCC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                455        465        475        485        495              
pa4975       GATCCCGACT ACCTGGTGTA CGCCCTGGAG CAGCGCGAGA GCGTCAAGCG  
FWD          GATCCCGACT ACCTGGTGTA CGCCCTGGAG CAGCGCGAGA GCGTCAAGCG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                505        515        525        535        545              
pa4975       CCAGAGCCTG GCCGCCGACA TCCAGGCCGA GCTGGACAAG CTGCTGTGGG  
FWD          CCAGAGCCTG GCCGCCGACA TCCAGGCCGA GCTGGACAAG CTGCTGTGGG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                555        565        575        585        595              
pa4975       CCGACCTGCT GATCCTCAAC TTTCCGATCT ACTGGTTCTC GGTGCCGGCG  
FWD          CCGACCTGCT GATCCTCAAC TTTCCGATCT ACTGGTTCTC GGTGCCGGCG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                605        615        625        635        645              
pa4975       ATCCTCAAGG GGTGGTTCGA CCGGGTACTG GTGTCCGGGG TCTGCTATGG  
FWD          ATCCTCAAGG GGTGGTTCGA CCGGGTACTG GTGTCCGGGG TCTGCTATGG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                655        665        675        685        695              
pa4975       CGGCAAGCGC TTCTACGACC AGGGTGGCCT GGCCGGCAAG AAGGCGCTGG  
FWD          CGGCAAGCGC TTCTACGACC AGGGTGGCCT GGCCGGCAAG AAGGCGCTGG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                705        715        725        735        745              
pa4975       TCAGCCTGAC CCTGGGCGGG CGCCAGCACA TGTTCGGCGA GGGTGCCATC  
FWD          TCAGCCTGAC CCTGGGCGGG CGCCAGCACA TGTTCGGCGA GGGTGCCATC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                755        765        775        785        795              
pa4975       CACGGACCGC TGGAGGACAT GCTGCGGCCG ATCCTGCGCG GCACCCTGGC  
FWD          CACGGACCGC TGGAGGACAT GCTGCGGCCG ATCCTGCGCG GCACCCTGGC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                805        815        825        835        845              
pa4975       CTATGTCGGC ATGCAGGTGC TGGAGCCCTT CGTCGCCTGG CACGTGCCAT  
FWD          CTATGTCGGC ATGCAGGTGC TGGAGCCCTT CGTCGCCTGG CACGTGCCAT  
197 
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                855        865        875        885        895              
pa4975       ACATCAGCGA GGAAGCGCGC GGCAACTTCC TGCGCGCCTA CCGGGCGCGG  
FWD          ACATCAGCGA GGAAGCGCGC GGCAACTTCC TGCGCGCCTA CCGGGCGCGG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                905        915        925        935        945              
pa4975       CTGGAAAATC TCGAGCAGGA TGTACCCCTG CGGTTCCCGC GGCTGGAGCA  
FWD          CTGGAAAATC TCGAGCAGGA TGTACCCCTG CGGTTCCCGC GGCTGGAGCA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                955        965        975        985        995              
pa4975       GTTCGACGCG CTGCTCCAGC CGCTGGCGCG CTGA------ ----------  
FWD          GTTCGACGCG CTGCTCCAGC CGCTGGCGCG CTGAGCCGGT CGACCTGCAG  
 
             ....|....| ....|. 
                1005       1015  
pa4975       ---------- ------ 
FWD          GCATGCAAGC TGGCAC 
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